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Introduction: Cervical cancer is the 4th most common cause of cancer-related death in 
women. It is caused by infection with high-risk HPV (HR-HPV). Current therapy with cisplatin 
and radiotherapy acts by damaging DNA. The DNA damage response (DDR), critical for 
survival following endogenous and therapeutic DNA damage, comprises signalling to cell 
cycle checkpoints and DNA repair. HR-HPV inactivates p53 and pRB and thereby the GI/S 
checkpoint, making cervical cancer an ideal target for inhibition of intra-S and G2/M cell 
cycle checkpoints. This thesis directly compares the efficacy of inhibitors of the S and G2/M 
checkpoints: ATR, CHK1 and WEE1 as single agents and as sensitisers to cisplatin and ionising 
radiation in cervical cancer cell lines 
Methods: A panel of 6 cervical cancer cell lines with different histopathology and HPV status 
were used. DDR protein expression and inhibition of ATR, CHK1 and WEE1 by VE-821, PF-
477736 and MK-1775, respectively were measured by Western blot. Checkpoint proteins 
were measured in a TMA of human cervical cancer by IHC. Cytotoxicity of inhibitors and 
combinations with cisplatin or IR was determined by clonogenic assay. Cell cycle analysis 
with propidium iodide was used to investigate cell cycle changes.   
Results: The expression of DDR and checkpoint proteins varied in both cell lines and the 
TMA. There was a modest spectrum of sensitivity to cisplatin, IR and the inhibitors but the 
rank order was different for each agent, which was not related to the levels of DDR proteins 
in general but low ATM was associated with VE-821 sensitivity. The inhibitors were used at 
fixed concentrations for chemo- and radio-sensitisation studies: 1 µM VE821, 50 nM PF-
477736 and 100 nM MK-1775 reflecting their relative target inhibition potency and intrinsic 
cytotoxicity. Greater sensitisation was observed with cisplatin than IR, with VE-821 having 
the greatest and MK-1775 the least effect. Cisplatin caused S-phase accumulation that was 
reduced by the kinase inhibitors in 4/6 cell lines but increased in the other 2. The effects 
were more marked for VE-821 and PF-477736 vs MK-1775 and were not related to cisplatin 
sensitisation.  
Conclusions: Cytotoxicity and sensitisation effects were not explained by protein expressions 
or enzyme inhibition. The effect of the inhibitors on cisplatin-induced S-phase arrest varied 
across the cell line panel and did not correlate with sensitisation data. Analysis was 
hampered by the size of the panel and their similarity. Further work with a larger, more 
 
 iii 
diverse panel of cell lines is required before the mechanisms and potential biomarkers of 
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1.1 Cervical cancer – Morbidity, mortality and current treatment 
 
Cervical cancer accounted for over 310,000 cancer deaths worldwide in 2018 despite 
important advances in the detection of pre-invasive disease through effective screening 
programmes (Landy et al., 2016, Rebolj et al., 2019) and the availability of vaccines targeted 
at high-risk human papillomavirus (HPV) (Simms et al., 2019). Cervical cancer remains 
stubbornly amongst the top four worldwide causes of female cancer death, accounting for 
7.5 % of cancer related mortality in women. In low Human Development Index (HDI) settings 
cervical cancer is the second most common cause of female cancer death and in Western 
and sub-Saharan Africa it is the most commonly diagnosed cancer in women (Bray et al., 
2018). The overwhelming majority of cervical cancers are carcinomas arising from the 
squamous cells of the ectocervical transition zone or adenocarcinomas (and a variant known 
as adenosquamous cancers) arising from the glandular endocervix. Both histopathological 
sub-types have the same aetiology: mucosal infection with human papillomavirus (HPV) and 
are treated similarly, although adenocarcinomas have a marginally poorer response to non-
surgical treatments and a slightly poorer prognosis (Katanyoo et al., 2012, Chen et al., 2014).  
 
In all settings, the likelihood of surviving cervical cancer depends on the stage of the disease. 
The five-year survival rates from cervical cancer range from 95% in stage 1 disease to just 5% 
for those with stage 4 disease (CRUK, 2019).  Cervical cancer is staged according to the 2018 
FIGO (International Federation of Gynaecology and Obstetrics) staging system (Bhatla et al., 
2018), which uses a combination of clinical and radiological findings (Table 1.1). Initial 
treatment is defined by stage at presentation. Early disease, confined to the cervix is usually 
treated surgically with either a local or radical excision of the tumour, cervix and uterine 
corpus along with common sites of metastases such as the parametrium and pelvic lymph 
nodes. Locally advanced disease in which there is evidence of spread to the parametrium or 
pelvic nodes is usually treated with concurrent radical radiotherapy and cisplatin 





Table 1.1 Cervical cancer treatment options and 5-year survival by stage at 
presentation.   
Staging does not include sub-categorisation that do not affect treatment choices or have 
significant impacts on survival outcomes, which are based on previous FIGO (2009) 
staging classifications. Local excision refers to cervical conisation or simple excision of the 
cervix ± uterine corpus (depending on the tumour size and fertility preservation wishes of 
the patient). Radical excision refers to excision of the cervix ± uterine corpus with excision 
of the parametria and upper vagina. Table derived from Bhatla et.al., 2018  
 
 
For patients who have disease outside of the pelvis at presentation or for those who have 
recurrent disease in anatomical areas previously treated with radiotherapy, therapeutic 
options are often limited to palliative chemotherapy, often with platinum-based regimes if 
the disease is not amenable to salvage surgery (Scatchard et al., 2012). Despite the recent 
introduction of newer agents such as the anti-vascular endothelial growth factor drug 
Bevacizumab (Bizzarri et al., 2016, Rosen et al., 2017) into chemotherapy regimens, the 
prognosis for advanced or recurrent disease remains poor.  This underlies the urgent need to 
find new and effective strategies to treat cervical cancer, including strategies aimed at 







1.2 Cervical cancer and high-risk HPV 
1.2.1 Cervical cancer is strongly associated with high-risk HPV 
Cervical cancer is almost ubiquitously a disease resulting from infection of the cervical 
transition zone by ‘high-risk’ HPV subtypes (HR-HPV). The HPV family of deoxyribonucleic 
acid (DNA)-viruses is large and diverse (Figure 1.1) (de Villiers, 2013). The majority of HPV 
viruses, especially from the beta- and gamma- types persist in host species as commensals, 
without causing disease. Others such as the ‘low-risk’ alpha-type HPV-3 can cause benign 
papillomatous diseases in humans, such as anogenital warts. A relatively small number of 
alpha-HPV viruses are regarded as HR-HPV and are capable of causing malignant disease, 
most notably in the cervix.  
 
Alpha- HPV types have a greater diversity in their E6 and E7 genes than other HPV types. The 
transcriptional products of these genes: virus proteins E6 and E7 play important roles in host 
immune evasion and virus genome amplification within the host cell replication machinery 
(Doorbar et al., 2015). An important feature of HR-HPV E6 and E7 is their respective 
interactions with host cell tumour protein 53 (p53) and retinoblastoma protein (pRB), and 
the resulting interference with cell-cycle DNA damage checkpoint control (see section 1.3.1).  
 
Confirmation of the association between HR-HPV and cervical cancer was provided by the 
International Biological Study on Cervical Cancer (IBSCC), which reported 93% positivity for 
HR-HPV in 981 cervical cancer patients from 22 countries (Bosch et al., 1995). The relative 
distribution of HR-HPV sub-types in this study confirmed a predominance of HPV-16 and 
related sub-types (16, 31, 33, 35, 52 and 58) in squamous cancers (68%), while HPV-18 and 
related sub-types (18, 39, 45, 59 and 68) predominated in adenocarcinomas and 
adenosquamous cancers (71% in each), findings that were subsequently corroborated in 
later studies (Zehbe and Wilander, 1997). Following this, re-analysis of many of the IBSCC 
HPV-negative specimens using polymerase chain reaction (PCR) targeting HR-HPV E6 and E7 
genes, which are integral to carcinogenesis established that the worldwide prevalence of 





Figure 1.1 Phylogenic tree of human papillomavirus (HPV). 
Most human-disease causing HPV are found amongst the alpha-types. The location of the 
high-risk HPV subtypes related to HPV-16: most common in squamous cervical cancers, and 




The possibility of a truly HPV negative cervical cancer cannot be completely ruled out. 
However, such an entity appears to be rare and the prevalence of HPV negative cervical 
cancers is universally accepted to be extremely low. The existence of human cervical cancer 
cell lines in which there are no detectable HPV DNA sequences, refutes the conclusion that 
these cancers are non-existent. Characterisation of these cell lines however, suggests that 
pathogenic mutations of one or both of the tumour suppressor genes: Tumour Protein 53 
(TP53 ) and; Retinoblastoma 1(RB1) are present. This is in contrast to the situation in HPV 
positive cell lines, where the cell lines expressed normal gene products at comparatively low 
levels, indicative of post transcription suppression by The HPV proteins E6 and E7 
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(Walboomers and Meijer, 1997). This evidence suggests that disruption of the functions of 
the tumour suppressor proteins p53 and pRB play a vital role in promoting human cervical 
cancer carcinogenesis in the presence or absence of HR-HPV. 
 
1.2.2 HPV-driven cervical cancer pathogenesis 
It is persistent infection of the cervical epithelium with HR-HPV sub-types that increases an 
individual’s risk of developing pre-invasive lesions or cervical cancer (Munoz et al., 2003). 
The development of pre-invasive cervical lesions known as cervical intra-epithelial neoplasia 
(CIN) is the pathognomonic prodrome in the development of cervical cancer and these 
lesions usually appear years before the development of a frankly malignant lesion.  
 
A detailed description of the pathophysiology of CIN progression is beyond the scope of this 
thesis and is summarised in Figure 1.2 however, it should be noted that the molecular 
processes in CIN lesions are identical to invasive cancer and the ability to detect CIN in 
cervical samples underlies the effectiveness of cervical cancer screening programmes. Low 
grade lesions (CIN-I) may, however regress spontaneously under the influence of host 
immunity (Tainio et al., 2018), whilst high grade CIN (CIN-II or CIN-III) have a higher risk of 
progression to cervical cancer (Vink et al., 2013).   
 
The prevalence of HR-HPV infection is as high as 20% in the UK female population 
(Ramanakumar et al., 2016). It is important to recognise that up to 50% of lower genital tract 
HR-HPV infections will clear spontaneously within 1 year of detection. The true prevalence of 
high grade cervical pre-invasive lesions amongst the population is difficult to estimate given 
the variable uptake of screening and the often-transient nature of the disease, which may 
not progress to cancer. A Canadian study, conducted in settings similar to the UK, with HPV 
vaccination and cervical screening programmes estimate an incidence rate for CIN-II or CIN-
III of between 1 and 2 per 1000 person years (Racey et al., 2020).   
 
The impact of HPV vaccination on cervical cancer rates is not yet fully understood. The 
incidence of cervical cancer across all regions of the UK from 2015 to 2017 was 
approximately 10 per 100,000 women per year. Whilst the incidence rates are projected to 
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fall under the continued influence of HPV vaccination, rates are expected to remain at above 
8 per 100,000 women per year until at least 2040 (Castanon et al., 2018). 
 
In the progression from viral infection, through CIN to cervical cancer, rather than a normal 
virus-host relationship in which HPV uses the host DNA replication machinery to propagate 
its life cycle, under certain circumstances viral DNA is integrated into the host genetic 
material. Viral integration represents a pre-cancer event for the host as integration is 
associated with dysregulation of the key E6 and E7 oncogenes resulting in the promotion of 
cell proliferation, checkpoint dysfunction and genetic instability through interaction with the 
gene products of the tumour suppressor genes, TP53 and RB1 (Jeon et al., 1995). The 
resulting clonal expansion of cells with integrated HR-HPV results in the characteristic pre-




Figure 1.2 HPV infection progressing to cervical cancer through pre-invasive disease 
Host factors including age, immunity and smoking status play a role in immune mediated 
virus clearance. Persistence of infection over years leads to the development of invasive 
disease in a small number of women. The risk of progression from CIN II/CIN III to invasive 
cancer is approximately 2% over 10 years. 50% of CIN II lesions may regress spontaneously 




1.3 Cell cycle control and the DNA damage checkpoints 
 
Non-dividing cells are frequently referred to as being in resting- or G0- phase. Dividing cells 
are described as being in one of four observable cell cycle phases at any one time: G1, S, G2 
or M (Figure 1.3). G1 and G2 phases represent periods of growth and biosynthesis in 
preparation for DNA replication or synthesis (S-phase) or cell division (M-phase or Mitosis). 
G1 cells may enter S-Phase and continue the cell cycle, undergo terminal differentiation 
(enter G0) or arrest in G1 in the face of DNA damage at the G1/S DNA damage checkpoint. 
G1 arrest prevents DNA replication in the presence of problematic DNA lesions and allows 
time for DNA repair. G2 cells may also arrest in response to DNA damage at the G2/M DNA 
damage checkpoint. This prevents potentially harmful DNA lesions that have occurred during 
synthesis from being incorporated into the genome of daughter cells following cell division 
(M-phase or mitosis) (Curtin, 2012, Sancar et al., 2004). A further check on the fidelity of the 
cell’s DNA occurs at the intra-S checkpoint.  
 
 
Figure 1.3 Schematic representation of the cell cycle and DNA damage checkpoints. 
The principal signalling pathways to each cell cycle checkpoint are shown. DNA damage is 
signalled to the intra-S and G2/M transition checkpoints mainly via ATR signalling through 
CHK1. The G1/S checkpoint is mainly signalled to via the ATM-CHK2 pathway leading to 
activation of p53. Closely related to the G1/S checkpoint is the pRB controlled G1 restriction 
point. There is some degree of crossover between ATM and ATR signalling to G1/S and G2/M 
checkpoints. Function of G1/S checkpoint is inhibited by interactions of p53 and pRB with 




During S-phase the DNA replication machinery: a complex interplay of helicases, primases 
and polymerases, operating at the replication fork encounters each base in the genome and 
is therefore a sensitive probe for DNA lesions (Lodish H, 2000). Lesions that block the 
progression of replication polymerases result in a stalled replication fork characterised by 
uncoupling of the helicase (unwinding) and polymerase (replication) functions of the 
replication machinery.  Replication fork stalling and the resulting generation of single 
stranded DNA is a powerful indicator of replication stress and inducer of signalling to intra-S 
and G2/M cell cycle checkpoints (Iyer and Rhind, 2017). This signalling occurs principally 
through Ataxia Telangiectasia and Rad3-related (ATR) mediated signalling pathways (Figure 




Figure 1.4 A stalled replication fork resulting from a DNA lesion 
The DNA replication machinery is preceded by helicase unwinding of the dsDNA. In this case 
replication of the leading strand is halted by the lesion on the leading strand template, 
resulting in the presence of ssDNA. The stalled replication fork is characterised by the 
presence of this ssDNA and the uncoupling of the helicase and polymerase functions of the 





1.3.1 p53 and pRB at the G1/S checkpoint 
In addition to its established roles in the detection and repair of DNA double strand breaks 
(Maréchal and Zou, 2013), ataxia telangiectasia mutated (ATM) and its immediate 
downstream kinase, checkpoint kinase 2 (CHK2) play important roles in signalling DNA 
damage to the G1/S checkpoint (Figure 1.3) (Sancar et al., 2004). ATM and CHK2, and to a 
lesser extent ATR and checkpoint kinase 1 (CHK1), directly phosphorylate p53. Accumulation 
of phosphorylated p53 and its action as a transcription factor for p21(CIP1) results in 
increased p21(CIP1) mediated inhibition of the cyclin dependent kinase-2 (CDK2)/cyclinE 
complex. CDK2/cyclinE complex function is crucial the progression of the cell into S-phase 
(Figure 1.5) (Bertoli et al., 2013, Kastan and Bartek, 2004).  
 
Further control of the G1/S transition is exerted by pRB through regulation of the E2F 
transcription factors. During early G1 phase, pRB binding of E2F proteins inhibits 
transcription of S-phase proteins. Phosphorylation of pRB under the influence of activated 
cyclin dependent kinase-4 (CDK4)/cyclinD complex, arising from cyclinD accumulation in 
response to mitogenic stimuli, results in the dissociation of pRB from E2F allowing E2F to 
initiate transcription of S-phase proteins (Molinari, 2000). Accumulation of p21(CIP1) also 
leads to inhibition of CDK4/cyclinD phosphorylation of pRB resulting in reduced E2F activity 
in the presence of DNA damage or replication stress (Dick and Rubin, 2013) A summary of 
the characteristics of the key G1/S cell cycle checkpoint proteins and  their function at the 










Figure 1.5 p53 and pRB at the G1/S cell cycle checkpoint. 
Activation of p53 resulting from phosphorylation by both ATM and CHK2 (and to a lesser 
extent, ATR and CHK1, not shown) results in increased transcription of p21(CIP1) and 
inhibition of CDK2 mediated promotion of transition to S-phase. This pathway interacts with 
the pRB controlled transcription of S-Phase proteins, needed for DNA synthesis by the E2F 





1.3.2 High-risk HPV interaction with p53 and pRB  
The most important feature associated with HR-HPV subtypes is the ability of viral proteins 
E6 and E7 to interact with and disrupt the activity of the tumour suppressor gene products: 
p53 and pRB. The vast majority of cervical cancers express wild-type p53 and pRB and it is 
thought that functional depletion of these proteins by E6 and E7 and the resulting loss of G1 
checkpoint control is key to carcinogenesis in HPV associated cervical cancer (Munger et al., 
1992). The loss of G1/S checkpoint function as a key inducer of cervical squamous carcinoma 
and adenocarcinoma is supported by the observation of mutated p53 and pRb in HPV 






Viral protein E6 interacts with a cellular protein known as E6 associated protein (E6AP). 
Following binding, E6AP catalyses degradation of p53 by multi-ubiquitination. E6AP is a 
prominent member of the HECT (homologous to E6AP C Terminus) E3 ubiquitin ligase family 
(Huibregtse et al., 1995): enzymes which mediate recognition of proteins targeted for 
degradation by the ubiquitin proteasome pathway (Livneh et al., 2016). The exact nature of 
the interaction between E6, E6AP and p53 is not clear, however recent evidence suggests 
that E6 binding of E6AP induces a conformational change in the protein-substrate complex 
allowing p53 access to the catalytic site of E6AP, facilitating ubiquitin transfer (Sailer et al., 
2018). Though low-risk HPV E6 may bind E6AP, the degradation of p53 by activated E6AP 
appears to be an exclusive property of E6 from HR-HPV subtypes (Tommasino et al., 2003, 
Thomas et al., 1999).   
 
Stable complex formation between HPV viral protein E7 and pRB is thought to interfere with 
CDK4/cyclinD phosphorylation of pRB when bound to E2F transcription factors (Songock et 
al., 2017), resulting in reduced free E2F and therefore inhibition of transcription of key S-
phase proteins in late G1 phase. Though this property of E7 appears to be consistent across 
multiple sub-types of human papilloma viruses, the affinity of E7 from low-risk HPV sub-
types for human pRB has been shown to be considerably lower than that for E7 from HPV-16 
and HPV-18, the most commonly identified HR-HPV sub-types detected in cervical cancer 
(Munger et al., 1989). 
 
Deficiency in G1/S checkpoint control by mutation or loss of either p53 or pRB are thought 
to be one of the most common defects in cancer cells (Massague, 2004). These defects, 
however open therapeutic opportunities through manipulation of the S-phase and G2/M 
checkpoints on which the cell has become reliant to prevent mitotic catastrophe (Curtin, 
2012). Targeting the checkpoint kinases ATR, CHK1 and WEE1 on whose function these 
checkpoints rely provides such a therapeutic opportunity. 
 
1.4 The DNA damage response and the ATR-CHK1-WEE1 axis 
DNA damage occurs continuously, with an estimated 104 – 105  lesions per cell per day 
caused by products of normal cell functions (Hoeijmakers, 2001). Endogenous lesions such as 
abasic sites and base transitions, caused by depurination or cytosine deamination, 
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respectively as well as methylations and oxidative lesions account for the majority of these 
(Ciccia and Elledge, 2010).  Environmental DNA damage may also result in a heavy burden 
for the cell through, for example, UV radiation induced pyrimidine dimers and 6-4 
photoproducts (Hoeijmakers, 2001).  
 
As well as the elimination of cells with irrevocably damaged DNA by apoptosis, and 
interruption of the cell’s progression through the cell cycle via activation of DNA damage 
checkpoints (Chapter 1.2), the cell’s response to DNA damage includes the removal of 
lesions through lesion-specific DNA repair pathways (Table 1.2) (Sancar et al., 2004). 
These three interconnected processes are collectively referred to as the DNA damage 
response (DDR). The DNA damage response is characterised by the presence and activity 
of detector, signalling and effector proteins in coordinated pathways that lead to the 
induction of DNA repair and checkpoint engagement. ATR recruitment to sites of DNA 
damage and the subsequent signalling of this damage to the cells DDR machinery is one 
such pathway. The ATR-CHK1-WEE1 pathway not only signals to checkpoint activation, as 
described in Chapter 1.3, but also to a number of DNA repair pathways. The following 
section briefly describes DNA repair pathways. This is followed by an overview of ATR-
CHK1-WEE1 activation, their roles at the intra-S and G2/M cell cycle checkpoint and 
finally, ATR-CHK1 signalling in DNA repair 
 
1.4.1 DNA repair pathways 
A summary of the principal described DNA repair pathways, the lesions that they repair 
and examples of endogenous, environmental and therapeutic inducers of those lesions 
are given in Table 1.3. Replication errors, resulting from mis-incorporation of bases into 
the DNA strand, base deletions or insertions are dealt with by mismatch repair (Jiricny, 
2006). The simplest lesions, resulting from S-adenosyl-methionine (SAM) methylation or 
alkylation of guanine are directly repaired by DNA methyltransferase (MGMT) 
demethylation (Curtin, 2012). Base modifications, reactive oxygen species (ROS)-induced 
oxidation (e.g. 8-OHdG), methylation and deamination (dC to dU) are repaired by base 
excision repair (BER), which includes base removal, SSB generation and the downstream 
 
 14 
pathway of SSB repair. SSBR can also act on frank SSB (e.g .ROS or IR-induced) or 
topoisomerase I-linked lesions (Curtin, 2012, Wallace, 2014).  
 
DNA double strand breaks (DSB) are less numerous though more toxic to the cell than 
SSBs. DSBs also occur as a result of ROS induced damage, directly or through a failure to 
repair SSBs. Therapeutic induction of DSBs commonly occurs through the use of 
topoisomerase II (TOPOII) poisons, or antimetabolites that cause collapsed replication 
forks and ionising radiation (Curtin, 2012). The cell is reliant on two pathways for the 
restoration of DNA integrity in the face of DSBs. Non-homologous end joining (NHEJ) 
accounts for the repair of the majority of lesions in all phases of the cell cycle but 
predominates in G0 and G1 phase (Shrivastav et al., 2008). NHEJ is rapid and not without 
error (Mahaney et al., 2009). In G2 and M-phase, where a template strand of DNA is 
available, DSBs may be repaired by homologous recombination repair (HRR). HRR is a 
highly complex process that results in high fidelity re-synthesis of the damaged segment 
of DNA (Shrivastav et al., 2008).  
 
Platinum exposure results in the formation of bulky DNA adducts, which along with intra-
strand crosslinks, UV induced 6-4 photoproducts (6-4PPs) and damage resulting from 
aromatic hydrocarbon exposure are repaired by the nucleotide excision repair (NER) 
pathway (Marteijn et al., 2014). Along with these helix distorting adducts, exposure to 
platinum agents also results in inter-strand strand crosslinks. NER shares components 
with and contributes to inter-strand crosslink (ICL) repair (Deans and West, 2011). The 
role and contribution of the ATR-CHK1 pathway in DNA repair will be further discussed in 









Table 1.3 Principal described DNA repair pathways, activating lesions and causative agents 
or insults 
Table is derived from Curtin 2012 and gives examples of endogenous and environmental 
agents which may give rise to lesions repaired by the specific DNA repair pathways listed. 
Therapeutic insults refer to commonly used DNA damaging cancer therapies.  
 
1.4.2 ATR-CHK1-WEE1 activation  
ATR is a phosphatidyl inositol 3' kinase-related kinases (PIKK) family member that is closely 
related in structure to ATM, another DNA damage sensing kinase that has considerable 
crossover in signalling function with ATR (Figure 1.3) (Maréchal and Zou, 2013). ATR is 
activated by the presence of single stranded DNA (ssDNA) that arises at stalled replication 
forks (Figure 1.4) or DNA damage repair pathway intermediates such as nucleotide excision 
repair (NER)  intermediates and resected double strand breaks (DSB) (Figure 1.6) 
(MacDougall et al., 2007, Cimprich and Cortez, 2008). The scale of ATR activation may be 
proportional to the amount of ssDNA present, signalled through increasing complexation of 
replication protein-A (RPA) with the exposed ssDNA lengths (Choi et al., 2010).  
 
ATR interacting protein (ATRIP) localises ATR to the ssDNA-RPA complex (Cortez et al., 2001, 
Ball et al., 2007). RPA-ssDNA complexation also results in the RAD-17 mediated recruitment 
of the heterotrimeric ring complex: 9-1-1 comprised of RAD9-RAD1-HUS1. The 9-1-1 complex 
recruits DNA-topoisomerase-2-binding protein-1 (TOPBP1) to the site of DNA damage. The 
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recruitment of TOPBP1 appears to be a crucial step in ATR activation and subsequent 
phosphorylation events (Burrows and Elledge, 2008, Shiotani and Zou, 2009). Following 
activation by TOPBP1, ATR phosphorylates its main effector kinase, checkpoint protein 1 
(CHK1). 
 
ATR activates CHK1 by phosphorylation at two serine residues (S317 and S345) in a claspin 
dependent reaction (Walworth and Bernards, 1996, Walworth et al., 2000, Liu et al., 2000). 
Claspin transiently localises CHK1 to the site of DNA damage following recruitment by 
phosphorylated-RAD17 (Liu et al., 2006, Kumagai and Dunphy, 2000). RAD17 is 
phosphorylated by ATR following ATR localisation at the DNA damage site (Wang et al., 
2006). Following activation, CHK1 dissociates from the nuclear chromatin, signalling the DNA 
damage to ATR-CHK1 dependent checkpoint reactions and DDR pathways (Smits and 





Figure 1.6 ATR recruitment and activation at stalled replication forks and sites of DNA 
damage and repair. 
A: Lesions that activate ATR are stalled replication forks, resected DSBs and NER 
intermediates. All lesions have the presence of ssDNA in common, which complexes with RPA 
and recruits ATR to the lesion via ATRIP. B: The ssDNA-RPA complex also recruits 9-1-1 and 
TOPBP1 to the damage site. TOPBP1 mediated ATR activation results in CHK1 
phosphorylation and activation of the downstream, DDR effects of ATR activation. Figure 
derived from Rundle et al, 2017. 
 
1.4.3 ATR, CHK1 and WEE1 at the Intra-S and G2/M checkpoints. 
Following activation of ATR and CHK1 at sites of DNA damage, during DNA repair or through 
replication stress characterised by stalled replication forks, phosphorylation of CHK1 
substrates may result in arrest in S-phase or at the G2/M transition.  Important CHK1 
phosphorylation targets are WEE1 and the cell division cycle (cdc) proteins: cdc25A and 
cdc25C. WEE1 activation results in direct inhibitory phosphorylation of cyclin dependent 
kinase 1 (CDK1) and CDK2 at threonine14/tyrosine15. CHK1 phosphorylation of cdc25 
phosphatases targets these proteins for degradation, resulting in a reduction in the removal 
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of the inhibitory phosphorylations from CDK1/2. The combined effect is one of a reduction in 
CDK activity (Figure 1.7) (Sorensen and Syljuasen, 2012). 
 
 
Figure 1.7 The regulation of CDK activity by ATR, CHK1 and WEE1. 
CDK phosphorylation at tyrosine 15 results in negative regulation of cell cycle progression at 
the G2/M transition and negative regulation of replication origin firing in S-phase. DNA 
damage or replication stress signalled though ATR activation results in CHK1 phosphorylation 
of WEE1 and the cdc25 phosphatases. Activated WEE1 phosphorylates CDK1/2, inhibiting M-
phase entry and replication origin firing. CHK1 phosphorylation of cdc25A/C targets these 
proteins for degradation, reducing CDK dephosphorylation. 
 
In S-phase, CDK2 activity initiates replication origin firing. Inhibition of CDK2 by 
phosphorylation (maintained through the combined effects of CHK1 mediated inhibition of 
the phosphatase cdc25A and WEE1 kinase activation) therefore reduces the accumulation of 
stalled replication forks and the depletion of nucleotides in the face of DNA lesions that 
prevent replication fork progression (Beck et al., 2012, Parsels et al., 2018). This effectively 
prevents the cell from progressing through S-phase, resulting in S-phase arrest. Active CDK2 
is a key protein in the pathway for the loading of cdc45L and co-factors onto the nuclear 
chromatin and the subsequent binding of helicase and DNA polymerase-a (pol-a) that is 
required for replication initiation (Zheng et al., 2017).  In addition to contributing to the 
inhibition of new replication origin firing, ATR and CHK1 appear to have important roles in 
the stabilisation of stalled replication forks, preventing replication fork collapse and thus 
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further reducing DNA-damage induced replication stress (Paulsen and Cimprich, 2007, 
Friedel et al., 2009).  
 
At the G2/M checkpoint, CHK1 phosphorylation of WEE1 and cdc25C results in inhibition of 
CDK1 through the maintenance of the inhibitory phosphorylation at tyrosine residue 15: 
CDK1(Y15) (Mueller and Haas-Kogan, 2015). Arrest at the G2/M transition prevents entry of 
the cell to mitosis. This action then, prevents either the permanent loss or disruption of 
genetic information through passage to daughter cells, or in the case of major DNA damage, 
immediate mitotic catastrophe (Sorensen and Syljuasen, 2012, Chen et al., 2003, Dai and 
Grant, 2010) A summary of the characteristics of the key G2/M and intra-S cell cycle 
checkpoint proteins and their function through S-phase and at the G2/M transition is given 





Table 1.4 Key cell cycle factors at the intra-S and G2/M DNA damage cell cycle 
checkpoints  
 
1.4.4 ATR, CHK1 and WEE1 in DNA repair 
The removal of DNA lesions and restoration of DNA integrity is performed by discreet DNA 
repair pathways that are largely dependent on the nature of the DNA lesion and therefore, 
the causative insult or DNA damaging agent as described in section 1.4.1 (Table 1.3). Current 
therapies for cervical cancer: platinum chemotherapy and ionising radiation cause different 




In addition to its role in in DNA damage checkpoint reactions, ATR and its associated 
downstream kinase: CHK1 play important roles in a number of DNA repair pathways. These 
include a role for ATR in the regulation of recruitment of key proteins to the Fanconi 
anaemia pathways for inter-strand crosslink repair (Shigechi et al., 2012, Andreassen et al., 
2004) and also to nucleoside excision repair (NER) (Wu et al., 2007). 
 
 
Table 1.5 DNA damaging agents, lesions and repair pathways. 
DNA damaging agents cause distinct DNA lesions that are repaired though specific repair 
pathways. Table derived from Hoeijmakers 2001. 
 
 
ATR, CHK1 and WEE1 are also involved in the regulatory mechanisms of homologous 
recombination repair (HRR), an important repair pathway for lesions associated with both 
cisplatin and ionising radiation (IR) treatment.  ATR phosphorylates and activates the key 
HRR regulatory protein BRCA1 (Tibbetts et al., 2000), whilst CHK1 is involved in the 
recruitment and activation of BRCA2 and RAD51 recombinase (Sorensen et al., 2005) (Figure 
1.8). Cells treated with ATR or CHK1 inhibitors show reductions in HRR function by RAD51 
foci assays in response to hydroxyurea or gemcitabine induced replication stress (Parsels et 
al., 2009, Morgan et al., 2010, Peasland et al., 2011). A coupling of the HRR and checkpoint 
signalling roles of ATR has recently been described. ATR inhibits cyclin dependent kinases 
(CDKs) at the cell cycle checkpoint through phosphorylation of CHK1 and subsequently of 
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WEE1 (section 1.3.2). Evidence now exists to suggest that CDK inhibition also promotes HRR 





Figure 1.8 Simplified schematic diagram of the role of ATR, CHK1 and WEE1 in 
homologous recombination repair (HRR). 
 BRCA1 phosphorylation by ATM and ATR is a key step in the initiation of HRR. ATR further 
promotes HRR function through activation of CHK1, which has a role in the recruitment and 
activation of BRCA2. BRCA2 is necessary for RAD51 recruitment. CHK1 activation of WEE1 






1.5 ATR, CHK1 and WEE1 inhibitors 
1.5.1 Target validation by genetic downregulation 
Homozygous disruption of ATR or CHK1 or WEE1 is incompatible with life at an early 
embryonic stage, highlighting the importance of the pathway (Brown and Baltimore, 2000, 
Takai et al., 2000). Seckel syndrome, a human genetic condition caused by reduced 
expression of ATR secondary to a hypomorphic mutation of the ATR gene is characterised by 
growth retardation and microcephaly, but not increased carcinogenesis (O'Driscoll et al., 
2003). Kinase-dead ATR cells, where an inactive form of the kinase acts as a negative 
inhibitor to native ATR function have been shown to be sensitive to DNA damaging agents 
(Cliby et al., 2002, Nghiem et al., 2001) including IR and platinum and failed to arrest at the 
G2/M checkpoint (Cliby et al., 1998).  
 
CHK1 knockdown by small interfering RNA (siRNA) or short hairpin RNA (shRNA) also 
sensitises cells to a variety of DNA damaging agents (Carrassa et al., 2004, Flatten et al., 
2005, Ganzinelli et al., 2008, Pan et al., 2009, Azorsa et al., 2009). However, unlike ATR 
knockdown, the results are less convincing for sensitisation of platinum agents: for example, 
CHK1 downregulation failed to sensitise HCT-116, HeLa or U2OS cells to cisplatin (Wagner 
and Karnitz, 2009). Genetic downregulation or knockdown of WEE1 has been reported to 
increase cell susceptibility to DNA damage by exogenous DNA damaging agents and also to 
result in increased apoptotic cell death in p53 deficient cervical cancer cell lines through 
G2/M checkpoint abrogation (Pappano et al., 2014, Wang et al., 2004), though studies are 
fewer in number than those for ATR and CHK1. 
 
It has been suggested that the downregulation of ATR, CHK1 or WEE1 sensitises p53 
deficient cells to a greater extent than cells with normal p53 function (Pan et al., 2009, 
Ganzinelli et al., 2008) and that targeting the ATR-CHK1-WEE1 pathway would lead to 
greater effects in p53-mutant tumours. However, this has been contradicted in some 
studies: siRNA downregulation of ATR has been observed to be equally efficacious as a 
sensitiser of U2OS p53-wild type and HeLa p53-defective cells to the topoisomerase I 
poisons camptothecin and SN-38 (Flatten et al., 2005). In addition, CHK1 downregulation by 
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siRNA caused similar sensitisation of paired p53-wild type and p53-defective U2OS cells to 
irinotecan and cisplatin (Zenvirt et al., 2010). Furthermore, in U2OS cells with G1-checkpoint 
deficiencies caused by other abnormalities (cyclin D1, cyclin E1, MDM2 or CDK2 
overexpression or infection by HPV) ATR knockdown resulted in sensitisation to DNA damage 
that was reversed by p21 or p27 induced expression (Nghiem et al., 2001). Overall, it is likely 
that G1/S checkpoint deficiency, rather than p53 status is a key determinant of sensitivity to 
downregulation of ATR, CHK1 or WEE1 function. A similar pattern of results is seen when the 
enzymes are inhibited by specific, potent small molecule inhibitors. 
 
 
1.5.2 Development of ATR, CHK1 and WEE1 inhibitors 
The potent and selective kinase inhibitors targeting ATR, CHK1 and WEE1 that have been 
developed for clinical use (listed in Table 1.6) are reversible, ATP competitive inhibitors. 
These molecules bind to the target principally through hydrogen bond formation between 
the inhibitor molecule and residues within the ATP binding pockets of the kinases (Knight 
and Shokat, 2005). A common feature of the inhibitor molecules is a hydrophobic tail which, 
following binding interacts with the catalytic sites on the enzyme. This interaction prevents 
conformational changes that are required for activation and cycling of the target enzyme 
(Roskoski, 2015). 
 
Early inhibitors of ATR and CHK1, such as UCN-01 were initially developed with other targets 
in mind and consequently showed poor selectivity and potency against these enzymes 
(Senderowicz, 2000). More recently, potent and selective inhibitors have been developed, 
though the development of WEE1 inhibitors has lagged behind that of ATR and CHK1 
inhibitors. A number of these compounds, with a focus of those for which significant pre-
clinical data is available are detailed in Table 1.3 and their development is described herein.   
 
ATR inhibitor development 
Caffeine was amongst the first natural product observed to inhibit ATR, sensitising cells to 
UV induced DNA damage (Sarkaria et al., 1999). However, other DDR enzymes including ATM 
and DNA protein kinase catalytic subunit (DNA-PKcs) are also inhibited by caffeine and its 
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potency against ATR is much less than that seen for more modern inhibitors (ATR IC50 = 1.1 
mM). Schisandrin B was another naturally occurring compound that was identified as a 
potent ATR inhibitor (ATR IC50 = 7.3 µM). It is much more specific for ATR than caffeine 
making abrogation of UV induced G2/M checkpoint induction much more readily 
attributable to inhibition of ATR (Nishida et al., 2009).  
 
Amongst the first novel compounds, NU6027 was found to be a more potent inhibitor of ATR 
than of its intended developmental target, CDK2 (Peasland et al., 2011). The first highly 
specific and potent ATR inhibitor identified with this target in mind was ETP-46464, which 
was identified by screening a pool of PI-3K inhibitors (likely to be enriched for ATR inhibitors 
due to the similarities between the two PIKK enzyme family members), utilising a screening 
platform specific for ATR inhibition (Toledo et al., 2011). Poor pharmacokinetics, however 
prevented its development into a clinical candidate.  
 
Further ATR specific screening assays enabled the identification of precursors to the related 
aminopyrazine compounds VE-821 and VE-822 (Charrier et al., 2011, Fokas et al., 2012). 
Both compounds show >100-fold selectivity for ATR versus other DDR kinases such as ATM 
and DNA-PKcs and have extensive pre-clinical data related to them in anti-cancer 
investigations. Favourable toxicological profiles and pre-clinical in vivo performance have led 
to VE-822 being introduced into clinical trials as VX-970 (Fokas et al., 2012, O'Carrigan B, 
2016). Another screen using compounds with structural similarities to known PIKK inhibitors 
led to the development of a series of morpholone compounds into AZ20 (Foote et al., 2013) 
and AZD6738 (Vendetti et al., 2015). AZ20 development was limited by its poor aqueous 





Table 1.6 Potent and specific small molecule inhibitors of ATR, CHK1 and WEE1. 
Inhibitors for which there is considerable pre-clinical data available are given, along with the 
chemical group to which they belong and data supporting their specificity for the target 






CHK1 inhibitor development 
Structure based drug design led to the development of AZD7762 from a thiophene 
carboxamide urea compound identified in high throughput screening (Oza et al., 2012). Like 
the similarly developed compound, V158411 (Massey et al., 2015) these small molecule 
inhibitors show dual CHK1 and CHK2 inhibitor activity with greater CHK1 selectivity in cell-
based assays. Truly selective CHK1 inhibitors were first seen with the development of PF-
477736 (Blasina et al., 2008) and the pyrazole compound SCH900776 (now known as MK-
8776) (Guzi et al., 2011), which show a 100-fold and 500-fold selectivity for CHK1 over CHK2, 
respectively (Matthews et al., 2013). Extensive pre-clinical data is available for both drugs 
though detailed descriptions of their development are limited.  
 
A number of pyrazine compounds have been developed and described as potent and specific 
inhibitors of CHK1: high throughput and virtual screening for fragment hits, followed by 
structure-based drug design led to the development of CCT244747 and CCT245737 (Walton 
et al., 2012, Walton et al., 2016). These compounds show over 1000-fold selectivity for CHK1 
over CHK2 and were the first orally bioavailable CHK1 inhibitors. CCT245737 has now 
entered clinical trials as SRA-737. A further pyrazine derived compound, LY2603618 and its 
follow-on drug LY2606368 also show >1000-fold selectivity for CHK1 and the latter has also 
entered clinical trials (King et al., 2014, Hong et al., 2016).  
 
WEE1 inhibitor development 
The development of clinically promising WEE1 inhibitors has been hindered by difficulties in 
establishing target specificity. Early WEE1 inhibitors such as the pyrido-pyrimidine derivative, 
PD0166285 or the pyrolo-carbazole derivative, PD0407842 were potent (WEE1 IC50 < 100 
nM) but non-selective. These compounds showed significant interference with other DDR 
targets such as MYT1 and CHK1 (Panek et al., 1997, De Witt Hamer et al., 2011). MK-1775 is 
a pyrazolo-pyrimidine derivative that is the first and so far, only potent selective inhibitor of 
WEE1 that has shown promise as a clinical candidate (Mizuarai et al., 2009, Hirai et al., 
2009). Now known as AZD1775 or its commercial name: Adaversotib, it has been taken 
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forward into clinical trials and used in combinations including with platinum agents (Pilie et 
al., 2019). 
 
1.6 Single agent activity and determinants of sensitivity for inhibition of the 
ATR-CHK1-WEE1 axis 
1.6.1 Oncogene driven replication stress as a sensitiser to ATR, CHK1 or WEE1 
inhibition 
Whilst much attention is focussed on the ability of these potent and specific inhibitors of 
ATR, CHK1 and WEE1 to potentiate the cytotoxic effects of existing genotoxic chemotherapy 
treatments (section 1.6), investigations of the potential for existing characteristics of cancer 
cells to act as determinants of sensitivity are also described. Oncogene transformations, with 
particular focus on those which promote S-phase entry or result in increased levels of 
replication stress through loss of control of the G1/S cell cycle checkpoint have been shown 
to promote sensitivity to inhibition G2/M checkpoint manipulation by ATR-CHK1-WEE1 axis 
inhibition. A summary of this evidence is presented in Table 1.7.  
 
Whist the oncogene transformations that are detailed in Table 1.7 are rarely present in 
cervical cancer cells, the evidence presented supports the hypothesis that inhibitors of ATR, 
CHK1 and WEE1 are a potentially effective strategy as single agents against cervical cancer 
cells rendered G1/S checkpoint deficient through p53 or pRB insufficiency either by HPV 





Table 1.7 Studies describing replication stress inducing transformations that promote S-
phase entry that evidence potential synthetic lethality with ATR, CHK1 or WEE1 
inhibition. 
 The Oncogene is the mutation or transformation which renders the cell susceptible to ATR, 
CHK1 or WEE1 inhibition. The sensitiser is the mode of ATR, CHK1 or WEE1 inhibition or 
silencing used. ATRi = small molecule ATR inhibitor, CHK1i = small molecule CHK1 inhibitor 
and WEE1i = WEE1 small molecule inhibitor. (Murga et al., 2011, Gilad et al., 2010, Vendetti 
et al., 2015, Toledo et al., 2011, Morgado-Palacin et al., 2016, Williamson et al., 2016, Chen 





1.6.2 DDR abnormalities as determinants of sensitivity to ATR, CHK1 or WEE1 
inhibition. 
Exploiting the concept of synthetic lethality for cancer treatment is well described. In its 
simplest form, the simultaneous alteration of the function of two genes or proteins that, in 
isolation are not essential for cell viability, causes cell death. In the case of cancer treatment, 
if one of these genes represents an oncogene, tumour suppressor gene or oncogenic 
process/pathway that is dysfunctional in the cancer cell, the other may become a candidate 
for inhibition or knockdown. The result of endogenous dysfunction of one gene product plus 
inhibition of the other would result in selective killing of the cancer cell (Curtin, 2012, Lord 
and Ashworth, 2017). 
 
The most commonly cited example of therapeutic synthetic lethality is the use of poly (ADP-
ribose) polymerase (PARP) inhibitors (PARPi) to selectively kill cells that are HRR defective 
(Bryant et al., 2005, Farmer et al., 2005). The enzyme PARP1 is an essential component of 
the cell’s response to endogenous or therapy induced SSB. PARP1 binding to DNA induces its 
catalytic function. This function synthesises negatively charged poly (ADP-ribose) chains on 
target proteins (PARylation), which acts as a recruitment signal for DNA repair effector 
proteins. Dissociation of PARP1 from the site of DNA damage occurs following auto-
PARylation (Eustermann et al., 2015), however PARPi function to disrupt auto-PARylation, 
trapping PARP1 on the DNA double helix (Pommier et al., 2016). The result is disruption of 
PARP1 catalytic function, as well as the inability of the cell to process the DNA-PARP1 
complex at the replication fork. Resolution of this lesion requires HRR function, involving 
BRCA1 and BRCA2 tumour suppressor genes. In cells that have defective BRCA1/2, HRR is 
also dysfunctional, leading to the inability to resolve the replication fork lesion and cell death 
(Lord and Ashworth, 2017). 
 
ATR and CHK1 are crucial to the functioning of HRR and inhibition of these kinases has been 
shown to convey synthetic lethality in cells lacking BER function through knockdown of x-ray 
cross-complimenting protein 1 (XRCC1) in a reversal of the situation described for PARP 
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inhibitors (Peasland et al., 2011, Sultana et al., 2013, Middleton et al., 2015). Defects in BER 
are relatively common in cancers and exploiting this through ATR pathway inhibition is a 
therapeutic option. Defects in HRR itself have also been shown to confer sensitivity to ATR, 
CHK1 and WEE1 inhibition: Chinese hamster ovary cells with inactivated XRCC3 or BRCA2 
(both of which are involved in recruitment and function of RAD51 to HRR) resulted in 
increased sensitivity to the ATR inhibitor, VE-821 and inhibition of RAD51 itself conferred 
sensitivity to VE-821 and the CHK1 inhibitor AZD7762 (Middleton et al., 2015, Krajewska et 
al., 2015). In an siRNA screen for determinants to sensitivity to the WEE1 inhibitor MK-1775, 
HRR genes including RAD51,BRCA1 and BRCA2 increased sensitivity in short survival assays 
but validation in clonogenic survival assays was hindered by the effects of silencing the HRR 
genes themselves on cell viability (Aarts et al., 2015).  
 
Other DNA repair related determinants of sensitivity to ATR and CHK1 inhibition include 
disruptions in non-homologous end joining (NHEJ), Fanconi anaemia (FA) and nucleotide 
excision repair (NER) pathways. Knockdown of the key nucleotide excision repair (NER) 
enzyme: excision repair cross-complimenting protein 1 (ERCC1) and its co-factors has been 
shown to render cells sensitive to ATR and CHK1 inhibition, though the validity of this as a 
therapeutic strategy for NER deficient cancers is unclear as inactivation of other NER 
enzymes did not increase sensitivity to ATR or CHK1 inhibition (Mohni et al., 2014).  
 
The NHEJ heterotrimer DNA protein kinase (DNA-PK) consists of the catalytic sub-unit DNA-
PKcs, Ku70a and Ku80. High levels of DNA-PKcs expression have been correlated with 
sensitivity to ATR and CHK1 inhibition. In contrast to this, Ku80 depletion was observed to be 
associated with sensitivity to ATR inhibition with VE-821 (Middleton et al., 2015). 
Interestingly pRB has been reported to have a role in Ku protein stabilisation within the 
DNAPK complex in addition to its role in the G1/S cell cycle checkpoint (Cook et al., 2015, 
Huang et al., 2015). This may be an important factor when considering the sensitivity of 
cervical cancer cells to ATR inhibition given the effects of HR-HPV protein E7 on pRB 
function.  
 
Isogenic cell line pairs differing in FA pathway function alone were differentially sensitive to 
pharmacological CHK1 inhibition with UCN-01 and another early CHK1 inhibitor GO6976, 
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with FA deficient cells showing the greater sensitivity. Confirmation that this relationship 
was valid in vivo was achieved using pharmacological CHK1 inhibition in FANCD2 knockdown 
zebra fish embryos (Chen et al., 2009). Knock down of FA pathway genes FANCM and BRIP1 
also sensitised a variety of human cancer cell lines to WEE1 inhibition with MK-1775 (Aarts 
et al., 2015). 
 
Finally, due the complimentary functions and close relationships between ATR and ATM in 
the DDR, it has been suggested that ATM deficiency may prove to be synthetically lethal with 
ATR inhibition. ATR inhibition by AZD6738 and VE-821 has shown selective cytotoxicity in 
ATM deficient cells and this was further confirmed in ATM deficient chronic lymphocytic 
leukaemia (CLL) xenografts (Kwok et al., 2016, Middleton et al., 2015). The mechanism of 
ATRi cytotoxicity in ATM deficient cells is proposed to involve a loss of ATM stimulated HRR 
function, and therefore reduced ablity of the cell to resolve lesions arising from collapsed 
replication forks that result from the replication stress induced by ATR inhibition. 
Additionally, the combined loss of cell cycle control that results from defective or impaired 
ATR/CHK2 and ATM/CHK1/p53 pathways is likely to compound the sensitivity of the ATM 
deficient cell to ATR inhibition (Kwok et al., 2016).  
 
1.7 Pre-clinical data: chemo-sensitisation and radio-sensitisation  
Potent and selective inhibitors of ATR, CHK1 and WEE1 have been developed as outlined in 
the previous sections. These drugs have been extensively investigated with respect to their 
single agent cytotoxicity and as sensitisers of DNA damaging chemotherapy agents and IR 
(Rundle et al., 2017, Pilie et al., 2019). The following sections review the literature that 
describes the effects of these drugs for sensitising cancer cells, in-vitro and in vivo, with 
particular reference to potentiation of existing standard of care treatment in cervical cancer: 
platinum-based chemotherapy and IR. 
 
1.7.1 Combinations with platinum chemotherapy agents 
ATR inhibitors 
ATR is activated by the single-stranded DNA fragments that arise from NER intermediates 
and at stalled replication forks, both of which arise as a result of inter- and intra-strand 
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crosslinks caused by platinum agents. ATR is also a key enzyme in the FANC/HRR DNA repair 
pathways that resolve inter-strand crosslinks, which also arise following platinum treatment 
(Eastman, 1990, Siddik, 2003, Demarcq et al., 1994). It is not surprising then, that 
potentiation of platinum agents by ATR inhibitors is widely reported. Caffeine mediated 
potentiation of cis-platin cytotoxicity through ATR inhibition and abrogation of the G2/M 
checkpoint was one of the earliest observations made regarding prototype ATR inhibitors 
(Roberts and Kotsaki-Kovatsi, 1986, Yazlovitskaya and Persons, 2003) and was a precursor to 
investigations using the more selective, specifically developed inhibitors.  
 
The potent and selective ATR inhibitor, VE-821 caused a 10-fold potentiation of cisplatin 
cytotoxicity in p53-mutant or ATM deficient human colon cancer cells and showed 
synergistic activity in ATM-null fibroblasts in combination with cisplatin (Reaper et al., 2011, 
Teng et al., 2015). VE-822 (VX-970) showed promise as a potentiator of cisplatin in lung 
cancer cells with similar results seen in gemcitabine-VX-970 combinations (Hall et al., 2014). 
In this study, p53 deficient cells again showed the greatest potentiation of cisplatin by VX-
970 but a significant potentiation was also seen with AZD6738 in a further panel of non-
small cell lung cancer (NSCLC) cell lines with other DDR abnormalities including ATM 
deficiency and K-ras mutation (Vendetti et al., 2015). ETP-46464 increased the cytotoxic 
effects of cisplatin in a range of gynecological cancer cell lines including those derived from 
ovarian, endometrial and cervical cancers. These results were independent of p53 status 
(Teng et al., 2015).   
 
VE-822 and AZD6738 have shown promise with respect to anti-tumour performance in vivo 
in combination with platinum, underlying their progression to clinical trials. VE-822 
significantly enhanced the efficacy of cisplatin in mice xenograft models of lung cancer 
including complete tumour growth inhibition in three platinum insensitive models (Hall et 
al., 2014). Additionally, a complete response to combination treatment was observed in a 
cisplatin sensitive tumour, which was sustained for three weeks following cessation of 
treatment. AZD6738 combinations with cisplatin also resulted in significant tumour growth 
delay in NSCLC xenograft models in which neither AZD6738 nor cisplatin monotherapy was 
effective (Vendetti et al., 2015). No significant increase in toxicity was observed in these 





There is inconsistency in the reported effects of CHK1 inhibitors as a strategy for 
potentiating platinum induced cytotoxicity and it is suggested that CHK1 activity is not 
required for resistance to cisplatin (Wagner and Karnitz, 2009). The CHK1/2 inhibitor 
AZD7762 reversed cisplatin resistance in a panel of p53 mutant NSCLC cell lines (Bartucci et 
al., 2012) and the same drug also reversed cisplatin resistance in a panel of clear cell ovarian 
cancer and p53 mutant head and neck squamous cell cancer (HNSCC) cell lines (Itamochi et 
al., 2014). AZD7762 also potentiated cisplatin toxicity in neuroblastoma cells lines that were 
G1 checkpoint deficient due to MDM2 amplification or p14 deletion as well as in p53 
mutated cases. In this study, an effect was not seen in G1 checkpoint proficient cell lines (Xu 
et al., 2011).  
 
In contrast to the above examples, MK-8776 failed to sensitise p53 mutated triple negative 
breast cancer (TNBC) cells to cisplatin (Montano et al., 2012) and whilst V158411 
potentiated the effects of platinum agents in a number of cell line panels in a p53 dependent 
manner, the effects were substantially less than those reported in the same studies for 
gemcitabine potentiation (Bryant et al., 2014).  
 
Perhaps due to the mixed results observed for CHK1 inhibitor potentiation of cisplatin, in 
vivo xenograft data is less extensive than for ATR inhibitors. Studies with AZD7762, however 
showed some encouraging results. Co-treatment of xenograft models of ovarian clear cell 
cancer showed with cisplatin and AZD7762 resulted in greater inhibitory effects than with 
cisplatin alone (Itamochi et al., 2014) and the same drug was also shown to significantly 
enhance tumour growth reduction versus cisplatin alone in a variety of NSCLC models with 




Fewer reports exist of WEE1 inhibitors in combination with cisplatin or carboplatin. Much of 
the literature concerned with WEE1 potentiation of genotoxic agents focussed on 
combinations with anti-metabolites such as gemcitabine or cytarabine, where a p53 
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dependent sensitisation has been reported across a number of human cancer cell lines 
including in cervical cancer cell lines (Matheson et al., 2016). MK-1775 has, however been 
observed to potentiate cisplatin in medulloblastoma cells (Harris et al., 2014) and also 
increased sensitivity to cisplatin in combination with shRNA p53 knockdown in ovarian 
cancer cells, with no effect seen in cells with intact p53 (Hirai et al., 2009).  
 
In vivo, MK-1775 potentiated carboplatin in cervical cancer xenografts and showed a 
reduction in tumour growth when combined with cisplatin in murine models of ovarian 
cancer (Hirai et al., 2009). As with the data for ATR and CHK1 inhibition, combinations with 
platinum agents do not appear to significantly alter the toxicity profiles compared to 
platinum treatment alone in these models and at the doses or concentrations used.  
 
 
1.7.2 Combinations with ionising radiation 
Ionising radiation, usually in combination with cisplatin is the most important treatment 
modality for locally advanced cervical cancer. IR causes a variety of DNA lesions (Table 1.2) 
that are potent inducers of the ATR mediated DNA damage response reactions. As such, 
ATR, CHK1 and WEE1 inhibitors have all been shown to be effective sensitisers of IR effects 
on tumour cells, in-vitro and in vivo. 
 
ATR inhibitors 
VE-821 has been shown to increase cell killing in combination with IR in a variety of human 
cancer cell lines, including those derived from cervical cancer, TNBC, HNSCC and colon 
cancer (Zhang et al., 2016, Pires et al., 2012).  Following successful potentiation of IR in 
pancreatic cancer cells in-vitro, VE-822 enhanced tumour growth delay of both single 
fraction and fractionated IR in pancreatic ductal carcinoma xenografts without increasing 
toxicity (Fokas et al., 2012). Reports also suggest that VE-821 sensitised cancer cells to IR 
under hypoxic conditions. Treatment of hypoxic cells (often associated with large, solid 
organ tumours such as that found in cervical cancer) is often difficult due to their aggressive 
phenotype and tendency to chemo- and radio-resistance (Bristow and Hill, 2008). However, 





The dual CHK1/2 inhibitor AZD7762 caused p53 dependent radio sensitisation of 
glioblastoma, colon, lung, and pancreatic cancer cell lines in clonogenic assays (Mitchell et 
al., 2010). Conversely, other studies demonstrate sensitisation by AZD7762 of a large 
number of human cell lines to IR independent of p53 status (Yang et al., 2011, Dillon et al., 
2017). In contrast to these results neither AZD7762 or the CHK1 specific inhibitor LY2603618 
sensitised a range of radio-resistant cell lines with high levels of DDR protein and oncogene 
expressions to IR (Zhang et al., 2016). However, both drugs suppressed growth of the radio-
resistant cell lines when used as single agents, but not their radio-sensitive parental cells, 
supporting evidence for CHK1 inhibition as a therapeutic strategy for cells with high levels of 
endogenous replication stress (see Chapter 1.5.1).  
 
The in vivo performance of CHK1 inhibitors as a sensitiser of IR mirrors the results of in-vitro 
reports. AZD7762 prolonged survival in mouse models of lung cancer metastases (Yang et al., 
2011) and more than doubled tumour growth delay following fractionated IR in colorectal 
cancer xenografts (Mitchell et al., 2010). 
 
WEE1 inhibitors 
Whilst there are fewer reports of WEE1 radio-senstisation, results of MK-1775 combinations 
with IR appear to be positive. MK-1775 has sensitised high grade glioma (HGG) cells to IR in-
vitro and this translated into a significant survival advantage for mice bearing HGG 
xenografts treated with the combination over those treated with IR alone (Mueller et al., 
2014). As with ATR and CHK1 inhibitors, there are reports of p53 dependent sensitisations 
that are likely to represent the importance of G1/S checkpoint deficiency rather that p53 
mutated status specifically: a p53-defective panel of human lung, prostate and breast cancer 
cell lines showed sensitisation by MK-1775 to IR but no effect was measured in wild-type 




1.8 ATR, CHK1 and WEE1 inhibitors in clinical practice 
Four ATR inhibitors are currently undergoing clinical trials and have shown anti-tumour 
activity as single agents and in combination with other chemotherapy drugs. Amongst these 
are VE-822 (VX-970) and AZD6738, for which a description of the available pre-clinical data is 
given in sections 1.5 and 1.6 have been tested in combinations with platinum chemotherapy 
agents and have available results. VE-822 (as M6620) showed good tolerability as a single 
agent and achieved a complete response (CR) in patient with metastatic colorectal cancer 
that showed 100% ATM loss on immunohistochemistry (O'Carrigan B, 2016). AZD6738 
monotherapy appeared to be less well tolerated with bone marrow suppression observed 
with continuous dosing schedules. However, two partial responses (out of 26 enrolled 
patients) were observed in patients with advanced solid organ tumours (Dillon, 2017).  
 
Combinations with either VX-970/M6620 or AZD6738 have proved to be more problematic 
with respect to dose limiting toxicities, particularly in relation to bone marrow suppression. 
Despite frequent dose delays and interruptions due to neutropenia, a phase 1 trial, which 
combined VX-970 with carboplatin in 15 patients saw a sustained partial response in one 
patient and stable disease maintained in 8 others over 6-months (O'Carrigan B, 2016). 
Furthermore, in another cohort, combinations of VX-970 with cisplatin showed anti-tumour 
activity in patients with previously platinum resistant or refractory disease (Shapiro, 2016). 
AZD6738 combinations with carboplatin have resulted in 3 three observed partial responses, 
two of which were in patients with ATM deficient tumours (ovarian clear cell cancer and 
colorectal cancer) (Yap, 2016). 
 
Trials of CHK1 inhibitors as single agents and in combinations with other chemotherapy 
drugs have been hampered by severe dose limiting toxicities including bone marrow 
suppression, cardiotoxicity and severe thrombo-embolic events (Pilie et al., 2019). Three 
CHK1 inhibitors are currently undergoing clinical trials, including LY2602638 (Prexasertib) 
and CCT245737 (SRA737). A phase II trial of Prexasertib has demonstrated tumour responses 
in 5 out of 22 patients with advanced BRCA wild-type high grade serous ovarian cancer 
(HGSOC) (Lee, 2016). This result is notable due to the high frequency of p53 mutation 




The only selective WEE1 inhibitor to enter trials is AZD1775 (MK-1775). The progress of this 
drug through trials has been hampered by the need for unconventional dosing schedules 
dictated by cumulative toxicity effects. A phase I study has reported a PR in two out of 25 
patients, both of whom had BRCA-2 mutant tumours. However, given the pre-clinical data 
that suggests a strong selectivity for response to WEE1 inhibition in p53 deficient tumours, 
none of the p53 mutant tumours in this trial responded to AZD1775 therapy (Do et al., 
2015). However, a phase II trial reported that addition of AZD1775 to carboplatin and 
paclitaxel chemotherapy in 122 patients with advanced p53-mutant ovarian cancer resulted 
in an increase in progression free survival (Oza, 2015). Another Phase II trial reported a 
greater overall response rate in p53 mutant vs p-53 null-type tumours (Leijen et al., 2016). 
 
1.9 Aims and Objectives: 
Cervical cancer is associated with HR-HPV infection, and the E6 and E7 viral proteins are 
responsible for p53 degradation and inactivation of pRb, thereby abrogating the G1 
checkpoint in a similar manner to cells with pathogenic mutations in p53 and pRB. 
Inhibition of the intra-S and/or G2/M checkpoint with an ATR, CHK1 or WEE1 inhibitor 
may therefore selectively sensitise cervical cancer cells with dysfunctional G1 control to 
DNA damaging agents (e.g. IR and cisplatin). Furthermore, data indicates that DNA-PKcs 
overexpression and ATM deficiency are potential determinants of sensitivity to ATR-CHK1 
pathway inhibition and therefore may render cells more sensitive to ATR, CHK1 and 
WEE1 inhibition alone or in combination with IR and cisplatin. The aim of this work was 
(i) to directly compare ATR, CHK1 and WEE1 inhibitors for their ability to kill cervical 
cancer cells and to chemo- and radio-sensitise these cells, (ii) identify determinants of 
sensitivity and (iii) to explore the underlying mechanisms.  
 
Hypotheses to be tested: 
1. The cervical cancer cell lines will display a spectrum of sensitivity to cisplatin and IR 
as well as ATR, CHK1 and WEE1 inhibitors alone that will be related to the expression 




2. ATR, CHK1 and WEE1 inhibitors will sensitise cervical cancer cells to IR and cisplatin 
and that sensitisation will be dependent on HR-HPV and p53/pRb status and 









2 Materials and Methods 
 
2.1 General laboratory practice 
All experiments were performed to Newcastle University standards for safe working 
regulations and with adherence to the Control of Substances Hazardous to Health (CoSHH) 
and Biological CoSHH (BioCoSHH) regulations. Culture of live cell line material was conducted 
in a class II biosafety cabinet within in a dedicated tissue culture laboratory.  
 
2.2 Chemicals and Reagents 
Unless stated otherwise, chemicals and reagents were purchased from Sigma-Aldrich (Poole, 
Dorset UK). Cisplatin (cis-Diammineplatinum(II) dichloride) stock solution was prepared by 
dissolution in sterile 0.9% w/v sodium chloride (NaCl) solution at 1 mM, filter sterilised 
through a 0.2 micron filter, aliquoted and stored at -20 °C. All inhibitors were purchased 
from Selleckchem.com. (Houston, Texas USA). A stock solution of VE-821 (ATR inhibitor) was 
prepared by dissolution inflame sealed, sterile dry dimethyl-sulfoxide (DMSO) from flame-
sealed vials at 20 nM, aliquoted and stored at -80 °C. Stock solutions of PF-477736 (CHK1 
inhibitor) and MK-1775 (WEE1 inhibitor) were prepared by dissolution in dry DMSO at 10 
mM, aliquoted and stored at -80 °C. 
 
2.3 Cell Culture 
Six human cervical cancer cell lines were used: HeLa; SiHa; C33A; CaSki; ME-180; and HT-3. 
Cell lines were purchased from the American Type Culture Collection (ATCC) cell biology 
collection and authenticated by short tandem repeat (STR) profiling according to 
institutional protocols. Cells were stored under liquid nitrogen at -190 °C. For experimental 
use, cells were thawed and transferred to 25 cm2 tissue culture flasks in cell specific growth 
media containing 2 mM L-glutamine and 10% v/v foetal bovine serum (FBS) (table 2.1). Cells 
were then incubated at 37 °C, 5% CO2 and 95% humidity. Growth medium was changed after 
24 hours, once the cells were observed to have adhered to the bottom of the culture flask. 
When the cells reached 60% confluence, they were harvested: cells were washed twice with 
10 ml sterile phosphate buffered saline (PBS) and incubated in 10% Trypsin-
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ethylenediaminetetraacetic acid (trypsin-EDTA) for 5-10 minutes until they were observed to 
have detached from the flask. Cells were then resuspended in full culture medium to 
neutralise the trypsin and seeded into 75 cm2 tissue culture flasks for ongoing culture.  
 
Continuous cell culture was maintained by serial passage of cells at 60% – 80% confluence to 
maintain exponential growth. Cells were used for experiments at post-authentication 
passage number 30 or less to limit the effects of genetic drift that can occur at high passage 
numbers. Cells were passaged at least once following thawing and prior to use. For 
experimental use, cultured cells were harvested as outlined above. Early passage, 
exponentially growing cells were frozen for future use in 2 ml aliquots of 1 - 2 x 106 cells/ml 
and in cell specific freezing medium (cell specific growth medium with 10% FBS and 10% 
DMSO). Cells in freezing medium were immediately frozen at -80 ºC for 24 hours prior to 
transfer to storage under liquid nitrogen.  
 
To avoid cross contamination, one cell line and corresponding dedicated media and reagents 
were handled exclusively at any one time within the biosafety cabinet. The cabinet was 
cleaned thoroughly with 70% ethanol between experiments using different cell lines. All 
media was prepared in aseptic conditions, sterility checked, stored at 4 °C and warmed to 37 
°C prior to use. All continuously cultured cells lines were regularly tested for mycoplasma 






Cell line Growth medium 
HeLa 
EMEM +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
SiHa 
EMEM +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
C33A 
EMEM +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
CaSki 
DMEM +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
ME-180 
RPMI +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
HT-3 
RPMI +2 mM L-glutamine, 10% FBS,  
100 IU/ml penicillin and 100 ug/ml streptomycin 
Table 2.1 Human cervical cancer cell lines used and their specific growth media for 
continuous culture. EMEM = Eagle’s Minimum Essential Medium, DMEM = Dulbecco’s 
Modified Eagles Medium, RPMI = Roswell Park Memorial Institute (medium), FBS = Fetal 










2.4 SRB assay 
The Sulforhodamine B (SRB) assay relies on the stoichiometric binding of SRB dye to cell 
proteins under mildly acidic conditions. The dye is then solubilised into a defined volume of 
basic solvent. This produces a dye concentration that is directly proportional to the cell mass 
being measured. Measurement of absorbance at wavelength 510 nM then allows for 
estimation of the quantity of cell material present (Skehan et al., 1990). 
 
2.4.1 Determination of cell line growth rate by SRB assay 
Cell preparation and fixation 
Exponentially growing cells were harvested as described in section 2.3, above at 60% 
confluence and seeded into five rows of six separate 96-well plates in 100 µl full growth 
medium per well. Each row of an individual 96-well plate contained cells seeded at a 
different seeding density ranging from 6.75 x103 cells/well to 1.0 x 105 cells/well to allow for 
selection of the optimal seeding density for each cell line, as shown in figure 2.1. Cells were 
incubated at 37 °C and allowed to adhere to the bottom of the wells for 24 hours prior to 
fixation of the first plate: the ‘Day 0 plate’. An individual 96-well plate was then fixed at a 
recorded time on each of the following 5 days. 
 
Cells were fixed by addition of 25 µl fresh methanol-acetic acid 3:1 (v/v) to each cell-
containing well and incubated at 4 °C for at least 60 minutes. Following fixation of the cells 
in an individual 96-well plate, the plate was washed in slow running tap water and allowed 





Figure 2.1 Diagram showing the layout of an individual 96-well plate used for SRB 
growth assays. 
Each of five rows (B-F) of a 96-well plate contained cells in full growth media at increasing 
seeding densities ranging from 6.75 x103 cells/well to 1.0 x 105 cells/well. Experimental cells 
are surrounded by wells containing growth media only to reduce ‘edge effect’ associated 
with microplate-based assays. 
  
SRB staining and absorbance measurement 
When all of the 96-well plates had been fixed, they were allowed to attain room 
temperature prior to addition of 20 µl 0.04% w/v SRB to each well. Cells were incubated with 
the dye at room temperature for 1 hour, washed briskly four times in 1% acetic acid and 
dried in a drying cabinet at 37 °C. Once dry, 100 µl of 10 mM Tris-base (pH 10.5) was added 
to each well and the plates agitated on a plate shaker at room temperature for 10 minutes 
to solubilise the bound dye. Absorbance at wavelength 510 nM was measured using a 
FLUOstarâ Omega microplate reader.  
 
2.4.2 Data analysis 
Absorbance measurements for each individual seeding density (averaged over each row) for 
each 96-well plate was measured.  Data was exported to Graphpad Prismâ and curves of 
log10 Absorbance vs time were constructed. Points on the curve that fall along a straight line 
represent cells in exponential growth phase, and these were used to calculate the doubling 




2.5 Colony formation assay 
A colony formation (clonogenic survival) assay is a cell survival assay based on the ability of a 
single cell to grow into a colony of cells. Developed as a method for determining 
reproductive death of cells after exposure to IR, it can also be used to test the cytotoxic 
effects of agents in solution (Franken et al., 2006). Cells are seeded out at known densities 
and the fractional survival of cells following treatment with a cytotoxic insult is calculated 
based on the number of colonies observed to have survived over the number of cells 
seeded. When the dose of IR, or concentration of the cytotoxic drug is varied, a survival 
curve can be constructed 
 
In-vitro results from clonogenic assays have been shown to correlate with in vivo clinical 
drug trial results and tumour response to chemotherapy agents (Salmon et al., 1978). Colony 
formation assays do, however have some limitations:  Whilst the seeding of cell aggregates 
can be guarded against by disaggregation techniques, this action in itself may disrupt normal 
cell-cell interactions of importance in the three-dimensional tumour system or micro-
environment (Miller et al., 1984); non-dividing and reversibly resting G0 cells are not 
assessed in colony formation assays as they are not dividing (Hoffman, 1991). However, 
while this may be problematic in assessing cells derived from clinical tumours that may be 
enriched with G0 phase cells, it is unlikely to represent a significant problem in rapidly 
proliferating, cell line culture experiments. Overall, colony formation assays represent a 
convenient and reliable way of assessing the cytotoxic effects of drugs and IR on 
proliferating cell populations.  
 
2.5.1 Cell preparation and fixation 
Exponentially growing cells were harvested as described in section 2.3, above at 60% 
confluence and seeded into 6-well plates at three different seeding densities per drug 
concentration to allow for differential plating efficiencies and expected cytotoxicity. Cells 
were incubated at 37 °C and allowed to adhere for 24 hours. Growth media was aspirated 
from the wells and replaced with medium containing drug, diluted to the desired 
concentration. All control wells were exposed to growth media with DMSO at an identical 
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concentration to that used for dilution of the inhibitor drug and not more than 0.5% v/v. 
Exposure times were 24 hours unless otherwise stated.  
 
At 24 hours exposure, the drug-containing media was aspirated and replaced with full 
growth media (table 2.1). The cells were incubated for 8 – 14 days, depending on the 
doubling time of the cell line, allowing for at least 5 doubling-times. Following the desired 
incubation period colonies were fixed with methanol-acetic acid 3:1 (v/v) and stained with 
0.4% w/v crystal violet solution. Colonies of over 30 cells were counted to determine colony 
survival at each drug concentration used. 
 
2.5.2 Single agent cytotoxicity assay 
Serial dilutions of drugs for cytotoxicity assays were made according to the individual 
experiment requirements. Stock solutions of cisplatin or inhibitor were removed from 
storage and allowed to thaw to room temperature prior to serial dilution with either 0.9% 
w/v NaCl (for cisplatin) or DMSO (inhibitors). Final dilutions to achieve experimental 
concentrations were made in cell line specific growth medium at a DMSO concentration of 
not more than 0.5% v/v. 
 
2.5.3 Cisplatin potentiation cytotoxicity assay 
For colony formation assays investigating the potentiation of the cytotoxic effects of 
cisplatin by inhibitors of ATR, CHK1 and WEE1, single concentrations of inhibitor drugs were 
used to potentiate the effects of a range of cisplatin concentrations. Inhibitor concentrations 
were chosen at which substantial enzymatic inhibition was observed in Western blot analysis 
of target inhibition, but little inherent cytotoxicity was observed in single agent cytotoxicity 
assays.  
 
Serial dilutions of cisplatin stock solution in NaCl were prepared as described in section 2.5.2, 
above. Final dilutions were prepared in duplicate in growth media containing either: the 
chosen concentration of inhibitor in DMSO; or an equivalent concentration of DMSO only as 
control. Identical series of 6-well plates (Figure 2.2) were therefore incubated, fixed and 
 
 47 
analysed. The percentage survival of colonies in wells treated with cisplatin + inhibitor 
relative to the cisplatin only controls represents the potentiation effect of the inhibitor drug. 
 
 
Figure 2.2 Example of 6-well plate layout for cisplatin potentiation colony formation 
assay. 
Identical series of 6-well plates containing media with either A: DMSO + cisplatin 
concentrations or B: inhbitor + cisplatin concentrations were incubated as described in 
chapter 2.5.3. Colony survival was normalised to DMSO or inhibitor only controls (Row 1). 





2.5.4 Radio-potentiation cytotoxicity assay 
The same concentrations of inhibitors were used to investigate any potential of these drugs 
to potentiate the cytotoxic effect of ionising radiation (IR) in colony formation assays. 
Growth media containing either: the chosen concentration of inhibitor in DMSO; or an 
equivalent concentration of DMSO only as control were added to each well of a series of 6 
well plates. Each plate contained 1 row of three wells containing inhibitor, and one row of 
three wells as control. The 6-well plates containing known seeding densities of cells, and 
inhibitor or DMSO in growth media were then immediately exposed to increasing doses of 
ionising radiation and incubated, fixed and analysed as described in section 5.1 (figure 2.2). 
The percentage survival of colonies in wells treated with IR + inhibitor relative to the IR only 
controls represents the potentiation effect of the inhibitor drug. 
 
 
Figure 2.3 Example of 6-well plate layout for IR potentiation colony formation assay.   
Identical series of 6-well plates containing cells + media with either DMSO or inhibitor were 
exposed to no IR (plate 1) increasing doses of IR (Plate 2 and higher) and incubated as 
described in chapter 2.5.3. Colony survival was normalised to DMSO or inhibitor controls 




2.5.5 Data Analysis 
Following fixation and staining, colonies were counted manually, and the percentage survival 
calculated in Microsoft Excelâ. Percentage survival results for each cell for each biological 
repeat were copied to Graphpad Prismâ and the mean and standard deviation of survival 
for each individual condition calculated. Survival curves were plotted. For cisplatin and IR 
potentiation experiments, two-way analysis of variance (ANOVA) was conducted to detect 
significant potentiation effects.  
 
2.6 Western blot 
Western blot was used to measure the relative expression of cell cycle checkpoint kinases 
and other DDR proteins. Western blot was also used to assess the activation of ATR, CHK1 
and WEE1 by cisplatin in each cell line and the inhibition of these kinases by their respective 
small molecule inhibitors: VE-821; PF-477736; and MK-1775, by staining for the principle 
activation target of each enzyme (Table 2.2, Target Protein). 
 
Western blot is a semi-quantitative method for assessing protein expression. Proteins from 
whole cell lysates are separated by their molecular weight by gel electrophoresis and 
transferred onto a cellulose blotting membrane. The membrane is incubated with a 
sequence of primary antibodies (antibodies raised against the protein under investigation) 
and secondary antibodies that are conjugated to horseradish peroxidase (HRP). Addition of a 
chemi-luminescence substrate to the HRP conjugated secondary antibody allows for analysis 








Mol. Wt. of target 
protein (kDa) Antibody used Supplier, product Antibody dilution 
ATR pCHK1S345 56 Anti-Phospho-CHK1 (S345) Rabbit mAb Cell Signalling, 2348 1:1000 in 5% BSA 
CHK1 pCHK1S296 56 Anti-Phospho-CHK1 (S296) Rabbit pAb Cell Signalling, 2349 1:1000 in 5% BSA 
WEE1 pCDK1Y15 34 Anti-Phospho-CDK1 (Y15) Rabbit pAb Cell Signalling, 9111 1:1000 in 5% BSA 
 Protein Mol. Wt. of protein (kDa) Antibody used Supplier, product Antibody dilution 
 ATR 250 Anti-ATR (N-19) Goat mAb Santa-Cruz, 1887 1:500 in 5% milk 
 CHK1 56 Anti-CHK1 (G-4) Mouse mAb Santa-Cruz, 8408 1:500 in 5% milk 
 WEE1 96 Anti-WEE1 (B-11) Mouse mAb Santa-Cruz, 5285 1:500 in 5% milk 
 CDK1 34 Anti-CDK1 (POH1) Mouse mAb Cell signalling, 9116 1:1000 in 5% BSA 
 ATM 350 Anti-ATM (D2E2) Rabbit mAb Cell signalling, 2873 1:1000 in 5% BSA 
 DNA-PKcs 450 Anti-DNA-PKcs (H-163) Rabbit pAb Santa-Cruz, 9051 1:500 in 5% milk 
 Ku80  Anti-Ku80 (EPR3468) Rabbit mAb Abcam, ab3114 1:500 in 5% milk 
 Ku70  Anti-Ku70 (N3H10) Mouse mAb Abcam, ab80592 1:500 in 5% milk 
 a-tubulin 50 Anti-a-tubulin Mouse monoclonal Sigma, T6074 1:80000 in 5% milk 
   Polyclonal goat anti-rabbit IgG/HRP Dako, PO447 1:2000 in 5% milk 
   Polyclonal goat anti-mouse IgG/HRP Dako, PO448 1:2000 in 5% milk 
   Polyclonal Donkey anti-goat IgG/HRP Santa-Cruz, 2020 1:2000 in 5% milk 
Table 2.2 Primary and secondary antibodies used for Western blot experiments to determine the baseline expression of key DDr and cell 
cycle checkpoint proteins, their manufacturer, and experimental dilutions. 
HRP = Horseradish Peroxidase, pAB = polyclonal antibody, mAb = monoclonal antibody, 5% BSA = Bovine serum albumin % w/v in TBS-Tween 20, 




2.6.1 Preparation of cell lysates 
Preparation of lysates from untreated cells 
For the determination of baseline protein expression in each of the cell lines, cell lysates 
were prepared from cells that were not exposed to genotoxic agents or inhibitors. 
Exponentially growing cells were seeded into 10 cm tissue culture dishes and incubated at 37 
°C in 10 ml of growth media. At 60% confluence, cells were washed twice in PBS. Cells were 
incubated for 5 minutes at room temperature with 300 µl radioimmunoprecipitation (RIPA) 
lysis buffer and 1:100 protease inhibitor cocktail (ThermoFisher-Scientific, Rockford, USA) 
prior to mechanical agitation and transfer to Eppendorf tubes for centrifugation at 16000 g 
for 5 minutes. The supernatant was removed and stored at -80 °C until analysis.  
 
Preparation of lysates from drug-treated cells 
For the determination of the levels of phosphorylated proteins associated with activation or 
inhibition of enzymes by the genotoxic agents and inhibitors under investigation, cells were 
treated with combinations of drugs as described in the individual experimental protocols 
(see sections 3.3 and 4.3). Exponentially growing cells were seeded into wells of 6-well plates 
and cultured at 37 °C to 60% confluence. Growth media was replaced with treatment media 
containing the drug combinations and cells were further cultured until the desired time for 
lysis. Cells were washed twice in PBS and cultured for 10 minutes on ice with 70 µl per well 
of Phosphosafe extraction reagent (Novogen/Merk KGaA, Darmstadt, Germany) with 1:100 
protease inhibitor cocktail (ThermoFisher-Scientific, Rockford, USA) prior to mechanical 
agitation, transfer to Eppendorf tubes and centrifugation at 16000 g for 5 minutes. 
Supernatant was removed and stored at -80 °C. To avoid repeated freeze-thaw cycles, a 10 
µl aliquot of all lysate samples was diluted with 40 µl de-ionised water (DIW) and used for 







2.6.2 BCA assay  
In order to measure the relative amounts of specific proteins in multiple samples by Western 
blot, each experimental sample analysed should be of identical overall protein 
concentration. This is achieved by dilution of whole cell lysates for each experimental sample 
to the equivalent protein concentration of the sample with the lowest value. In order to 
determine the overall protein concentration of the lysate, bicinchoninic acid assay (BCA 
assay) was performed using a Pierce protein assay kit (ThermoFisher-Scientific, Rockford, 
USA).  
 
The BCA assay relies on the ability of peptide bonds within proteins to reduce copper (II) 
sulphate (Cu2+ ions) to Cu+. The amount of Cu2+ reduced is stoichiometric with the amount of 
protein present. Following this reduction reaction, bicinchoninic acid molecules complex 
with the Cu+ ions forming a purple coloured complex that absorbs light at a wavelength of 
562 nm. Therefore, absorption of light at 562 nm correlates with the amount of protein 
present in the reaction solution (Smith et al., 1985). 
 
The protein concentrations in 1:5 dilutions of whole cell lysates were measured in 
quadruplicate alongside known dilutions of a standard solution of bovine serum albumin.  
10 µl aliquots of dilute lysate and protein standards were pipetted in quadruplicate into 
individual wells of a 96-well plate as shown in figure 2.3. Using deionised water (DIW) as a 
blank-control, 190 µl Pierce assay reagent was added to each well and the plate was 
incubated at 37 °C for 30 minutes. Absorbance at 562 nM was measured using a FLUOstarâ 
Omega microplate reader.  Protein concentrations were calculated by fit to a standard curve 






Figure 2.4 The layout of a 96 well plate used for BCA protein assays 
DIW was used as a blank control in column A. Protein standard dilutions were added to 
columns B to D. 1:5 dilutions of whole cell lysates were added to remaining wells in 




Figure 2.5 Example of a standard curve generated by linear regression analysis of 
absorbance at 256 nm for a series of standard serum albumin solutions. 
Protein concentrations of whole cell lysates were determined by fit of the average of 





2.6.3 Gel electrophoresis 
Unless otherwise stated all reagents for electrophoresis were purchased from Bio-Rad 
laboratories (Hercules, California USA). Cell lysates were thawed on ice and diluted to a 
maximum protein concentration of 1.0 mg/ml in DIW, 25% XT sample buffer and 0.5% XT 
reducing agent. Samples were heated to 94 °C for 5 minutes to allow for protein 
denaturation and epitope exposure. Once cooled, Samples were loaded as 30 µl aliquots into 
separate wells of an XT precast 3% - 8% tris-acetate electrophoresis gel. High-mark protein 
ladder (ThermoFisher-Scientific, Rockford, USA) was loaded into wells at either side of the 
gel to estimate the molecular weight of the protein bands.  
 
Electrophoresis was driven by a potential difference down the gel of 150 V for 65 minutes in 
10% tris-glycine running buffer. Following electrophoresis, the proteins were transferred to a 
nitrocellulose blotting membrane (Amersham Protran premium 0.45 µm NC) across a 
potential difference of 100 V for 60 minutes in 10 % tris-glycine transfer buffer and 20% 
methanol. The membrane was then placed in 5% milk in Tris-Buffered Saline + Tween 20 
(TBST) and incubated for at least 60 minutes at room temperature on a rocking platform to 
prevent non-specific antibody binding during antibody staining.  
 
2.6.4 Antibody staining and chemi-luminescence 
The membrane was cut at the appropriate molecular weight markers, to enable multiple 
proteins to be analysed without stripping and re-probing, as desired and incubated with 
primary antibodies at the dilutions given in table 2.2. All primary antibodies were incubated 
with the membrane at 4°C, overnight. Membranes were washed with TBST for 20 minutes 
prior to incubation with the secondary antibodies at room temperature for at 60 minutes. 
Following incubation with the secondary antibodies, the membrane was exposed to Clarity 
Western enhanced chemiluminescence (ECL) substrate for 5 minutes and chemi-
luminescence was measured and quantified using a G-boxâ image analyser (Syngene, 





2.6.5 Data Analysis 
Once the intensity of chemiluminescence associated with each protein band of interest was 
measured it was recorded in Microsoft Excelâ. The ratio of intensity of the band of interest 
to its corresponding loading control protein band minus the background fluorescence was 
calculated. Values were then imported to Graphpad Prismâ for further evaluation and 
display as detailed in chapters 2 and 3. 
 
2.7 Cell cycle analysis  
The cell cycle profile of a population of cells within a sample can be used to determine the 
effects of drugs and other exogenous influences on the progression of proliferating cells 
through the cell cycle. The cell cycle profile of a sample containing proliferating cells can be 
determined using a fluorescent dye that binds to the DNA of the cells and then measuring 
the intensity of the fluorescence from each cell as it passes through a laser. Propidium Iodide 
(PI) is a dye that binds stoichiometrically to the DNA and RNA of fixed, permeable cells. PI is 
maximally excited by lasers at wavelength 493 nM and has maximal emission spectra at 636 
nM. 
 
Proliferating cells are fixed and permeabilised with Ethanol, treated with ribonuclease 
(RNase) to degrade RNA content and then exposed to saturating concentrations of PI. The 
stoichiometric relationship between bound PI and the DNA content of the cell results in a 
direct correlation between cell DNA content and cell fluorescence, measured by flow 
cytometry. Cells in G2-/M-phase will have roughly twice the fluorescence of either G0 
(resting) or G1-phase cells, due to there being twice the DNA content in these cells, as they 
have duplicated their DNA in preparation for mitosis. S-phase cells will have fluorescence on 





Figure 2.6 An example of a cell cycle profile of unperturbed HeLa cells. 
The populations of G0-/G1-phase, S-phase and G2-/M-phase cells are shown along an 
arbitrary fluorescence scale. G2- or M-phase cells have twice the fluorescence of the G1- or 
G1-phase cells owing to DNA duplication that occurs in S-Phase. S-phase cells have a DNA 
content and fluorescence on a scale between the G0/G1 and G2/M populations. Apoptotic 
cells have fragmented DNA and their fluorescence is less than that of G-phase1 cells (sub-
G1). 
 
2.7.1 Preparation of samples for cell cycle analysis 
Cell harvesting and permeabilisation 
Serial dilutions of cisplatin stock solution in NaCl were prepared as described in section 2.5.2, 
above. Final dilutions were prepared in duplicate in growth media containing either: the 
chosen concentration of inhibitor in DMSO; or an equivalent concentration of DMSO only as 
control. 
 
Cells were cultured in 10 cm tissue culture dishes until they were 60% confluent. Growth 
media was aspirated from the wells and replaced with drug, diluted to the desired 
concentration in growth media. All control wells were exposed to growth media with DMSO 
at an identical concentration to that used for dilution of the inhibitor drug and not more 




Following the drug exposure, the drug-containing media was aspirated and reserved to 
ensure non-adhered cells were not lost to analysis. The cells were washed twice with PBS 
and incubated with 4 ml trypsin-EDTA until all cells were observed to have detached from 
the bottom of the culture dish. The cells were then re-suspended in 5 ml PBS and transferred 
to 20 ml universal tubes with the reserved media and centrifuged at 250G for 3 minutes.  
The supernatant was discarded, the cells were resuspended in 1 ml ice-cold PBS and 
transferred to Eppendorf tubes. Following further centrifugation at 250G for 5 minutes, the 
supernatant was again discarded, and the cells were resuspended in 1 ml 70% ethanol. Cells 
in ethanol were stored at 4 °C for no longer that 2 weeks. 
 
RNA digestion and PI staining 
Cells were removed from cold storage and allowed to reach room temperature before 
centrifugation at 250 g for 5 minutes. The ethanol supernatant was then discarded, and cells 
resuspended in 800 µl PBS for 20 minutes. This step was repeated to ensure adequate 
elimination of ethanol. Bovine RNase A at a final concentration of 1 mg/ml was added to the 
cell suspension and the cells were incubated at 37 °C for 30 minutes. PI at a final 
concentration of 400 µg/ml was added to the RNA free cell suspension followed by further 
30 minutes at 37 °C. 
 
2.7.2 Fluorescence cytometry and data analysis 
Permeabilised and PI stained cells were analysed for DNA content using a BD FACSCanto II 
flow cytometer. Data was stored and transferred to FCS Express 6â software for analysis. 
Doublets were excluded, as described in chapter 6 and the sub-G1, G0/G1, S and G2/M 
populations were determined from the cell cycle histogram.  
 
2.8 Tissue microarray and Immunohistochemistry 
A tissue microarray (TMA) was constructed from formalin fixed and paraffin embedded 
cervical cancer tissue following diagnosis or treatment from patients who consented to 
biobanking under existing ethical permissions (2012 REC: 12/NE0395. R&D sponsor: NUTH 
NHS foundation trust No. 6579). The TMA was prepared and IHC undertaken according to 




2.9 Data analysis and statistics 
Statistical analysis of all experimentally generated data was undertaken using Graphpad 
Prismâ statistics software. Pearson correlation analysis was used to explore relationships 
between data. Where correlation analyses are given, r2 represents the goodness-of-fit of 
the data to the linear regression line and the p-value represents the probability that the 





3 Characterisation of cervical cancer cell lines 
 
3.1 Introduction 
Due to the strict measurement of tumour dimensions necessary for the accurate staging of 
cervical cancer and the often-small volume of primary tumour present at diagnosis, 
harvesting adequate tissue for primary tumour cultures from cervical cancer is rarely 
possible. Even in advanced or recurrent disease, small biopsies are usually taken to confirm 
diagnosis, again necessitating fixation and paraffin section of the whole specimen to ensure 
that adequate material is available for diagnosis and histopathological subtyping prior to 
non-excisional treatments being undertaken.  
 
3.1.1 Cervical cancer cell lines as a useful pre-clinical tool 
Cancer cell lines offer a readily available alternative to primary cultures. Immortalised cell 
lines have the advantage of providing a theoretically limitless supply of consistent material, 
supporting reproducible outcomes between researchers and over long-time periods 
compared to non-immortalised primary cultures. However, care must be taken when 
interpreting results from experiments with cell lines: while cell lines aim to reproduce the 
features of their parent primary cells, genotypic and phenotypic characteristics may change 
over time and serial passage. Additionally, significant heterogeneity may exist in a single 
culture. Cross culture and contamination with either other cell lines or infective agents such 
as mycoplasma species may also affect or disrupt cell behaviours or gene expression and 
must be guarded against and regularly tested for (Kaur and Dufour, 2012). To avoid these 
problems, one individual cell line of post-authentication passage < 30 was handled 
exclusively at any one-time, biological safety cabinets were thoroughly cleaned between 
experiments using different cell lines and regular mycoplasma contamination testing was 
conducted.  
 
A limited range of cervical cancer cell lines are commercially available, however within their 
number are some of the most widely used human cancer cell lines used in research today. 
Most notable are HeLa cells, immortalised from primary cell culture in 1951 this cell line is 
perhaps the most prolific in modern research (Lucey et al., 2009). HeLa cells have been used 
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to successfully inform clinical practice in fields as diverse as vaccine development to cancer 
research (Skloot, 2010). HeLa cells have been reported to be a viable cell line for tumour 
xenografts in mice (Rastogi et al., 2015, Nin et al., 2014). Similarly, other human cervical 
cancer cell lines used in the investigations described in this thesis (ME-180, CaSki, SiHa and 
C33A) have been successfully used to produce murine models of human cervical cancer 
(Cairns and Hill, 2004, Donat et al., 2014).  
 
3.1.2 Choosing cervical cancer cell lines to represent clinical conditions 
Choosing cell lines from a limited commercially available range to be representative of the 
prevalence and distribution of HPV and histological sub-types prevalent in cervical cancers 
requires an appreciation of the distribution of these factors in the worldwide population as 
considered in Chapter 1.  Considering the variance in histological and HPV sub-type 
distribution as well as presence or absence of HPV DNA, and within the limitations of the 
small number available commercially, a panel of cervical cancer cell lines was chosen to 
represent: squamous and glandular cancers with common high-risk HPV sub-type (HPV 16 
and 18); a rare but observed HPV subtype infection with uncertain oncological significance 
(HPV 68) (Longuet et al., 1996); and for completeness, two cervical cancer cell lines with no 
detectable HPV DNA but known pathogenic BP53 and RB1 mutations (Table 3.1).  
 
3.2 Aims and Objectives 
The aims of the investigations described in this chapter are threefold:  
1. to determine the growth rate (doubling time) of the cell lines, as this may be a 
determinant of sensitivity to cytotoxic drugs and inhibitors of ATR, CHK1 and WEE1; 
2. to determine the clonogenic potential (cloning efficiency) of the cervical cancer cell lines 
for use in future cytotoxicity assays;  
3. to establish baseline DDR and G2/M cell cycle checkpoint protein expression as this may 





3.3 Materials and methods 
3.3.1 Cervical cancer cell lines 
The cervical cancer cell lines used for experiments described herein were purchased from 
the American Type Culture Collection (ATCC) Cell Biology Collection and stored in the 
authenticated cell bank within the Northern Institute for Cancer Research (NICR). The ATCC 
lists 9 commercially available cell lines derived from human cervical cancer, of which, 6 were 
chosen for their array of known HPV subtype infection and genotypic characteristics as 
outlined, above (Table 3.1).  
 
Three of the cell lines are known to be high risk HPV positive: HeLa (HPV 18+), SiHa (HPV 
16+) and CaSki (HPV16+ and HPV18+). Two are HPV negative but harbour TP53 +/- RB1 
mutations: C33A; and HT-3. One: ME-180, is positive for HPV 68. 
 
3.3.2 Determination of cell doubling times by SRB assay 
The doubling times of two cervical cancer cell lines (ME-180 and HT-3) were determined by 
SRB assay. Cells were seeded in six identical 96 well plates at seeing densities from 6.75 x103 
cells/well to 1.0 x 105 cells/well and incubated for 6 days with fixation of a single 96 well 
plate at a documented time on each successive day of incubation, as described in section 
2.4. The doubling times of the remaining four cell lines used for the experiments described in 
this thesis (HeLa, SiHa, C33a and CaSki) were determined by SRB assay in work carried out by 




Table 3.1 Cervical cell lines used in experiments, their HPV status, histological sub-type 
and TP53/RB1 status. 
 
3.3.3 Determination of cloning efficiency by colony formation assay 
In order to determine the optimal seeding densities for cytotoxic colony formation assays, 
the cloning efficiency of the six cell lines were determined by undertaking colony formation 
assays in the absence of cytotoxic agents. Cells were seeded in individual six well plates at 
known seeding densities and incubated for 7 – 14 days in cell specific full growth media, as 
described in Chapter 2.5. Incubation time depended on the doubling time of the cell line, 
allowing for at least 5 doubling-times. Following the desired incubation period colonies were 
fixed with methanol-acetic acid 3:1 (v/v) and stained with 0.4% crystal violet solution. 
Colonies of over 30 cells were counted by eye to determine colony survival at each drug 
concentration used (Figure 3.1). Mean cloning efficiencies in the absence of cytotoxic agents 
were calculated from three individual experiments. The cloning efficiency for a cell line 
seeded at a known seeding density in an individual well of a 6-well plate is calculated as 
follows: 
!"#$%$%&	())$*$(%*+	(%) = 	 0
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Figure 3.1 Photograph showing HeLa cell colonies. 
HeLa cells were seeded at seeding densities of 50, 100 and 200 cells per well in duplicate 
from left to right. Cells were incubated in full growth media for 10 days (>5 doublings) prior 
to fixation with methanol-acetic acid 3:1 (v/v). Colonies were stained with 0.4% crystal violet 
and counted manually. 
 
 
3.3.4 Determination of baseline protein expression by Western blot 
Western blot was used to measure the relative expression of cell cycle checkpoint kinases 
and DDR proteins. Whole cell lysates were prepared from unperturbed and exponentially 
growing cells, separated by gel electrophoresis and transferred to a blotting membrane, as 
described in chapter 2.6. Membranes were incubated with primary and secondary 
antibodies (table 2.2) prior to exposure to a chemiluminescence agent. The fluorescence of 





3.4.1 Cell line doubling times and cloning efficiency 
Antiproliferative anticancer agents and cell cycle checkpoint inhibitors are likely to be more 
cytotoxic to rapidly dividing cells, so it was important to calculate the cell cycle time. 
Additionally, the cell doubling time is a useful indicator of how long is needed for colony 
formation in cytotoxicity assays. Calculating the population doubling time is also a useful 
surrogate for estimating the rate at which the cells grow and the length of the cell cycle for 
each of the individual cell lines used. Representative growth curves for ME-180 and HT-3 cell 
lines are shown in Figures3.2.  
 
When plotted on a log scale, exponentially growing cells will have absorbance values that fall 
along a straight line. Cells that are confluent, or that are not growing in an exponential 
growth phase will show a ‘plateau’. Data points which indicated pre- or -post exponential 
growth ‘plateau’ phase cells, were omitted from the doubling time calculation. Doubling 
times for each of two replicate experiments for ME-180 cells and HT-3 cells were calculated 
from the exponential growth phases observed from each of the five technical replicates 
within that experiment.   
 
Mean doubling times and the standard error of the means for these experiments and those 
previously undertaken by I. Kotsopoulos are presented in Table 3.2. Hela, C33A and Caski 
displayed broadly similar doubling times (around 45 h). SiHa cells grew the slowest (59 












Figure 3.2 Representative examples of growth curves for ME180 and HT-3 cells at five 
different seeding densities.   
Cells were seeded at the densities shown in replicate 96-well plates. After overnight 
incubation the first plate was fixed (time 0) and the remainder were fixed at daily intervals 
for 6 days prior to staining all plates with SRB and reading the optical density at 450 nm. 
Data are mean and SD from a single representative experiment with 6 replicate wells/cell 



































































Table 3.2 Doubling times and cloning efficiency for six cervical cancer cell lines. 
Doubling times were calculated from experiments as shown in Fig 3.2 and 3.1. Data are mean 
and SEM of the mean doubling time/individual experiment (which was the mean of the 5 
technical replicates/experiment). For ME-180 cells, the mean doubling time of two biological 
replicates are given. Points that fell outside of exponential growth were excluded from 
analysis. For all other data, the mean and SEM of three biological replicates are given. 
 
The mean cloning efficiencies for each cell line are also shown Table 3.2. CaSki cells and HT-3 
cells showed the poorest cloning efficiencies at 22 percent and 23 percent, respectively. 
C33A cells showed the greatest cloning efficiency at 79 percent. Relative cloning efficiencies 
showed no relationship to the cell doubling times.  
 
3.4.2 Baseline expression of checkpoint and DDR proteins 
In order to confirm that the cells expressed the protein kinases that are key to the 
functioning of the G2-M cell cycle checkpoint and that are under investigation in this thesis, 
their expression in unperturbed exponentially growing cells were measured. ATR, CHK1, 
WEE1 and the principal WEE1 target protein CDK1 levels were measured. Additionally, 
expression of the important DNA damage signalling kinase: ATM and the key NHEJ proteins: 
DNA-PKcs; Ku70; and Ku80 were also measured, due to the previously described correlations 
between expression of these proteins and sensitivity to inhibition of ATR (Chapter 1.6.2). 
Representative Western blots for the six cervical cancer cell lines used are shown in  
Figure 3.3. 
 
Potential differences in the expression of cell cycle checkpoint and DDR proteins between 
the cell lines were investigated. Protein expression was quantified by expressing the 
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absolute densitometry value associated with the band corresponding to the protein of 







Variation in α-tubulin expression was noted across the cell line panel. Tubulin and other 
housekeeping proteins can vary between cells (Li and Shen, 2013). This variation was 
consistent across individual experimental repeats and was unlikely to represent chance 
differences in total protein content of individual Western Blot electrophoresis lanes.  
 
There was substantial inter-assay variation, despite normalising expression to the loading 
control (Figure 3.5). Nevertheless, differences could be detected between the cell lines. 
Amongst the G2/M checkpoint protein kinases under investigation: there was a 2-fold 
variation in ATR expression between Caski (lowest) to SiHa (highest); a 3-fold variation in 
CHK1 expression between SiHa (lowest) to HT3 (highest); and a 5-fold variation in expression 
of WEE1 between CaSki (lowest) to ME-180 (highest).   
 
HT-3 cells appeared to have very little baseline expression of ATM when compared to the 
other five cell lines, with a marked difference of over 20-fold in the expression of this protein 
when compared to any of the other cell lines. In contrast, a difference of less than 3-fold was 
observed when ATM expression was compared between the other five cell lines. 
With regard to the NHEJ proteins measured:  DNA-PKcs expression varied considerably 
across the six cervical cancer cell lines, with a greater than 5-fold variation between HeLa 
cells (highest) and HT-3 cells (lowest); both Ku70 and Ku80 proteins appeared to be 
expressed at higher levels in HeLa cells than in any of the other cell lines and this difference 
was greatest in the case of Ku80, with a 5-fold greater expression that in the cells with the 








Figure 3.3 Baseline protein expression in unperturbed cells. 
Baseline Expression of G2-M cell cycle checkpoint kinases and other key DDR proteins were 
measured by western blot of cell lysates from exponentially growing cells in the absence of 
DNA damaging agents. Individual blots showing the expression of cell cycle and DDR proteins 
representing two individual measurements of expression of each protein are shown. Protein 






Figure 3.4 Expression of cell cycle checkpoint and NHEJ proteins. 
The protein content of exponentially growing cell lysates was measured by densitometry 
analysis of Western blots. Data are mean and range of expression normalised to the loading 


















































































































































































































































































































3.4.3 Correlations between protein expressions 
Relationships between the expression of the key G2/M checkpoint proteins and DDR 
proteins were investigated by correlation analysis. The baseline expressions of individual 
proteins were compared between cell lines. No correlations were observed between the 
levels of expression of ATM and any of the other proteins measured in the cell lines. 
Similarly, no proteins correlated with the expression of WEE1 in the cell lines. The expression 
of the Ku proteins, Ku 70 and Ku 80 showed a very strong positive correlation (r2 = 0.93, p < 
0.01), as expected. The human Ku protein is a heterodimer made up of a single Ku70 and a 
single Ku80 domain and therefore proportional expression of each protein would be 
expected in each cell. DNA-PKcs is the catalytic sub-unit of the nuclear DNA dependent 
protein kinase, DNA-PK. DNA-PK is formed from a stoichiometric interaction between the Ku 
heterodimer and the DNA-PKcs catalytic sub-unit. Despite this, a correlation between either 
Ku protein and DNA-PKcs expression was not observed. 
 
Significant negative correlations were observed between: the expression of ATR and both 
CHK1 and CDK1; and the expression of DNA-PKcs and both CHK1 and CDK1 (figure 3.6). 
Positive correlations were observed between the expression of CHK1 and CDK1; and 






Figure 3.5 Scatter plots showing correlations between baseline protein expressions of 
pairs of proteins in human cervical cancer cell lines. 
Correlations between all combinations of pairs of proteins was undertaken. Scatter plots for 
those pairs that showed significant Pearson correlations, along with the relevant p-values are 
shown: ATR and CHK1 (A); ATR and CDK1 (B); DNA-PKcs and CHK1 (C); and DNA-PKcs and 
CDK1 (D): and CHK1 and CDK1 (E). ATR and DNA-PKcs (E), though this did not reach statistical 







3.4.4 Correlations between cell growth and protein expressions 
Correlation analyses were performed to determine if there was any relationship between 
the expression of cell cycle checkpoint or DDR proteins measured and the growth rate of the 
six cervical cancer cell lines. The individual scatter plots for protein expressions vs doubling 
time are shown in Figure 3.6. No Significant correlation was observed between the doubling 





Figure 3.6 Scatter plots of cell cycle checkpoint and DDR protein expression vs cell line 
doubling times. 
Data are mean values calculated and displayed in table 3.2 and figure 3.5. 
 
3.5 Discussion 
Knowledge of the basic growth characteristics of the cell lines under investigation allows for 
consistent experimental conditions to be created with respect to exposure to genotoxic 
agents, enzyme inhibitors and post exposure incubation for colony formation and 
cytotoxicity assays. The doubling times calculated for the individual cell lines during 
exponential growth fell within a narrow range, with a less than two-fold difference in the 
doubling time between the ME-180 cell line (shortest doubling time) and the SiHa cell line 
(longest doubling time). It should be noted that whilst the calculated doubling times of HeLa, 
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SiHa, C33A and ME-180 cell lines were consistent with that reported in the accepted 
literature (Artimo P, 2012), the calculated doubling times for CaSki and HT-3 cells were 
found to be significantly shorter under experimental conditions in our laboratory than that 
reported previously (Kalu et al., 2017). In order to ensure the most consistent conditions for 
the experiments described in subsequent chapters, the doubling time determined under 
experimental conditions in our laboratory was used to calculate appropriate post drug-
exposure incubation times. 
  
Though doubling time does not have any bearing on colony formation the demonstration of 
the ability of the cell lines to form colonies under non-perturbed conditions provides a 
second measure of their intrinsic viability. All six of the cell lines used in experiments 
described in this thesis demonstrated the ability to form colonies under experimental 
conditions described in Chapter 2. It is difficult to estimate accepted literature values for 
cloning efficiencies for the cell lines used, as this value will be affected by such individual 
experimental parameters as the cell seeding density and volume of growth media used. The 
experiments described in this chapter therefore provide vital information to guide the 
appropriate conditions (seeding densities) to be used in cytotoxicity assays described in 
subsequent chapters, which were conducted under similar experimental conditions.  
 
Many researchers use the presence of mRNA as a marker for the expression of DDR pathway 
proteins and the lack of inclusion of mRNA data from the cell lines under investigation here, 
could be viewed as a potential weakness in this thesis. This approach, however, is not 
without disadvantage. Production and maintenance of cellular proteins requires complex 
integration of transcription, post-transcriptional modification and degradation processes 
(Vogel and Marcotte, 2012). Protein concentrations in the cell represent a dynamic balance 
between these processes. Several large studies comparing the transcriptome and proteome, 
including in human cancer systems have shown poor correlation between the two (Chen et 
al., 2002, Tian et al., 2004), whilst others have shown greater alignment (Orntoft et al., 
2002). Overall it is estimated that between 15% and 70% of the variation of protein levels in 
human cells might be explained by post-transcriptional processes, rather than variation in 




The overall aim of this thesis is to compare a panel of checkpoint protein inhibitors in their 
effects on cell survival through functional inhibition of their target proteins. The primary aim 
of the investigations described in this chapter was to demonstrate the presence of these 
proteins and that of selected DDR proteins which have previously been shown to be 
determinants of sensitivity to ATR, CHK1 Or WEE1 inhibition (Middleton et al., 2015, Kwok et 
al., 2016). Protein levels, determined by Western blot were felt to be a more appropriate 
measure for this aim and to correlate with kinase activity (Chapter 4) 
 
Despite the expectation that faster growing cells might have higher levels of replication 
stress, and therefore have higher levels of signalling to S and G2/M checkpoints via the ATR-
CHK1 pathway, there was no significant correlation between growth rate (doubling time) 
and baseline expression of any of the key checkpoint proteins: ATR; CHK1; WEE1; and CDK1. 
While it is accepted that the principal activator of the ATR-CHK1 pathway is replication 
stress, characterised by lesions arising from stalled replication forks and the resulting 
dsDNA-ssDNA junction (Zeman and Cimprich, 2014), evidence suggests that this higher level 
of activation arises out of the complex interplay of ATR, CHK1 and their co-factors (Zeman 
and Cimprich, 2014, Shiotani and Zou, 2009) with the damaged DNA molecule rather than by 
increasing the expression of these proteins in their non-activated form. It cannot, however 
be ruled out that a rapidly dividing cell might adapt to increased replication stress by 
increasing expression of these DNA damage sensing, signalling and effector proteins.  
 
When considering relationships between the baseline expression of cell cycle checkpoint 
proteins and DDR proteins, it is important to bear in mind the small sample size of cell lines 
under consideration in these experiments. Nevertheless, there appear to be highly 
significant inverse correlations between ATR and both CHK1 and CDK1. Additionally, and in-
keeping with this finding is the significant positive correlation between CHK1 and CDK1. 
There is a paucity of published evidence to confirm any relationships between the 
expression of these proteins in either human cell lines or clinical tumour specimens.  Whilst 
it might be expected that all components in a given pathway would be upregulated together, 
or expressed in similar quantities, this inverse relationship between ATR and CHK1/CDK1 
might suggest some functional redundancy in the pathway that warrants further exploration 




Concerning the positive correlation observed between CDK1 and CHK1: it could be 
hypothesised that a cell with high levels of CDK1 might require high levels of CHK1, acting 
though CDC25C and WEE1 in order to prevent inappropriate entry to mitosis at the G2/M 
checkpoint. These correlations, while interesting are however observed in a small panel of 
cell lines. The cell may have adapted to high levels of replication stress by over-expression of 
proteins that are not measured in these experiments. Verification of these findings would 
require a substantial expansion of the sample size, including in clinical tumour samples 
before any definitive conclusion of their significance could be drawn. 
 
Relationships between DNA-PKcs and the G2/M cell cycle checkpoint signalling kinases were 
also observed. Though there is, again little in published evidence to support a relationship 
between DNA-PKcs expression and that of CDK1 in either pre-clinical or clinical tumour 
samples, correlations between CHK1 and DNA-PKcs mRNA expression levels have been 
observed in publicly available data sets derived from tumour samples from a variety of 
tissues including lung, hepatocellular, ovarian and colon carcinomas. Less convincing 
correlations have been observed in ovarian cancers and there was no observed correlation 
in breast cancer samples (Massey et al., 2016). Though no negative correlations between 
these two proteins were observed, cervical tissue was not included in the analysis. In this 
study a positive correlation was noted to be present between the expression of DNA-PKcs 
and ATR. This relationship has previously been shown to exist in glioma samples using mRNA 
expression data, following the observation that high DNA-PKcs expression conferred 
sensitivity to ATR inhibition (Middleton et al., 2015). Furthermore, both high ATR and high 
DNA-PKcs expression have been shown to correlate with survival in ovarian cancer patients, 
though no correlation was performed between DNA-PKcs and ATR expression in individual 
tumour samples in this study (Abdel-Fatah et al., 2014). 
 
The presence of high-risk HPV (HPV 16/18) has been previously shown to have an impact on 
the sensitivity of head and neck squamous cell cancers (HNSCC) to PARP inhibitors through 
reduced recruitment or expression of NHEJ and HRR pathway proteins including DNA-PK 
(Weaver et al., 2015). High-risk HPV positivity has also been shown to be related to the 
upregulation of other proteins involved in BER and SSB repair pathways (Nickson et al., 
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2017). Though the HPV negative cell lines, C33A and HT-3 showed the lowest overall 
expression of ATM, no other relationships were noted between high-risk HPV status and 
expression of any of the other DDR or cell cycle checkpoint proteins measured.  
 
3.6 Conclusions 
• The cervical cancer cell lines HeLa, SiHa, C33A, CaSki, ME-180 and HT-3 have doubling 
times that show a less than two-fold difference. The differences in doubling time do not 
correlate with expression of any of the cell cycle checkpoint or DDR proteins measured, or 
the HPV status of the cell line. 
• The cervical cancer cell lines form colonies with cloning efficiencies that are high enough 
to allow for cytotoxicity clonogenic assays to be conducted using standard techniques. 
• Significant correlations were observed between ATR, CHK1 and CDK1, which are all 
components of a common pathway signalling DNA damage to the G2/M cell cycle 
checkpoint.  
• CHK1 expression was seen to correlate with DNA-PKcs expression in an inverse 
relationship, contrary to that observed in mRNA expression from other cancer tissues. 
• ATR expression was seen to correlate with DNA-PKcs expression. Though this 
relationship was non-significant, it is consistent with previously observed correlations in 
brain cancer tissue.  
• DDR protein expression in unperturbed cells was not influenced by HPV status 
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4 Target enzyme activity and single agent cytotoxicity 
 
4.1 Introduction 
A panel of six human cervical cancer cell lines, with known HPV status and pathogenic 
mutations of TP53 and RB1 tumour suppressor genes were characterised for doubling times, 
DDR protein expressions and cloning efficiencies in the previous chapter so that subsequent 
data could be interpreted in light of this knowledge. 
 
The loss of G1 checkpoint control through inactivation of TP53 and/or RB1 is likely to result 
in increased replication stress and a reliance on the Intra-S and G2/M cell cycle checkpoints 
(Chapter 1.3). It might be anticipated that inhibition of ATR, CHK1 or WEE1 and hence S and 
G2/M checkpoints would result in increased in cell death in the face of (endogenous) DNA 
damage. Evidence supporting p53 mutation or loss as a sensitiser to ATR or CHK1 inhibition 
is derived from experiments conducted on isogenic cell lines and the results are less 
consistent in unmatched, wild-type and dysfunctional cells (Rundle et al., 2017). Recent 
evidence also suggests that p53 deficiency may only confer sensitivity to ATR-CHK1 inhibition 
in the presence of a genotoxic insult, such as that delivered by co-treatment with IR or 
gemcitabine (Middleton et al., 2018). 
 
Defects in the DDR pathways HRR, BER and NHEJ have previously been shown to confer 
sensitivity to inhibition of ATR, CHK1 and WEE1 (Chapter 1.6.2). Of particular interest are 
observations that aberrations in the expression of components of NHEJ confer sensitivity to 
ATR-CHK1 pathway inhibition: overexpression of DNA-PKcs (a marker for replication stress 
and catalytic sub-unit of DNA-PK) is associated with sensitisation of cells to ATR and CHK1 
monotherapy (Middleton et al., 2015, Massey et al., 2016). Conversely, loss or knockdown of 
the DNA-PK components, Ku70 and Ku80 are also associated with sensitisation of cells to 
ATR and CHK1 inhibition (Middleton et al., 2015, Massey et al., 2016, Sultana et al., 2013). 
 
ATM deficiency has also been suggested as a potential sensitising characteristic for ATR, 
CHK1 or WEE1 inhibition, due to the complimentary functions of the ATR-CHK1 and ATM-
CHK2 mediated pathways in the DDR. ATM deficiency has been shown to sensitise leukeamic 
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cells to ATR inhibition (Kwok et al., 2016) though convincing evidence of a similar effect on 
CHK1 and WEE1 inhibitors is lacking. 
 
Investigations described in this chapter will measure the potency of the inhibitors: VE-821; 
PF-477736; and MK-1775 against their respective kinase targets in intact cells and 
investigate whether this target inhibition or the characteristics described in chapter 3, 
including baseline expression of DDR proteins has an impact on the cell’s sensitivity to the 
single agent cytotoxicity of the inhibitors.  
 
4.2 Aims and objectives 
The aims of the investigations described in this chapter are: 
1. To demonstrate the target enzyme inhibition of ATR, CHK1 and WEE1 by VE-821, PF-
477736 and MK-1775, respectively in each cervical cancer cell line. 
2. To determine the single agent cytotoxicity of VE-821, PF-477736 and MK-1775 in each 
cervical cancer cell line. 
 
This will enable the following hypotheses to be tested: 
1. The inhibitors will have similar potencies against their target across all cell lines. 
2. The cytotoxicity of the inhibitor will be dependent on the baseline expression level of 
the target enzyme and its inhibition. 
3. The cytotoxicity of the inhibitors will be dependent on the expression levels of other 
DDR proteins (ATM, DNA-PKcs, Ku70 and Ku80). 
An additional aim will be to determine suitable concentrations of VE-821, PF-477736 and 




4.3 Materials and methods 
4.3.1 Investigations of enzyme activation and inhibition by western blot 
Activation of the ATR-CHK1-WEE1 pathway by cisplatin 
Exponentially growing HeLa cells were exposed to cisplatin at a concentration of 3 µM for 
time intervals of between 1 hour and 24 hours. Cell lysates were prepared as described in 
chapter 2.6 and analysed by western blot. Western blot membranes were incubated with 
antibodies raised against the principal phosphorylation target of ATR, CHK1 and WEE1 (Table 
2.2 and section 1.4). Following HRP-conjugated secondary antibody binding and exposure to 
ECL substrate, the intensity of chemiluminescence at bands corresponding to pCHK1S345, 
pCHK1S296 and pCDK1Y15 (O'Connell et al., 1997, Peasland et al., 2011, Okita et al., 2012) at 
each time-point was compared (Figure 4.1). Activation by cisplatin was compared to a 
positive control using 4-Nitroquinoline 1-oxide (4NQO), a known potent UV mimetic and 
activator of ATR (Chen et al., 2015).  
 
Target enzyme inhibition as a function of inhibitor concentration 
The extent to which each of the three inhibitors under investigation is able to prevent 
phosphorylation of the principal phosphorylation target of their respective substrate enzyme 
was investigated at multiple inhibitor concentrations. Exponentially growing HeLa, SiHa, 
C33A and CaSki cells were concurrently exposed to 3 µM cisplatin alone or with increasing 
concentrations of VE-821, PF-477736 or MK-1775 for 24-hour incubations. ME-180 and HT-3 
cells were exposed to 3 µM cisplatin alone or with a single fixed concentration of inhibitor 
drug, determined in initial experiments with the other four cell lines. Cell lysates were 
prepared immediately following 24 hours exposure to the drug combinations and analysed 
by Western blot as described in Chapter 2.6. ATR activity was determined by measuring 
pCHK1S345, CHK1 activity by measuring pCHK1S296 and WEE1 activity by measuring pCDK1Y15. 









Control	(DMSO)		 	 =		 X	
3	µM	Cisplatin	 		 =	 Y	
3	µM	Cisplatin	+	inhibitor		 =	 Z	
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4.3.2 Single agent cytotoxicity of inhibitors of ATR, CHK1 and WEE1 
Exponentially growing cells were seeded at known densities in 6 well plates and exposed to 
increasing concentrations of inhibitor in growth medium for 24 hours using an equivalent 
concentration of DMSO as a vehicle control as described in section 2.5. Following incubation 
in fresh medium for 10 - 14 days (dependent on cell growth rate) to allow colonies to form 
they were fixed, stained and counted. The survival at each inhibitor concentration was 
calculated relative to the DMSO control. Survival curves of relative colony survival against 
inhibitor concentrations were used to calculate the inhibitor concentration that resulted in 
50% inhibition of colony survival relative to control (LC50) for each of the inhibitors: VE-821; 
PF-477736; and MK1-775 as well as survival at a defined concentration. Inhibitor 
concentrations were chosen to range between those which caused minimal cytotoxicity to 






4.4.1 Activation of the ATR-CHK1-WEE1 pathway by cisplatin 
Activation of all three enzymes, ATR, CHK1 and WEE1 by cisplatin (3 µM), at levels 
comparable with positive control, 4NQO was observed at 8 hours and 24 hours (Figure 4.2). 
Subsequent activation and inhibition assays were therefore conducted following 24-hour 
exposure to cisplatin.  
 
 
Figure 4.1 Representative Western blots showing protein bands corresponding to ATR 
and the principal phosphorylation targets of ATR CHK1 and WEE1 in HeLa cells. 
 HeLa cells were exposed to 3 µM cisplatin for periods of time between 1 and 24 hours. 
Reliable activation of ATR, CHK1 and WEE1 was seen at 8 hours and 24 hours. Kinase 
activation by cisplatin was compared to that seen in a positive control using 4NQO 
 
 
4.4.2 Target enzyme inhibition: ATR and VE-821  
Concentration dependent inhibition of ATR by VE-821 
HeLa, SiHa, C33A and CaSki cells were cultured in media containing 3 µM cisplatin ± VE-821 
at increasing concentrations between 0.3 µM and 30 µM. After 24-hours exposure, cell 
lysates were prepared and analysed by Western blot as outlined, above. Concentration vs 
inhibition curves were used to calculate the concentration of VE-821 needed to achieve 50% 
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enzymatic inhibition (VE-821 IC50) for each of these four cell lines. The mean IC50 values for 
VE-821 fell over a narrow range of concentrations from 620 nM (C33A) to 840 nM (CaSki) 
(Figure 4.2). 
 
Inhibition of ATR by equimolar concentrations of VE-821 
Greater than 50% inhibition of ATR phosphorylation of CHK1 was observed at concentrations 
of VE-821 ≥ 1 uM in all four cell lines: HeLa, SiHa, C33A and CaSki (Figure 4.2) so this 
concentration of VE-821 was further evaluated across the complete panel of six cell lines. To 
minimise inconsistencies associated with constitutive ATR activity, these assays were 
normalised to a control in which cells were exposed to DMSO only. This also revealed 
differences in the extent of ATR activation by cisplatin across the cell line panel. Activation 
was strongest in HeLa cells with a mean of 106-fold activation observed, and least in SiHa 
cells, with a mean activation of just 1.3-fold. Inhibition of cisplatin mediated ATR activation 
by 1 µM VE-821 was observed to be more consistent, with greater than 50% inhibition 
observed in five out of the six cell lines. The greatest inhibition was seen in SiHa cells, with a 
mean inhibition of 93% and the lowest in ME-180 cells, with a mean inhibition of 43%  




Figure 4.2 Concentration dependent inhibition of ATR by VE-821. 
A: Representative Western blots for HeLa, SiHa, C33A and CaSki cells. B: pCHK1S345 levels in 
cells treated with cisplatin (3 µM) and increasing concentrations of VE-821 relative to levels 
in cells treated with cisplatin alone. Data are mean and SEM of 3 independent experiments C: 
Concentration of VE-821 required to achieve a 50% reduction in expression of pCHK1S345 
compared to a cisplatin control (VE-821 IC50) was calculated from the expression vs 








Figure 4.3 Activation of ATR by cisplatin and inhibition by VE-821. 
Cells were cultured with 3 µM cisplatin (C) ± 1 µM VE-821 (VE). Representative Western blots 
are shown. Fold activation of ATR by cisplatin is given as a ratio of the pCHK1S345 band 
intensity to that of the untreated (DMSO) control. % inhibition is the percent-reduction in 
pCHK1S345 band intensity of the Cisplatin + VE-821 treated cells compared to that of cisplatin 
alone and normalised to the control. Figures given are a mean of at least two independent 
experiments. Experiments in which high levels of background ATR activity, out of keeping 
with other results, were excluded. 
 
 
4.4.3 Target enzyme inhibition: CHK1 and PF-477736  
Concentration dependent inhibition of CHK1 by PF-477736 
The inhibition of CHK1 by increasing concentrations of PF-477736 (10 nM – 200 nM) was 
investigated in HeLa, SiHa, C33A and CaSki cells treated with 3 µM cisplatin ± PF-477736 
prior to cell lysis and analysis of pCHK1S296 by Western blot. Concentration vs inhibition 
curves were used to calculate the concentration of VE-821 needed to achieve 50% enzymatic 
inhibition (PF-477736 IC50) for each of these four cell lines (Figure 4.4). The mean values of 
PF-477736 IC50 fell over a narrow (2-fold) range from 6.5 nM (CaSki) to 15 nM (SiHa). 
 
Inhibition of CHK1 by equimolar concentrations of PF-477736 
Greater than 50% inhibition of CHK1 auto-phosphorylation at Serine 296 by PF-477736 was 
observed at the concentrations ≥50 nM in the cell lines for which IC50 values were calculated. 
This concentration of inhibitor was then further evaluated in the complete panel of six 
cervical cancer cell lines. Normalising this panel of activation and inhibition results to an 
untreated control, again revealed that while there was considerable variation in the 
activation of CHK1 by cisplatin from just over two-fold (CaSki) to 141-fold (HeLa). Inhibition 
of cisplatin mediated activation of CHK1 was, however consistent across the cell line panel, 





Figure 4.4 Concentration dependent inhibition of CHK1 by PF-477736. 
 A: Representative Western blots for HeLa, SiHa, C33A and CaSki cells. B: Phospho-
CHK1(S296) levels in cells treated with cisplatin (3 µM) and increasing concentrations of PF-
477736 relative to levels in cells treated with cisplatin alone. Data are mean and SEM of 3 
independent experiments C: Concentration of PF-477736 required to achieve a 50% reduction 
in expression of pCHK1S296 compared to a cisplatin control (PF-477736 IC50) was calculated 
from the expression vs concentration curves (B). Data are the mean and individual values 






Figure 4.5 Activation of CHK1 by cisplatin and inhibition by PF-477736. 
Cells were cultured with 3 µM cisplatin (C) ± 50 nM PF-477736 (PF). Representative Western 
blots are shown. Fold activation of CHK1 by cisplatin is given as a ratio of the pCHK12965 band 
intensity to that of the untreated (DMSO) control. % inhibition is the percent-reduction in 
pCHK1S296 band intensity of the Cisplatin + PF-477736 treated cells compared to that of 
cisplatin alone and normalised to the control. Figures given are a mean of at least two 
independent experiments. Experiments in which high levels of background CHK1 activity, out 
of keeping with other results, were excluded 
 
 
4.4.4 Target enzyme inhibition: WEE1 and MK-1775  
Concentration dependent inhibition of WEE1 by MK-1775 
HeLa, SiHa, C33A and CaSki cells were cultured with 3 µM cisplatin ± MK-1775 at 
concentrations between 50 nM and 800 nM prior to probing for pCDK1Y15. MK-1775 IC50 was 
calculated for each of these four cell lines (Figure 4.6). In contrast to the results described for 
ATR and CHK1, the inhibition of WEE1 by MK-1775 in HeLa, SiHa, C33A and CaSki cells 
showed less consistency with an approximate 4-fold range in IC50 values ranging from 130 





Figure 4.6 Concentration dependent inhibition of WEE1 by MK-1775. 
A: Representative Western blots for HeLa, SiHa, C33A and CaSki cells. B: pCDK1Y15 levels in 
cells treated with cisplatin (3 µM) and increasing concentrations of MK-1775 relative to levels 
in cells treated with cisplatin alone. Data are mean and SEM of 3 independent experiments C: 
Concentration of MK-1775 required to achieve a 50% reduction in expression of pCDK1Y15 
compared to a cisplatin control (MK-1775 IC50) was calculated from the expression vs 
concentration curves. (B). Data are the mean and individual values from independent 
experiments. 
 
Inhibition of WEE1 by equimolar concentrations of MK-1775 
Greater than 50% inhibition of WEE1 by MK-1775 was not consistently observed in all four of 
the cell lines in the concentration range used. Given the substantial inhibition seen in HeLa 
and CaSki cells at 100 nM MK-1775 and the fact that higher concentrations resulted in 
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substantial single agent cytotoxicity (see section 4.5), a concentration of 100 nM was 
selected to expand into the full panel of six cervical cancer cell lines. In these experiments, a 
high level of constitutive pCDK1Y15 was noted. When the WEE1 inhibition was calculated and 
normalised to the background WEE1 activity, consistent inhibition of >50% was observed at 
100 nM MK1775, ranging from 54% (SiHa) to >100% (ME-180): representing less than 
constitutive levels of phosphorylated CDK1 (Figure 4.7). Activation of WEE1 by cisplatin was 
more consistent that that seen of ATR and CHK1 but overall was less marked with a range of 
1.2-fold (ME-180) to 2.8-fold (SiHa) (figure 4.7). This is likely to be a consequence of the high 
level of constitutive CDK1 phosphorylation observed.  
 
Despite the differences described, none of the cell lines were consistently either the least or 
most susceptible to enzymatic inhibition by the three inhibitors under investigation. The 
results of these experiments confirm that the cell lines have intact ATR-CHK1-WEE1 
pathways and that the individual constituent kinases are susceptible to inhibition by the 




Figure 4.7 Activation of WEE1 by cisplatin and inhibition by MK-1775. 
Cells were cultured with 3 µM cisplatin (C) +/- 100 nM MK-1775 (MK). Representative 
Western blots are shown. Fold activation of WEE1 by cisplatin is given as a ratio of the 
pCDK1Y15 band intensity to that of the untreated (DMSO) control. % inhibition is the percent-
reduction in pCDK1Y15 band intensity of the Cisplatin + MK-1775 treated cells compared to 
that of cisplatin alone and normalised to the control. Figures given are a mean of at least 
three independent experiments. Experiments in which cisplatin appeared to reduce WEE1 




4.5 Single agent cytotoxicity 
4.5.1 ATR inhibitor single agent cytotoxicity: VE-821 
The single agent cytotoxicity of VE-821 at concentrations of 300 nM to 30 µM was 
determined. Four out of the six, cell lines: HeLa; C33A; CaSki; and HT-3 showed very similar 
survival across the range of VE-821 concentrations used (Figure 4.8) and the calculated mean 
VE-821 LC50 values fell within a narrow range for these cell lines of between 5.0 µM (C33A) 
and 6.6 µM (HeLa). The survival of both SiHa and ME-180 cells however, was substantially 
greater across all concentrations tested. The mean LC50 for ME-180 was 14 µM. SiHa cells 
failed to reach 50% survival in two out of three experiments and in a third the LC50 was 
calculated to be 22 µM. 
 
 
Figure 4.8 Single agent cytotoxicity of VE-821 in the cervical cancer cell line panel. 
A: The Survival of six cervical cancer cell lines at increasing concentrations of VE-821. Cells 
were exposed to VE-821 at concentrations of 300 nM to 30 µM in growth media for 24 hours. 
Following exposure, cells were incubated in fresh full growth media for at least five doubling 
times prior to fixation and staining. Survival is given as a percentage relative to the survival in 
a DMSO only control. Data are the means ± SEM for three independent experiments. B: LC50 
values for VE-821 in six cervical cancer cell lines. The calculated mean value for the 
concentration of VE-821 required to achieve a 50% reduction in survival compared to a 
DMSO control for each of the cervical cancer cell lines, along with the individual values for 
three independent experiments are shown. 50% survival was reached in one out of three 
experiments with SiHa cells. 
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4.5.2 CHK1 single agent cytotoxicity: PF-477736 
The single agent cytotoxicity of PF-477736 at concentrations of 100 nM to 800 nM was 
determined. In contrast to the results for VE-821, the cells lines showed a greater variation 
in survival across the range of concentrations used (Figure 4.9). Despite this, the range of PF-
477736 LC50 in five of the six cell lines: HeLa; SiHa; C33A; CaSki; and ME-180 fell within a < 4-
fold range of between < 100 nM (CaSki) and 320 nM (ME-180). This inhibitor, however 
showed substantially less cytotoxicity in HT-3 cells than the other cell lines with two out of 
three experiments failing to reach 50% survival and a third giving an LC50 value of 1300 nM. 
At higher concentrations of PF-477736 the survival of the cell lines appeared to diverge, with 
400 nM PF-477736 giving survivals in a range from 5% (CaSki) to 36% (ME-180).  
 
 
Figure 4.9 Single agent cytotoxicity of PF-477736 in the cervical cancer cell line panel. 
A: The Survival of six cervical cancer cell lines at increasing concentrations of PF-477736. Cells 
were exposed to PF-477736 at concentrations of 100 nM to 800 nM in growth media for 24 
hours. Following exposure, cells were incubated in fresh full growth media for at least five 
doubling times prior to fixation and staining. Survival is given as a percentage relative to the 
survival in a DMSO only control. Data are the means ± SEM for three independent 
experiments.  B: LC50 values for PF-477736 in six cervical cancer cell lines. The calculated 
mean value for the concentration of PF-477736 required to achieve a 50% reduction in 
survival compared to a DMSO control for each of the cervical cancer cell lines, along with the 
individual values for three independent experiments are shown. 50% survival was reached in 




4.5.3 WEE1 inhibitor single agent cytotoxicity: ML-1775 
The single agent cytotoxicity of MK-1775 at concentrations of 50 nM to 1.6 µM was 
determined. The cell lines showed a variation in survival across the concentration range with 
some clustering of LC50 values (Figure 4.10). Four out of the six cell lines showed MK-1775 
LC50 values in a narrow range of between 250 nM (C33A) and 300 nM (CaSki). ME-180 
showed a slightly higher LC50 of 400 nM and the value for HT-3 cells was substantially higher 
at 720 nM.  
 
As with experiments using PF-477736, divergence of survival between the cell lines was seen 
at higher concentrations of MK-1775. At 800 nM MK-1775 the difference in survival between 
the least and most sensitive was greater than 20-fold, with Hela survival being 2% and HT-3 
survival being 46%.  
 
 
Figure 4.10 Single agent cytotoxicity of MK-1775 in the cervical cancer cell line panel. 
A: The Survival of six cervical cancer cell lines at increasing concentrations of MK-1775. Cells 
were exposed to MK-1775 at concentrations of 100 nM to 1.6 µM in growth media for 24 
hours. Following exposure, cells were incubated in fresh full growth media for at least five 
doubling times prior to fixation and staining. Survival is given as a percentage relative to the 
survival in a DMSO only control. Data are the means ± SEM for three independent 
experiments. B: LC50 values for MK-1775 in six cervical cancer cell lines. The calculated mean 
value for the concentration of MK-1775 required to achieve a 50% reduction in survival 
compared to a DMSO control for each of the cervical cancer cell lines, along with the 
individual values for three independent experiments are shown.  
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The results of the single agent cytotoxicity assays are summarised by the inhibitor LC50 
values obtained as given in Table 4.1. Notable results include that SiHa cells were the most 
resistant to the cytotoxic effects of VE-821, despite being the cell line which showed the 
most overall inhibition of ATR at 1 µM. HT-3 cells were the most resistant to the cytotoxic 
effects of both PF-477736 and MK-1775 but showed average inhibition of CHK1 and WEE1, 
respectively at the concentrations tested. ME-180 cells were amongst the two most resistant 
cell lines for all of the inhibitors and whilst this cell line showed the greatest inhibition of 
WEE1 by MK-1775, it also showed the least inhibition of ATR by VE-821. The single agent 
cytotoxicity results are unlikely to be explained by the extent of inhibition of the target 
kinases alone and point to a much more complex interplay of factors that determine 
sensitivity to these drugs. 
 
 
Table 4.1 LC50 values for each VE-821, PF-477736 and MK-1775 in all six cervical cancer 
cell lines. 
The mean ± Standard error of the mean for three independent experiments is given 







4.6 Correlations between cell line characteristics, target inhibition and single 
agent cytotoxicity. 
Correlation analyses were performed to investigate relationships between the cell line 
characteristics, described in Chapter 3, and the activity of the inhibitors determined in this 
chapter.  
 
4.6.1 Correlations between enzyme inhibition and single agent cytotoxicity 
It would be expected that some relationship should exist between the activity of the 
inhibitor against its target enzyme and the relative cytotoxicity of that inhibitor to the cancer 
cell. However, no correlation was observed between the cytotoxicity (LC50) and target 
inhibition at a fixed concentration for any of the three inhibitors (Figure 4.11). When an 
alternative measure of cytotoxicity (colony survival at a fixed concentration of inhibitor) is 
used in order to avoid the clustering of LC50 values seen with all inhibitors, neither is there a 
relationship observed between cytotoxicity and target enzyme inhibition for any of the three 
inhibitors (Figure 4.12). 
 
Figure 4.11 Scatter plots of target enzyme % inhibition vs cytotoxicity (LC50). 
 Inhibition is given as the % inhibition at a fixed concentration of inhibitor drug (1 µM VE-821, 
50 nM PF-477736 and 100 nM MK-1775). Cytotoxicity is given as the inhibitor specific 






Figure 4.12 Scatter plots of target enzyme % inhibition vs cytotoxicity (% colony survival 
at fixed inhibitor concentrations). 
 Inhibition is given as the % inhibition at a fixed concentration of inhibitor drug (1 µM VE-821, 
50 nM PF-477736 and 100 nM MK-1775) as determined in experiments described in chapter 
4.4). Cytotoxicity is given as % colony survival at a fixed concentration of inhibitor drug (10 




Given the lack of correlation between target enzyme inhibition and the LC50, the % enzyme 
inhibition was compared to the % inhibition of colony survival at the concentrations used for 
the enzyme activation/ inhibition assays. This showed that at the specific concentrations 
used for each enzyme (1µM VE-821, 50 nM PF-477736 and 100 nM MK-1775) greater than 
50% enzyme inhibition and less than 30% inhibition of colony survival was seen for the 
majority of cell line-inhibitor combinations, though ME-180 cells were particularly sensitive 
to VE-821 and CaSki cells were particularly sensitive to PF-477736 (Table 4.2). These 
concentrations of inhibitors, therefore gave a pragmatic balance between adequate enzyme 
inhibition without excessive single agent cytotoxicity for investigating the relative potential 





Table 4.2 Concentration specific target enzyme inhibition and inhibition of colony 
survival for the cervical cancer cell lines using 1 µM VE-821, 50 nM PF-477736 and 100 
nM MK-1775. 
Enzyme inhibition data is derived from that given in section 4.4 and is data derived from at 
least 2 independent experiments. For colony survival data Mean ±  SEM is given from at least 
three independent experiments. *Data for colony survival at 50 nM PF-477736 is interpolated 
from the survival curves.  
 
 
4.6.2 Correlations with baseline protein expressions 
Single agent cytotoxicity 
There was no relationship between the cytotoxicity (LC50) of VE-821, PF-477736 or MK-1775 
and the expressions of the kinases targeted by them in this cell line panel. Neither was there 
any significant correlation between the expression of the key DDR proteins ATM, DNA-PKcs, 
Ku 70 or Ku 80 and the single agent cytotoxic effects of PF-477736 or MK-1775 (data not 
shown). However, ATM and DNA-PKcs did appear to show some relationship to VE-821 
cytotoxicity. Neither correlation significant was significant, but HT-3 cells had particularly low 





Figure 4.13 Scatter plots of ATM and DNA-PKcs expression vs single agent cytotoxicity. 
The expressions of ATM and DNA-PKcs proteins are shown as a ratio to loading control (α-
tubulin). Cytotoxicity is given as the inhibitor specific concentration at 50% colony survival in 
colony formation assays (LC50). 
 
Given the observed clustering of LC50 values, as described in chapter 4.5 and the apparent 
divergence of colony survival results at higher concentrations of PF-477736 and MK-1775, 
further correlations were tested using colony survival at 400 nM PF-477736 and 800 nM MK-
1775 as the measure of cytotoxicity. There was however, no relationship seen between this 
measure of single agent cytotoxicity and baseline protein expressions using these values 
(data not shown). 
 
Target enzyme inhibition 
As IC50 values were calculable for just four of the six cervical cancer cell lines, correlations 
between the extent of inhibition at single inhibitor concentrations (1 µM VE-821, 50 nM PF-
477736 and 100 nM MK-1775) were tested for correlation with the baseline expression of 
the associated target enzyme. Potential relationships were observed between i) the baseline 
expression of ATR and the inhibition of ATR by VE-821, and ii) the baseline expression of 
WEE1 and the inhibition of WEE1 by MK-1775 (Figure 4.14). In both cases, higher baseline 
expression appeared to be associated with greater enzyme inhibition at the stated 
concentrations. Neither relationship reached significance on Pearson correlation testing, 
which may be due to the small number of data points. Additionally, the correlation between 
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WEE1 expression and inhibition by MK-1775, does appear to be driven by ME-180, which 
appears as an outlier in both expression and inhibition datasets.  
 
Figure 4.14 Correlations between inhibitor % target enzyme inhibition and baseline 
expressions of G2/M cell cycle checkpoint kinases. Scatter plots of the % inhibition of ATR, 
CHK1 and WEE1 at fixed concentrations vs the baseline expressions of the target enzyme for 
inhibition and the immediate downstream kinase or phosphorylation target.  The expression 
of ATR, CHK1 and WEE1 are shown as a ratio to loading control (α-tubulin).  
 
In summary, correlation analysis has revealed potential relationships between results 
described in this chapter and baseline characteristics of the cell lines explored in chapter 3. 
While there were no relationships seen between the target enzyme inhibition and single 
agent cytotoxicity of the ATR, CHK1 and WEE1 inhibitors, some degree of correlation was 
noted to exist between baseline expression of ATR and the extent of its inhibition by VE-821, 
and between baseline expression of WEE1 and its inhibition by MK-1775. Additionally, 
possible positive correlations were observed between VE-821 cytotoxicity and both ATM and 
DNA-PKcs baseline expression. Further correlation analysis between cell growth (doubling 




Consistent, concentration dependent inhibition of ATR and CHK1 was observed when HeLa, 
SiHa, C33A and CaSki cells were exposed to increasing concentrations of VE-821 and PF-
477736, respectively with IC50 and values falling within narrow ranges. Inhibition of WEE1 by 
MK-1775 showed a greater variation in these initial assays and with a wider range of MK-
1775 IC50 values. Expanding the inhibition assays at a fixed concentration of inhibitors to all 
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six cell lines and controlling for background revealed high levels of constitutive pCDK1Y15 . 
This resulted in comparatively small increases in CDK1 phosphorylation in response to WEE1 
activation by cisplatin and hence a smaller dynamic range from which to measure inhibition 
by MK-1775.  When the baseline levels of target phosphorylation were controlled for, 
consistent inhibition levels of > 50% were seen in all cell-inhibitor combinations except that 
with ME-180 cells and the ATR inhibitor VE-821. 
 
The presence of high levels of pCDK1Y15 in untreated cells could suggest a high level of WEE1 
activity. However, WEE1 activity promoted by high levels of replication stress would likely 
occur along with high levels of ATR and CHK1 activity in untreated cells, which was not seen, 
making an alternative explanation more likely. Phosphorylated CDK1 may exist in low levels 
of replications stress as phosphorylation of CDK1 at Y15 is not solely dependent on WEE1 
activity. Cdc25c (whose function is also dependent on CHK1 phosphorylation) also influences 
the phosphorylated state of CDK1 (Sorensen and Syljuasen, 2012). CDK1 also interacts with 
and is phosphorylated by a number of other important kinases that are not involved in the 
DNA damage response. One such kinase is Myelin transcription factor 1 (MYT1), which is 
implicated in the G2/M checkpoint response (de Gooijer et al., 2017, Chow and Poon, 2013). 
MYT1 phosphorylates CDK1 at tyrosine 15 (Y15) as well as at tyrosine 14 (Y14) (Welburn et 
al., 2007, Chow and Poon, 2013),and the antibody used may not discriminate between these 
residues. 
 
Overall, there was little consistency in the profile of cytotoxicity amongst the six cervical 
cancer cell lines across the three inhibitors used, however, a number of results are worthy of 
further discussion. ME-180 cells appeared amongst the most resistant to the cytotoxic 
effects of all three inhibitors. This was in keeping with the observation that these cells also 
expressed the highest levels of ATM: ATM having been previously described as a 
determinant of sensitivity to ATR inhibition (Kwok et al., 2016, Middleton et al., 2015). 
Consistent with this was the finding that the HPV-negative and RB1/TP53 mutated cell line 
HT-3 was amongst the most sensitive to the ATR inhibitor and expressed the least ATM in 
baseline expression assays (Chapter 3). HT3 cells were, however the least sensitive to both 




This difference in the response of the HT-3 cells to the cytotoxic effects of ATR inhibition 
versus CHK1 or WEE1 inhibition, despite similar levels of target enzyme inhibition across the 
three inhibitors, points at subtle differences in the roles of the kinases in the DDR and 
confirms that the ATR-CHK1-WEE1 pathway does not exist or act in isolation from other 
responses to DNA damage. The cells response to the inhibitors was also not solely 
dependent on the extent of enzymatic inhibition at a given concentration. This is further 
confirmed by the observation that whilst SiHa cells were the most resistant to VE-821 
cytotoxicity, they showed the greatest extent of inhibition of ATR at the concentration 
tested (Table. 4.2). 
  
Depletion of the human Ku proteins or upregulation of DNA-PKcs has previously been shown 
confer sensitivity to ATR and CHK1 inhibition (Middleton et al., 2015, Massey et al., 2016). 
No clear relationship was observed between the levels of expression of Ku70 or Ku80 and 
the cytotoxicity of the inhibitors in the cell line panel. However, in contrast to this evidence 
the cervical cancer cells with low DNA-PKcs expression reported here were more sensitive to 
ATR inhibitor cytotoxicity, though this should be interpreted with caution the non-significant 
nature of the correlation.  
 
4.8 Conclusions 
With reference to the aims and objectives set out at the start of this chapter: 
• ATR, CHK1 and WEE1 were inhibited in a concentration dependent manner by VE-821, 
PF-477736 and MK-1775, respectively. When the background activity or baseline 
phosphorylation of the downstream target kinase was controlled for, enzyme inhibitions fell 
within a consistent range, with similar potencies across the cell line panel.  
• The cervical cancer cell lines had a variable response to the cytotoxic effects of the ATR, 
CHK1 and WEE1 inhibitors that was not dependent of the extent of target inhibition or the 
baseline level of checkpoint kinase expression. 
• The cytotoxic effects of the ATR inhibitor VE-821 may be related to the baseline 
expression levels of both ATM and DNA-PKcs, though it is difficult to draw conclusions in this 
small cell line panel. VE-821 cytotoxicity did not appear to be related to expression of any of 
the other proteins measured 
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• CHK1 and WEE1 inhibition by PF-477736 and MK-1775, respectively did not show any 
correlation with baseline DDR proteins measured. 
Experiments reported in this chapter allowed the determination of suitable fixed 
concentrations of VE-821, PF-477736 and MK-1775 to use in cytotoxicity assays in 
combination with cisplatin and IR (1 µM VE-821, 50 nM PF-477736 and 100 nM MK-1775). 
These concentrations, in general, resulted in greater than 50% target enzyme inhibition 
while causing less than 30% inhibition of colony survival as single agents (Table 4.2). 
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5 Sensitisation of cervical cancer cell lines to cisplatin and 
ionising radiation using inhibitors of ATR, CHK1 and WEE1 
 
5.1 Introduction 
Results of experiments detailed in the previous chapter identified a spectrum of sensitivity 
to ATR, CHK1 and WEE1 inhibitor single agent cytotoxicity with no obvious consistency in the 
rank order of sensitivity or relationship with target inhibition or DDR protein expression. 
Western blot analysis provided confidence that substantial target enzyme inhibition was 
achieved at inhibitor concentrations that showed modest single agent cytotoxic effects.  
 
The overall aim of this thesis was to determine the potential of inhibitors of the intra-S and 
G2/M cell cycle checkpoint kinases to improve cervical cancer treatment and to understand 
the underlying biological mechanisms that may underlie such improvements. The standard 
of care treatments for cervical cancer are cisplatin and ionising radiation (IR) used alone or in 
combinations as described in Chapter 1. The aim of this chapter was to compare the extent 
to which the inhibitors enhance the cytotoxicity of IR and cisplatin and to determine if this 
ability was related to any of the parameters measured in chapters 3 and 4. 
 
Cisplatin and IR produce different DNA lesions that are repaired by different DNA repair 
pathways (Chapter 1). Both agents, however result in the key ATR-CHK1 activating single-
strand-double-strand junctions (Hoeijmakers, 2001) and, more importantly lead to the 
presence of collapsed replication forks (Paulsen and Cimprich, 2007, Nam and Cortez, 2011). 
It would therefore be expected that both insults will invoke a strong ATR-CHK1-WEE1 
pathway induction response that would be amenable to inhibition by inhibitors of these 
enzymes. In respect of cisplatin, this is shown in results described in Chapter 4 and the 
activation of this pathway by IR is established through investigations into inhibition of this 
pathway in radio-resistant breast cancer tissue (Zhang et al., 2016) and recently in studies 
involving human squamous cancers (HNSCC) (Dillon et al., 2017). The rationale for ATR, CHK1 
and WEE1 inhibitor combinations as a strategy in cervical cancer treatment is therefore 
strong and ATR, CHK1 or WEE1 knockdown or pharmacological inhibition has been reported 
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to sensitise human cancer cells and xenografts to cisplatin and IR, as reviewed in Chapter 
1.5.  
 
Single agent cytotoxicity did not reflect the extent of target inhibition across the cell line 
panel and there are limitations in estimating this inhibition by Western blot. For these 
reasons a fixed concentration of each of the inhibitors, rather that concentrations that 
caused a defined level of target inhibition, was used to study the chemo- and radio-
sensitisation. Concentrations were selected that showed good inhibition of the target 
enzyme as detailed in Table 4.2.  
 
5.2 Aims and Objectives 
The aims of the investigations described in this chapter were: 
1. To determine the relative sensitivity of the six cervical cancer cell lines to cisplatin and 
ionising radiation (IR). 
2.  To determine the relative potential of the ATR, CHK1 and WEE 1 inhibitors: VE-821, PF-
477736 and MK-1775, respectively to sensitise cervical cancer cell lines to cisplatin and 
ionising radiation. 
 
This will enable the following hypotheses to be tested: 
1. Sensitisation of cell lines to cisplatin by ATR, CHK1 or WEE1 inhibitors will be dependent 
on the intrinsic sensitivity of the cell lines to cisplatin. 
2. Sensitisation of cell lines to IR by ATR, CHK1 or WEE1 inhibitors will be dependent on the 
intrinsic sensitivity of the cell lines to IR. 
3. Sensitisation of cell lines to cisplatin or IR will depend on the single agent cytotoxicity in 
of the inhibitor. 
 
5.3 Materials and methods 
5.3.1 Colony formation assays with cisplatin and ionising radiation 
Exponentially growing cells were seeded at known densities in 6 well plates and exposed to 
increasing concentrations of cisplatin or increasing doses of ionising radiation (IR) in order to 
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assess the cell lines’ intrinsic sensitivity to cisplatin and IR. Exposure to cisplatin was for 24 
hours in all cases. Following exposure to cisplatin, the growth media was changed to fresh 
full media and the cells were incubated for at least five doubling times as described in 
Chapter 2.5.1. For IR sensitivity and sensitisation assays, the IR dose was delivered in a single 
fraction using a D3300 X-ray system (Gulmay Medical Ltd. Chertsey, UK). For IR-only assays, 
the growth media was not changed prior to incubation for five doublings. For IR + inhibitor 
assays, the growth media was changed to fresh full media following 24-hour drug exposure 
as described in Chapter 2.5.4. 
 
The results of these assays were used to determine suitable concentration and dose ranges 
for sensitisation experiments using fixed concentration ATR, CHK1 and WEE1 inhibitors in 
the cell lines. Colony formation assays assessing the sensitisation of the cell lines to cisplatin 
and IR were carried out as described in Chapter 2.5.3 and Chapter 2.5.4. In all sensitisation 
assays, fixed concentrations of inhibitor drug were used, as described in Chapter 5.1, above. 
These were 1 µM VE821, 50 nM PF-477736 and 100 nM MK-1775. 
 
5.4 Results 
5.4.1 Cell line sensitivity to cisplatin and ionising radiation alone 
Sensitivity to cisplatin 
The six cervical cancer cell lines showed a range of sensitivity to cisplatin. There was just 
over a two-fold difference in Cisplatin LC50 values between the least sensitive cell line (HeLa) 
and the most sensitive (SiHa), as shown in Table 5.1. There was no clear relationship 
between cisplatin cytotoxicity and cell line HPV, p53 or pRB status: the HPV negative and p53 
mutated cell lines C33A and HT-3 showed average sensitivity to cisplatin across the 
concentration range used (Figure 5.1).  Nor was there any relationship seen between 
cisplatin cytotoxicity and baseline expression of any of the cell cycle or DDR proteins 
measured, as described in Chapter 3 (data not shown).  
 
Potential relationships were found between cisplatin cytotoxicity and cisplatin mediated 
activation of both ATR and CHK1 (Figure 5.2). Cisplatin induced ATR, CHK1 and WEE1 activity 
to differing extents across the cell lines (Chapter 4). Activation of ATR and CHK1 was greatest 
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in HeLa cells, which showed the least sensitivity to cisplatin. SiHa cells, which were the most 
sensitive to cisplatin cytotoxicity had amongst the lowest ATR activation and CHK1 
activation. Though Pearson correlation analysis suggested a significant correlation in the 
case of ATR, the clustering of ATR activation and cisplatin LC50 and the likely heavy reliance 
of the outlying HeLa result for both parameters indicates that whilst extremes may fit the 
hypothesis that cisplatin sensitivity is related to ATR/CHK1 activity, it is not possible to 
determine if there is a true correlation with such a small panel of cells. There was no 




Figure 5.1 Cisplatin cytotoxicity in the cervical cell line panel. 
A: The survival of six cervical cancer cell lines at increasing concentrations of cisplatin. Cells 
were exposed to cisplatin at concentrations of 0.03 µM to 3 µM in growth media for 24 
hours. Following exposure, cells were incubated in fresh growth media for at least five 
doubling times prior to fixation and staining. B: LC50 values for cisplatin in the cervical cancer 
cell lines. The calculated mean cisplatin concentration required to cause 50% reduction in 
survival compared to control, along with the individual values for three individual 






Figure 5.2 Correlations between cisplatin cytotoxicity and relative activation of target 
enzymes by cisplatin in cervical cancer cell lines. 
Scatter plots of the concentration of cisplatin alone required to reduce colony survival to 50% 
compared to an untreated control vs the fold-activation over baseline of each of the 
enzymes: ATR, CHK1 and WEE1 in response to exposure to cisplatin, as determined in 
experiments described in chapter 4. All values correspond to the means of at least two 
independent experiments.  
 
 
Sensitivity to IR 
Similar to that found with cisplatin, there was some variation in the sensitivity of the cell 
lines to IR, but over a fairly narrow range (Figure 5.3). There was a just under two-fold 
difference between the dose of IR required to reduce colony survival by 50% compared to 
control (IR LD50) between the most sensitive (C33A: 1.3 Gy) and the least sensitive (HeLa: 2.5 
Gy). The four remaining cell lines all had LD50 values of between 1.5 Gy and 1.8 Gy. The order 
of sensitivity of the cell line panel was not similar for cisplatin and IR, though ME-180 and 
HT-3 cells were amongst the three most sensitive cell lines and HeLa was the least sensitive 







Figure 5.3 Ionising radiation cytotoxicity in the cervical cell line panel. 
A: The survival of six cervical cancer cell lines at increasing doses of cisplatin. Cells in full 
growth media were exposed to IR at doses of 2 Gy to 6 Gy. Following exposure, cells were 
incubated for at least five doubling times prior to fixation and staining. Survival is given as a 
percentage relative to the survival of untreated cells. B: LD50 values for IR in the cervical 
cancer cell lines. The calculated mean IR dose required to cause 50% reduction in survival 
compared to control, along with the individual values for three individual experiments are 
given. Data are from three individual experiments and normalised to control. 
 
 
Considering the relative similarity of the IR LD50 values and the impact that this could have in 
determining trends, an alternative measure of IR cytotoxicity: colony survival following 
exposure to a fixed dose of IR (4 Gy) was used to compare cytotoxicity with baseline 
expression of the cell cycle kinases and DRR proteins. When this alternative measure of 
cytotoxicity was used, potential relationships between IR cytotoxicity and both ATR and 






Figure 5.4 Correlations IR cytotoxicity and baseline expression of target enzymes 
cervical cancer cell lines. 
Scatter plots of the % colony survival following exposure to 4 Gy IR vs baseline expression of 
the enzymes: ATR, CHK1 and WEE1, as determined in experiments described in chapter 3. All 
values correspond to the means of three independent experiments.  
 
5.4.2 Sensitisation of cell lines to cisplatin by ATR, CHK1 and WEE1 inhibitors 
The cytotoxicity of increasing concentrations of cisplatin ± a fixed concentration of inhibitor 
drug was investigated. In addition to the survival curves, results for the sensitisation of cells 
to cisplatin by the inhibitors are given as potentiation factors (PF). PF50 is the ratio of LC50 in 
the absence or presence of the inhibitor.  PF0.3-cis is the ratio between survival at a fixed 
cisplatin concentration of 0.3 µM in the absence and presence of the inhibitor drug. 
 
VE-821 
VE-821 (1 µM) caused variable sensitisation to cisplatin cytotoxicity in the six cervical cancer 
cell lines. When survival curves for cisplatin ± inhibitor (Figure 5.5) were compared using 
two-way ANOVA, a significant potentiation of cisplatin across the range of concentrations 
was confirmed in four of the cell lines: HeLa; SiHa; C33A; and ME-180. The largest magnitude 
of potentiation was seen in C33A cells (PF50 = 5.9) and the smallest in CaSki cells (PF50 = 1.8) 
and SiHa cells (PF50 = 1.8). At higher concentrations the order of sensitisation appeared to 
change. The potentiation factor at 0.3 µM cisplatin was largest in ME-180 cells  
(PF0.3-cis = 12.7) and lowest in CaSki (PF0.3-cis =1.2) (Table 5.1).  
  
When either measure of sensitisation to cisplatin is used, there was no relationship between 
sensitisation by VE-821 and expression of baseline proteins across the cell line panel. VE-821 
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caused the least sensitisation to cisplatin in SiHa cells and the greatest in ME-180 cells. This 
appears at odds with the observation that SiHa showed the greatest inhibition of ATR by the 
same concentration of VE-821 and ME-180 the least. When the other cell lines are included, 
there was no relationship between either ATR activation by cisplatin or its inhibition by VE-
821 and VE-821 mediated sensitisation of the cell lines to cisplatin cytotoxicity. Neither is the 
extent of sensitisation to cisplatin by VE-821 predicted by single agent VE-821 cytotoxicity or 
cisplatin cytotoxicity. 
 
Figure 5.5 Colony survival of cervical cancer cell lines exposed to cisplatin ± VE-821. 
Cells were exposed to cisplatin at concentrations of 0.03 µM to 3 µM ± 1 µM VE-821 in 
growth media for 24 hours. Following exposure, cells were incubated in fresh growth media 
for at least five doubling times prior to fixation and staining. Data are the means and SEM 






Table 5.1 Sensitisation of cervical cancer cell lines to cisplatin by VE-821.   
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 1 µM VE-821. PFcis 0.3 (Potentiation Factor at 0.3µM cisplatin) is 
the factor by which % colony survival at 0.3µM cisplatin is reduced vs control by 1 µM VE-
821. The differences between the mean LC50/LC0.3-cis  ±  inhibitor was compared using a paired 
t-test.* = p < 0.05, ** = p < 0.005 
 
PF-477736 
Sensitisation of the cell lines to cisplatin by 50 nM PF-477736 was less than that seen for 1 
µM VE-821 (Figure 5.6), despite the observation that 50 nM PF-477736 inhibited CHK1 more 
than 1 µM VE-821 inhibited ATR across the cell line panel (Chapter 4.4). ME-180 cells again 
showed the greatest sensitisation by PF-477736 (PF50 = 2.5; PF0.3-cis = 1.8). PF-477736 did not 
sensitise HeLa cells to cisplatin. 
 
Analysis of the sensitisation effects of 50 nM PF477736 on cisplatin cytotoxicity in the 
individual cell lines were mixed. Comparison of the survival curves ± inhibitor by two-way 
ANOVA suggested a significant sensitisation was seen in HT-3 cells, however this was likely to 
be due to the results at low cisplatin concentrations and the curves appear to converge at 
higher concentrations. Differences in the ME-180 survival curves approached significance 
but neither the difference between LC50 or LC0.3-cis with and without inhibitor were significant 




There were no significant correlations found between PF-477736 sensitisation to cisplatin 
and PF-477736 single agent cytotoxicity. Despite the greatest activation of CHK1 by cisplatin 
in HeLa cells, the strong inhibition of CHK1 by PF-477736 and and the resistance of this cell 
line to cisplatin, PF-477736 did not enhance cisplatin cytotoxicity in HeLa cells. Across the 
cell line panel, sensitisation of cisplatin was not related to CHK1 activation by cisplatin or 
extent of inhibition of CHK1 by PF-477736 as measured in Chapter 4.4.3. In contrast to HeLa 
cells, ME-180 cells were most sensitive to cisplatin and were sensitised the most to cisplatin 
by PF-477736, though there was no relationship between cisplatin cytotoxicity and PF-
477736 sensitisation across the panel. 
 
Figure 5.6 Colony survival of cervical cancer cell lines exposed to cisplatin ± PF-477736. 
Cells were exposed to cisplatin at concentrations of 0.03 µM to 3 µM ± 50 nM PF-477736 in 
growth media for 24 hours. Following exposure, cells were incubated in fresh growth media 
for at least five doubling times prior to fixation and staining. Data are the means and SEM 






Table 5.2 Sensitisation of cervical cancer cell lines to cisplatin by PF-477736.   
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 50 nM PF-477736. PF0.3-cis (Potentiation Factor at 0.3µM cisplatin) 
is the factor by which % colony survival at 0.3µM cisplatin is reduced vs control by 50 nM PF-





There was a much smaller spectrum of potentiation of cisplatin by MK-1775 than by VE-821 
or PF-477736 at the concentrations used (Figure 5.7).  Comparison of the survival curves 
with and without inhibitor by two-way ANOVA revealed no significant differences. 
Consistent with results for VE-821 and PF-477736, ME-180 showed the greatest potentiation 
using both PF50 and PF0.3-cis but paired t-testing of the differences between the means used 






Figure 5.7 Colony survival of cervical cancer cell lines exposed to cisplatin ±  MK-1775. 
Cells were exposed to cisplatin at concentrations of 0.03 µM to 3 µM ±  100 nM MK-1775 in 
growth media for 24 hours. Following exposure, cells were incubated in fresh growth media 
for at least five doubling times prior to fixation and staining. Data are the means and SEM 







Table 5.3 Sensitisation of cervical cancer cell lines to cisplatin by MK-1774.   
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 100 nM MK-1775. PFcis 0.3 (Potentiation Factor at 0.3µM cisplatin) 
is the factor by which % colony survival at 0.3µM cisplatin is reduced vs control by 100 nM 




Whilst MK-1775 was more cytotoxic as a single agent to both HT-3 and ME-180 cells than in 
the other cell lines, MK-1775 only sensitised ME-180 cells and there was no trend for the 
sensitisation by MK-1775 across the panel. Neither was sensitisation predicted by sensitivity 
to cisplatin alone. Despite the narrow spectrum of sensitisation to cisplatin by MK-1775 and 
the lack of statistical significance in the differences in survival, a significant correlation was 
found between the sensitisation of cells to cisplatin by MK-1775 and baseline WEE1 
expression. This was observed when either measure of sensitisation was used (Figure 5.9). 
These results should be treated with caution due to the very small effects observed and the 
size of the panel, but it may be worth following up in a larger study. No relationship was 
seen between sensitisation and expression of any of the other proteins measured in Chapter 





Figure 5.8 Correlations between cell line sensitisation to cisplatin by MK-1775 and 
baseline expression of WEE1 in cervical cancer cell lines. 
Scatter plots of the calculated PF50 and PFcis. 0.3 values for MK-1775 sensitisation to cisplatin 
vs WEE1 expression as determined in experiments in chapter 3. All values are the mean of 
three individual experiments. 
 
 
5.4.3 Sensitisation of cell lines to IR by inhibitors of ATR, CHK1 and WEE1 
The cytotoxicity of increasing concentrations of IR ± a fixed concentration of inhibitor drug 
was investigated using the same fixed concentrations of individual inhibitors as above. In 
addition to the survival curves, PF50 and PF2-IR were calculated, as above. PF2-IR is the ratio 
between survival at a clinically relevant fixed IR dose of 2 Gy in the absence and presence of 
the inhibitor drug. 2 Gy IR is a standard fractional dose for clinical radiotherapy and gives a 
similar range of colony survival across the cell line panel as 0.3 µM cisplatin used for the 





VE-821 radio-sensitised HeLa cells and ME-180 cells the most (Figure 5.9, Table 5.4) and HT-3 
cells were radio-sensitised the least. Comparison of the survival curves with and without 
inhibitor by two-way ANOVA revealed significant potentiation for HeLa and ME-180 cells. 
Significant potentiation of IR cytotoxicity was also seen in HT-3 cells but the magnitude of 
the effect was much smaller. Paired t-test of the difference in mean LD2-IR revealed a 
significant difference in HeLa cells and CaSki cells only (Table 5.4).  
 
HeLa cells were the most radio-resistant and had amongst the greatest sensitisation to IR by 
VE-821 (at the LD50) whilst C33A cells were the most radio-sensitive and were amongst the 
least sensitised by VE-821 at the LD50 and at 4 Gy. VE-821 radio-sensitisation (PF50) was 
correlated with radio-resistance across the cell line panel (Figure 5.10).  
 
Sensitisation of cell lines to IR by VE-821 was not predicted by single agent VE-821 
cytotoxicity or the extent of inhibition of ATR by VE-821 calculated in experiments in Chapter 
3. VE-821 sensitisation of cell lines to IR did not correlate with cell line doubling time, HPV or 








Figure 5.9 Colony survival of cervical cancer cell lines exposed to IR ± VE-821. 
Cells were exposed to 2 Gy to 6 Gy IR ±  immediate 24-hour culture with 1 µM VE-821. After 
24 hours, cells were incubated in fresh growth media for at least five doubling times prior to 
fixation and staining. Data are the means and SEM from three independent experiments. 






Table 5.4 Sensitisation of cervical cancer cell lines to IR by VE-821.   
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 1 µM VE-821. PF2-IR (Potentiation Factor at 2 Gy IR) is the factor by 
which % colony survival at 2 Gy IR is reduced vs control by 1 µM VE-821. The differences 




Figure 5.10 Correlations between sensitisation to IR by VE-821 and sensitivity to IR 
alone. 
Scatter plots of calculated VE-821 PF50 values vs two measures of IR sensitivity: calculated IR 
dose resulting in 50% colony survival (LD50); and measured survival at 4 Gy IR alone. All 







Radio-sensitisation by PF-477736 was much more modest than that observed with VE-821 or 
cisplatin sensitisation by PF-477736 (Figure 5.11). Whilst it appeared that again, HeLa and 
ME-180 cells show the greatest sensitisation and HT-3 the least, there was no significant 
difference found between the colony survival ± PF-477736. Unsurprisingly, given the very 
modest potentiation at both 50% colony survival and at 2 Gy IR (Table 5.5), no significant 
correlations were observed between any of the cell line characteristics, determined in 
experiments from Chapter 3, or the cytotoxicity of IR or PF-477736 alone (Chapter 4 and 
section 5.4.1, above: data not shown).  
 
 
Table 5.5 Sensitisation of cervical cancer cell lines to IR by PF-477736.   
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 50 nM PF-477736. PF2 Gy IR (Potentiation Factor at 2 Gy IR) is the 
factor by which % colony survival at 2 Gy IR is reduced vs control by 50 nM PF-477736. The 





Figure 5.11 Colony survival of cervical cancer cell lines exposed to IR ± PF-477736. 
Cells were exposed to 2 Gy to 6 Gy IR ±  immediate 24-hour culture with 50 nM PF-477736. 
After 24 hours, cells were incubated in fresh growth media for at least five doubling times 
prior to fixation and staining. Data are the means and SEM from three independent 






MK-1775 was a poor radiosensitiser. There was no relationship seen between the 
sensitisation of cells to IR by MK-1775 and the cells’ intrinsic sensitivity to IR or MK-1775 
alone or the baseline expression of WEE1. Given the modest and non-significant radio-
sensitisation any correlations must be taken with caution, nevertheless, a significant 
correlation was seen with baseline expressions of ATR, CHK1, CDK1 and DNA-PKcs (Figure 
5.13). Cells with high expression of ATR and DNA-PKcs appeared to have greater sensitisation 
to IR by MK-1775. By contrast cells with high levels of either CHK1 or CDK1: the kinases 
directly upstream and downstream of WEE1, respectively at the G2/M cell cycle checkpoint, 
appeared to be less sensitised to IR by MK-15775. This may be a chance finding given the 
number of correlations investigated but is worthy of further investigation in other cell lines. 
 
 
Table 5.6 Sensitisation of cervical cancer cell lines to IR by MK-1775 
Two measures of sensitisation are given: PF50 (Potentiation Factor at 50% survival) is the 
factor by which the mean concentration of cisplatin causing 50% colony survival vs control is 
reduced in the presence of 100 nM MK-1775. PF2 Gy IR (Potentiation Factor at 2 Gy IR) is the 
factor by which % colony survival at 2 Gy IR is reduced vs control by 100 nM MK-1775. The 





Figure 5.12 Colony survival of cervical cancer cell lines exposed to IR ± MK-1775. 
Cells were exposed to 2 Gy to 6 Gy IR ±  immediate 24-hour culture with 100 nM MK-1775. 
After 24 hours, cells were incubated in fresh growth media for at least five doubling times 
prior to fixation and staining. Data are the means and SEM from three independent 







Figure 5.13 Correlations between MK-1775 sensitisation of cell lines to cisplatin 
cytotoxicity and baseline expression of target enzymes in cervical cancer cell lines. 
Scatter plots of the calculated MK-1775 PF50 values for IR sensitisation vs baseline expression 
of the enzymes: CHK1, CDK1 and DNA-PKcs, as determined in experiments described in 




The aim of this chapter was to relate the chemo- and radio-sensitivity of the cervical cancer 
cell lines to their baseline characteristics determined in previous chapters and to compare 
how effectively VE-821, PF-477736 and MK-1775 sensitise cervical cancer cell lines to 
cisplatin and ionising radiation. ATR, CHK1 and WEE 1 knockdown utilising siRNA/shRNA 
techniques have previously been used in validating these kinases as targets for inhibition 
with the aim of sensitising cancer cells to the effects of DNA damaging agents and are 
reviewed in Chapter 1.5.1. Similar experiments have not been repeated in these 
investigations. Whilst this raises the possibility that some of the enhanced cytotoxicity seen 
in combination with cisplatin or IR may be the result of off-target effects of the inhibitors, 
the experiments in previous chapters provide reassurance that substantial inhibition of ATR, 
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CHK1 and WEE1 by their inhibitors is achieved at the drug concentrations used. Though the 
small number of cell lines included in the cell line panel is another limitation to the wider 
applicability of the results, this is the first time that a direct comparison of inhibitors of ATR, 
CHK1 and WEE1 has been made.   
 
Similar survival was seen for the cervical cancer cell lines over the range of cisplatin 
concentrations / IR exposures used to determine the cisplatin and radio-sensitivity of the cell 
line panel. The rank order of cytotoxicity for cisplatin and IR was not the same (Figure 5.14). 
Whilst no relationships were found between protein expressions and cisplatin sensitivity, 
potential determinants of sensitivity to IR were seen. Hela and SiHa cells had high ATR and 
low CHK1 expression and were the least sensitive to IR. C33A, CaSki, ME-180 and HT-3 all 
expressed low ATR and high CHK1, and were more sensitive to IR. Interestingly HeLa and 
SiHa also showed the highest DNA-PKcs expression and SiHa showed the highest ATM 
expression, though no correlation was found when the other cell lines were considered.  
 
ATM and DNA-PKcs are important in the detection of IR induced DSBs and their repair by 
NHEJ (Hoeijmakers, 2001) and NHEJ function has previously been reported as a determinant 
of sensitivity to IR (Mahaney et al., 2009). NHEJ is less important in the repair of cisplatin 
induced DNA damage (Hoeijmakers, 2001, Curtin, 2012). The differences in the rank order of 
sensitivity to cisplatin and IR and the presence of potential relationships between key NHEJ 
proteins and IR sensitivity, supports the hypothesis that the determinants of sensitivity to 
cisplatin and IR are different, owing to the different DNA repair pathways involved.  
 
Inhibition of ATR by VE-821 caused greater cisplatin and IR sensitisation than either CHK1 
inhibition by PF-477736 or WEE1 inhibition by MK-1775 at the concentrations used. This may 
suggest that ATR is a better target for inhibition than either CHK1 or WEE1, however the 
overall lower inhibition of WEE1 activity by 100 nM MK-1775 compared to ATR inhibition by 
1 µM VE-821 should be considered when making this direct comparison. The smaller 
magnitude of cisplatin and IR sensitisations caused by PF-477736 and MK-1775 precluded 
meaningful correlations with the cytotoxicity of either agent or with single agent inhibitor 





ME-180 and HeLa cells appeared to show the greatest sensitisation across all inhibitors. HT-3 
cells and C33A cells were consistently amongst the least sensitised to IR (Figure 5.14), 
notable due to the HPV negative and TP53-/RB1- mutant status of these cell lines. Beyond 
those features described above it was not possible to relate any of the molecular 
characteristics of the cells, determined as part of this study, to intrinsic chemo- or 
radiosensitivity or significant sensitisation by the inhibitors. This was largely because of the 





Figure 5.14 Heatmaps showing the relative sensitisation of cervical cancer cell lines to 
cisplatin and IR by VE-821, PF-477736 and MK-1775. 
A: Cisplatin PF50 (potentiation factor at 50% survival) by cell line and inhibitor. B: Cisplatin 
PF0.3-cis (potentiation factor at 0.3 µM cisplatin) by cell line and inhibitor. C: IR PF50 by cell line 
and inhibitor. D: IR PF2-IR (potentiation factor at 2 Gy IR) by cell line and inhibitor. Data taken 




MK-1775 radio-sensitisation, though not-significant for any cell, correlated with high ATR 
and DNA-PKcs expression (Chapter 3). DNA-PKcs overexpression was previously described as 
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a determinant of sensitivity to ATR and CHK1 inhibitors (Middleton et al., 2015, Massey et 
al., 2016), however, this relationship has not previously been noted with respect to WEE1, 
either as a single agent or as a sensitising agent for IR. The very narrow and non-significant 
range of sensitisation by this inhibitor, however limits confidence that a true correlation 




With reference to the aims and objectives set out at the start of this chapter: 
• The cervical cancer cell lines showed a range of sensitivity to cisplatin and IR. 
• VE-821 was a more potent sensitiser to both cisplatin and IR than PF-477736 or MK-
1775 at the concentrations used. 
• Overall sensitisation of the cell lines to cisplatin or to IR by the inhibitors was not 
dependent on intrinsic sensitivity to the either agent, though a potential correlation 
between VE-821 sensitisation to IR and IR cytotoxicity was noted.  
• Sensitisation of the cell lines to cisplatin or IR by VE-821, PF-477736 or MK-1775 was not 








Experiments described in the previous chapters have demonstrated that in a panel of 
cervical cancer cell lines the spectrum of sensitivity to VE-821, PF-477736 and MK-1775 
induced cytotoxicity, or their sensitisation of cisplatin or IR, could not be explained by the 
extent of target inhibition (Table 4.2). Furthermore, no clear determinants of sensitivity to 
the inhibitors have been identified.  The mechanism of cisplatin sensitisation by ATR, CHK1 
and WEE1 inhibitors is hypothesised to be due to abrogation of S and G2/M checkpoint 
function in the presence of G1/S checkpoint deficiency (Chapter 1). 
 
ATR inhibition by VE-821 has been shown to reduce IR induced G2 arrest in a p53 
independent manner in paired cell lines (Middleton et al., 2018). Another ATR inhibitor 
AZD6738 has also been shown to successfully abrogate a cisplatin induced G2 arrest without 
causing significant cell cycle perturbations as a single agent at an equivalent concentration in 
NSCLC cells (Vendetti et al., 2015).  Whilst reports of the cell cycle effects of CHK1 
combinations with platinum agents are sparse. The CHK1 inhibitor AZD7762 was shown to 
abrogate the intra S and G2/M checkpoints, evidenced by loss of S/G2 arrest in 
neuroblastoma cells treated with the anti-mitotic agent, nocodazole or the topoisomerase 
inhibitor, SN38 (Xu et al., 2011). SN38 mediated G2 arrest was also shown to be abolished by 
co-incubation with the CHK1 inhibitor SCH900776 in breast cancer cell lines (Montano et al., 
2012). Likewise, the WEE1 inhibitor used in these experiments, MK-1775, has been reported 
to abolish G2 arrest in cisplatin treated p53-mutated ovarian cancer cells (Hirai et al., 2009). 
 
This chapter focuses on attempts to understand the underlying mechanisms that determine 
the differential cisplatin sensitisation observed across the cell line and inhibitor panel: with 
specific reference to changes in the cell cycle in response to treatment with cisplatin with 
and without ATR, CHK1 or WEE1 inhibitors. Cisplatin was used as the genotoxic agent in 
these experiments due to the larger magnitude and range of effects seen in previous 





6.2 Aims and objectives 
The aims of the investigations described in this chapter were: To determine the nature of 
cell cycle profile changes of the cervical cancer cell lines in response to cisplatin and 
inhibitors of ATR, CHK1 and WEE1 as single agents and in combination. 
 
This will enable the following hypotheses to be tested: 
1. Cisplatin will have similar effects on the cell cycle profiles of the cervical cancer cell 
lines, irrespective of HPV status 
2. The inhibitors will have similar effects on cisplatin-induced cell cycle profile changes. 
3. The effects of the inhibitors on cisplatin-induced cell cycle changes will be proportional 
to the degree of potentiation of cisplatin-induced cytotoxicity described in Chapter 5. 
4. The effects of the inhibitors on cisplatin-induced cell cycle profile changes will correlate 
with baseline expression of the target enzymes. 
 
6.3 Materials and Methods 
Permeabilised and PI stained cells were prepared, as detailed in Chapter 2.7. The DNA 
content of cells was determined using a BD FACSCanto II flow cytometer. Data was stored 
and transferred to FCS Express 6â software for analysis. Doublets were excluded by gating in 
area versus height plots. Histograms were generated for each experimental condition for 
each cell line (Figure 6.1) and the percent of cells in sub-G1, G1/0, S and G2/M phases were 





Figure 6.1 Representative example of cell cycle profile histograms showing cell cycle 
distributions of SiHa cells with and without treatment using cisplatin +/- VE-821, PF-
477736 and MK-1775. 
Cells were stained with PI and doublets were gated out using height vs area plots for more 
than 20000 individual events. Percent-populations of cells in sub-G1, G0/G1, S and G2/M 
were calculated by gating the histograms as shown. The PI content of individual cell cycle 
phases were determined on histograms from control cells and applied to histograms from 







6.4.1 Cell cycle responses to single agents 
Exposure to minimally cytotoxic concentrations of the checkpoint inhibitors alone for 24 h 
did not substantially affect the cell cycle profile of any of the cell lines (Table 6.1 and Figures 
6.2 – 6.4). However, cisplatin at a concentration of 3 µM for 24 hours (that causes > 90% 
inhibition of survival in all cell lines) resulted in marked changes in the cell cycle profiles.  
 
The most remarkable effect of cisplatin was a substantial and significant increase in the S-
phase fraction for all cell lines, which varied from 300% in Hela to 175% in C33A. In general, 
this was at the expense of the G1 fraction, which was correspondingly decreased. Because 
the G1 population was the largest, the proportional change was less than for S-phase. The 
decrease in G1 ranged from 69% (HeLa) to 36% SiHa and was significant (p<0.05 for all cells 
except CaSki (p=0.10). The shift from G1 to S could be a result of the lack of a functional G1 
checkpoint. The G2/M fraction was low in control cells and cisplatin had a modest and 
variable effect on percentage of cells in this fraction. 
 
6.4.2 Effect of ATR, CHK1 and WEE1 inhibitors on cisplatin-induced cell cycle 
profile changes. 
VE-821 caused substantial reductions in cisplatin induced S-phase accumulations in HeLa 
(57% reduction, p=0.02), SiHa (62% reduction, p=0.02) and C33A (24% reduction, p=0.05) 
cells. This was accompanied by corresponding increases in G2/M-phase populations in HeLa 
(250%, p<0.01), SiHa (200%, p=0.07) and C33A (100%, p=0.02) cells. A less marked decrease 
in G1 cells that varied between the cell lines was observed (Figure 6.2). In contrast, co-
incubation with VE-821 and cisplatin caused 50% increase in the S-phase populations in ME-
180 and 30% in HT-3 cells compared to cisplatin alone, but neither increase was statistically 





Table 6.1 Percent-single cell populations per cell cycle phase for six cervical cancer cell 
lines exposed to cisplatin +/- inhibitors drugs.   
Exponentially growing cells were treated with 1 µM VE821, 50 nM PF-477736 or 100 nM MK-
1775 +/-3 µM cisplatin for 24 hours. Control cells were co-incubated in fresh media + DMSO 
at an equivalent concentration. At least 20000 events per sample were recorded. Percent-
populations from single cells in each phase of the cell cycle were quantified using FCS Express 





Figure 6.2 Cell cycle profiles of cervical cancer cell lines treated with VE-821 and cisplatin 
as single agents and in combination. 
Exponentially growing cells were treated with 1 µM VE821, 3 µM cisplatin or both drugs in 
combination for 24 hours before being fixed in 70% ethanol. Cells were washed in PBS, treated 
with RNase and stained with PI. DNA content was analysed using a FACSCanto II flow 
cytometer. At least 20000 events per sample were recorded. Percent-populations from singlet 
cells in each phase of the cell cycle were quantified using FCS Express (De Novo software). Data 
are the mean and range of values from two independent experiments and are derived from 
values shown in Table 6.1 
 
 
Similarly, co-incubation with PF-477736 (50 nM) caused reductions in cisplatin induced S-
phase accumulations in HeLa (78% reduction, p<0.01), SiHa (75% reduction, p<0.01) and 
C33A (26% reduction, p<0.01) cells, accompanied by a corresponding increase in the G2/M 
fraction of HeLa (230%, p<0.01), SiHa (190%, p=0.08) and C33A (68%, p=0.06) cells. As with 
ATR inhibition, the CHK1 inhibitor increased the cisplatin-induced S-phase accumulation (by 
43%) and reduced the G2/M fraction in ME-180 (23% reduction) but these were not 
significant. PF-477736 did not substantially affect the cell cycle changes associated with 
cisplatin exposure in CaSki or HT-3 cells (Figure 6.5). Co-incubations with 100 nM MK-1775 
also reduced cisplatin-induced S-phase accumulation and increased the G2/M fraction in 
HeLa cells but to a lesser degree than with VE-821 and PF-47736. In general, the effects of 





Figure 6.3 Cell cycle profiles of cervical cancer cell lines treated with PF-477736 and 
cisplatin as single agents and in combination. 
Exponentially growing cells were treated with 50 nM PF-477736, 3 µM cisplatin or both drugs 
in combination for 24 hours before being fixed in 70% ethanol. Cells were washed in PBS, 
treated with RNase and stained with PI. DNA content was analysed using a FACSCanto II flow 
cytometer. At least 20000 events per sample were recorded. Percent-populations from 
singlet cells in each phase of the cell cycle were quantified using FCS Express (De Novo 
software). Data are the mean and range of values from two independent experiments and 








Figure 6.4 Cell cycle profiles of cervical cancer cell lines treated with MK-1775 and 
cisplatin as single agents and in combination. 
Exponentially growing cells were treated with 100 nM MK-1775, 3 µM cisplatin or both drugs 
in combination for 24 hours before being fixed in 70% ethanol. Cells were washed in PBS, 
treated with RNase and stained with PI. DNA content was analysed using a FACSCanto II flow 
cytometer. At least 20000 events per sample were recorded. Percent-populations from 
singlet cells in each phase of the cell cycle were quantified using FCS Express (De Novo 
software). Data are the mean and standard deviation of two independent experiments and 









Figure 6.5 Changes in S-phase and G2/M-phase populations in cells treated with 
cisplatin-inhibitor combinations compared to cells treated with cisplatin alone. 
A. % change in cisplatin induced S-phase accumulation of cells treated with cisplatin-inhibitor 
combinations. B. % difference in G2/M-phase populations of cells treated with cisplatin-
inhibitor combinations compared to cells treated with cisplatin alone. Raw data is taken from 
cell cycle profiles, as displayed in figures 6.1 to 6.3 and represent mean and SD resulting from 
two independent experiments. 
 
 
6.4.3 Correlations between cell cycle changes, cell line characteristics and 
cytotoxicity profiles 
Changes with cisplatin exposure compared to control 
Though HeLa cells are the least sensitive to cisplatin in survival assays (Chapter 5), they 
showed the greatest disturbance in their cell cycle profile in response to cisplatin exposure. 
Conversely, SiHa cells were the most sensitive to cisplatin but had one of the more modest 
disturbances in their cell cycle profile. When the other cell lines were considered, however 
no relationship was seen between sensitivity (survival) to cisplatin and the magnitude of 
changes G0/G1, S-phase or G2/M populations.  
 
It would be expected that changes in the cell cycle profile in response to cisplatin would be 
related to the activation of ATR, CHK1 or WEE1 by cisplatin. No such correlations were 
found. Neither was there any relationship with the characteristics of the cell lines described 




Changes with cisplatin + inhibitor co-exposure compared to cisplatin alone 
The effect of 1 µM VE-821 on cisplatin induced S-phase and G2/M cell cycle changes strongly 
correlated with the extent of ATR inhibition measured in the cell lines at this concentration 
(Chapter 4). There were, however no such relationships between cisplatin induced S-phase 
or G2/M changes and CHK1 or WEE1 inhibition in response to PF-477736 or MK-1775, 
respectively (Figure 6.6).  
 
Unsurprisingly, given the previously noted relationship between ATR expression and the 
magnitude of ATR inhibition by 1 µM VE-821, a relationship was also found to exist between 
baseline ATR expression and the S-Phase and G2/M changes, described above (Figure 6.7). 
Higher ATR expression resulted in larger reduction of the cisplatin induced S-phase 
accumulation in response to 1 µM VE-821, with a corresponding increase in G2/M 
populations. As would be expected given the relationship between ATR and CHK1 expression 
(Chapter 3), an inverse relationship between these cell cycle changes and CHK1 expression 







Figure 6.6 Correlations between target enzyme inhibition and effect of 1µM VE-821, 50 
nM PF-477736 and 100 nM MK-1775 on cell cycle profile changes induced by 3 µM 
cisplatin. 
A: Changes in S and G2/M populations vs inhibition of ATR by 1µM VE-821. B: Changes in S 
and G2/M populations vs inhibition of CHK1 by 50 nM PF-477736. C: Changes in S and G2/M 
populations vs inhibition of WEE1 by 100 nM MK-1775. All exposure times were for 24 hours. 
Data are taken from that displayed in Figures 4.3, 4.5 and 4.7 and Figures 6.2 to 6.3 and are 







Figure 6.7 Correlations between ATR and CHK1 expression and effect of 1 µM VE-821 
on cell cycle profile changes induced by 3 µM cisplatin. 
A: Changes in cisplatin induced S-phase accumulations vs expression of ATR and CHK1. B: 
Changes in G2/M populations vs expression of ATR and CHK1. All exposure times were for 24 
hours. Data are taken from that displayed in Figure 3.5 and Figures 6.2 to 6.4 and are the 
mean of at least two independent experiments.  
 
Changes in cisplatin induced S-phase and G2/M changes caused by 50 µM of the CHK1 
inhibitor PF-477736 also correlated with CHK1 and ATR baseline expressions, though the 
relationship did not reach significance for CHK1 expression (Figure 6.8), high ATR expression 
and Low CHK1 expression was associated with larger reductions in cisplatin induced S-phase 
accumulations and also with larger increases G2/M populations. No such correlations existed 





Figure 6.8 Correlations between ATR and CHK1 expression and effect of 50 nM PF-
477736 on cell cycle profile changes induced by 3 µM cisplatin. 
A: Changes in S-phase populations vs expression of ATR and CHK1. B: Changes in G2/M 
populations vs expression of ATR and CHK1. All exposure times were for 24 hours. Data are 
taken from that displayed in Figure 3.5 and Figures 6.1 to 6.3 and are the mean of at least 







Consistent with observations from previous studies (Middleton et al., 2018), at 
concentrations that were not profoundly cytotoxic (Table 4.2), VE-821, PF-477736 and MK-
1775 had no significant impact on cell cycle distributions despite substantial target inhibition 
(Chapter 4). In contrast to this, treatment of the cell lines with 3 µM cisplatin for 24 hours 
resulted in significant changes. Substantial increases in S-phase populations were seen, and 
this appeared predominantly at the expense of G1/S populations, indicative of dysfunction 
of the G1/S checkpoint in all cell lines. However, reductions in G2/M populations were also 
seen in C33A, CaSki and ME-180 cells. Only in HeLa cells did cisplatin cause an increase in 
G2/M cell population.  
 
The increase in S-phase populations seen across all cell lines points towards engagement of 
intra-S checkpoint functions as the dominant DDR component in response to cisplatin 
induced DNA damage in the cervical cancer cell lines. However, physical slowing of 
replication forks by ICLs and engagement of repair without checkpoint signalling could also 
contribute. This pattern was irrespective of HR-HPV, p53 or pRB status. Increased replication 
stress resulting from stalled replication forks will activate ATR-CHK1-WEE1 mediated 
signalling to slow replication origin firing and may be responsible for arrest of the cell in S-
phase, causing the measured cell cycle profile changes (Iyer and Rhind, 2017, Cimprich and 
Cortez, 2008, Maréchal and Zou, 2013). Consistent with this are the observations that the 
cells with highest ATR expression and the greatest ATR inhibition by VE-821 had the greatest 
reduction in cisplatin-induced S-phase arrest when treated with VE-821. However, the lack 
of corresponding correlations for CHK1 and WEE1, and their inhibitors make drawing 
conclusions on the importance of either the extent of the observed inhibition or level of 
baseline expressions of the enzymes difficult.  
 
Modest but non-significant increases in cisplatin-induced S-phase accumulations, particularly 
by VE-821 in ME-180 and HT-3 cells (Figure 6.5), may reflect its lower target inhibition in 
these cells (Chapter 4) but without further studies, including in additional cell lines, the 
mechanisms underlying this effect cannot be elucidated. With this evidence, we can only 
speculate that the increase in cisplatin induced S-phase accumulations arose out of other 
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mechanisms related to the cells difficulty in resolving platinum induced DNA lesions and the 
roles the kinases and inhibitors may play in these pathways.  
 
For HeLa, SiHa and C33A cells the decrease in S-phase accumulation was accompanied by a 
corresponding increase in G2/M cells and so for these cells at least, the intra-S checkpoint 
may be the most important for cisplatin induced DNA damage resolution. A limitation of PI 
staining is its inability to distinguish between G2 and M-phase cells. It could be hypothesised 
that in these cell lines, cells which have escaped G2 arrest and entered mitosis may be 
responsible for the apparent increase in G2/M phase cells, particularly as there was limited 
evidence for a corresponding increase in sub-G1 cell populations, indicating that most cells 
were still cycling at the point of fixation.  
 
Further studies are, however needed with additional DNA damaging agents (e.g. IR), 
additional methods for distinguishing G2 and M-Phase cells (e.g. staining for phospho-
histone-H3S10) and other cell lines. This will help to elucidate whether the inhibitors always 
have the greatest impact on the intra-S checkpoint. Whether it was a function of the type of 
DNA damage caused by cisplatin that primarily engaged intra-S DDR functions and whether 
the changes in G2/M fractions are due to G2 arrest and escape remain to be determined.  
 
6.6 Conclusions 
With reference to the aims set out at the start of this chapter: 
1. Minimally cytotoxic concentrations of all three inhibitor drugs caused little or no 
disturbance in the cell cycle profile of the cells across the cell line panel 
2. All three inhibitors caused similar pattern changes to cisplatin induced S-phase 
accumulations across the cell line panel 
3. The cells appeared to fall into two groups: 
a. HeLa, SiHa and C33A cells, which showed a reduction in cisplatin-induced S-phase 
accumulations in response to inhibitor treatment suggesting attenuation of cisplatin induced 
S-phase arrest 
b. ME-180, HT-3 (and CaSki) cells, which showed an increase in cisplatin-induced S-phase 
accumulations in response to inhibitor treatment and which is so far unexplained. 
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4. The magnitude or nature of cell cycle profile changes did not correlate with the extent 
of sensitisation to cisplatin across the cell line panel for any of the inhibitors.  
5. Some correlations were seen between the magnitude of effect of VE-821 on cisplatin-
induced S-phase accumulation and inhibition or expression of ATR and CHK1, but data with 









Earlier experiments, described in Chapter 3, have demonstrated that cervical cancer cell 
lines with known HR-HPV and oncogene status display a range of cell cycle checkpoint 
protein expression and that there appear to be relationships between the levels of 
expression of some of these proteins. Despite the small number of cell lines available for 
investigation, positive correlations were noted between CHK1 and CDK1 and a significant 
inverse correlation was found between ATR and CHK1 levels. An inverse correlation was 
also noted between ATR and CDK1, as might be expected given this result. There 
appeared to be limited evidence that the expressions of cell cycle proteins were 
significant determinants of sensitivity to the ATR, CHK1 or WEE1 inhibitors VE-821, PF-
477736 or MK-1775, respectively as single agents or sensitisers of cisplatin and IR, though 
WEE1 expression appeared to correlate with a narrow range of MK-1775 sensitisation of 
cell lines to cisplatin.  
 
Given the absence of a clear determinant of sensitivity to the inhibitors or cisplatin and IR 
amongst the cell line panel a decision was taken to investigate the expression of the cell 
cycle proteins: ATR; CHK1; and WEE1 by immunohistochemistry (IHC) in a panel of 
formalin fixed and paraffin embedded (FFPE) clinical cervical cancer tumour from 
patients, and to supplement this with expression data from publicly available datasets.  
The presence of a range of level of protein expression and any similar correlations to that 
seen in the cell line panel would provide further validation of the cervical cancer cell lines 
as a useful tool in pre-clinical investigations and provide confidence in the applicability of 






7.2 Aims and Objectives 
The aim of the investigations described in this chapter is to determine the range of 
expression of ATR, CHK1 and WEE1 in a panel of clinical cervical cancer tumour samples 
and to explore whether relationships between these proteins, as observed in cervical 
cancer cell lines, exist in clinical tumour samples. The clinical sample set will be 
supplemented by investigation of mRNA expression data from The Cancer Genome Atlas 
(TCGA) dataset.  
 
 
7.3 Materials and methods 
7.3.1 TMA construction and slide preparation 
Women with cervical cancer who underwent treatment or investigation at the Northern 
Gynaecological Oncology Centre, Queen Elizabeth Hospital (QEH), Gateshead between 
February 2017 and January 2018 were approached under existing ethical permissions 
(2012 REC: 12/NE0395. R&D sponsor: NUTH NHS foundation trust No. 6579) for 
retrospective written consent to biobank formalin-fixed, paraffin-embedded (FFPE) 
diagnostic or surgical specimens (blocks) containing primary cervical cancer tissue. 29 
women with cervical cancer consented. 10 blocks were available from storage at the QEH 
pathology lab following diagnosis or treatment that contained sufficient tumour material 
to allow for core extraction and inclusion in the tissue micro-array (TMA) along with one 
historical sample. Slides were prepared from candidate blocks by clinical scientists at the 
QEH laboratory and Haematoxylin and Eosin (H+E) stained prior to review by a consultant 
histopathologist pathologist to identify areas corresponding regions containing tumour 
for core extraction.  
 
The TMA assembly contained a total of 26 x 1 mm cores: duplicate samples from 11 
patients and 2 positive control blocks (human testes and a HeLa-agarose cell block). 
Cores were randomly assigned to TMA locations by the Galileo TMA CK3500Ò and 
associated computer software to reduce the risk of core loss or reading bias affecting 
results (Figure 7.1). Ideally a TMA will contain tumour known not to express the protein 
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under investigation to provide a further negative control. As ATR, CHK1 and WEE1 are 





Figure 7.1 Tissue microarray layout containing duplicate cores from 11 patient samples 
and 2 positive control cores. 
Core locations were randomly selected by computer software. S = patient sample. Control 
1= HeLa cells. Control 2 = human testes. 
 
Individual 5 µm sections were taken by microtome and positioned on glass slides for 
immunohistochemical staining. HeLa block preparation and microtome sectioning of the 
TMA and H+E staining were undertaken by a dedicated immunohistochemistry (IHC) 
technician at the NICR according to local protocols.  
 
7.3.2 Immunohistochemistry 
Primary and secondary antibodies used for IHC investigation of ATR, CHK1 and WEE1 
expression as well as antigen retrieval methods are given in Table 7.1. CHK1 antigen 
retrieval and antibody dilution optimisation was undertaken by MRES student, Mr Harry 
Robinson. Due to time limitations for these investigations, antigen retrieval methods for 
ATR and WEE1 were undertaken according to antibody manufacturer and expert advice. 
A range of three antibody dilutions were tested for each antibody including: the dilution 




Slides were de-waxed in xylene hydrated through graded ethanol (100% to 50%) and 
washed in tap water. Antigen retrieval was performed using citrate buffer (pH 6) heated 
to at 125 °C for 30 s under pressure. Slides were rinsed in tap water before and after 
exposure to 3% hydrogen peroxide solution for 10 minutes. Incubations were performed 
with diluted primary antibody (Table 7.1) for 60 minutes each at room temperature prior 
to application of MenapathÒ IHC kit HRP-polymer +/- universal probe (A. Menari 
diagnostics, USA) for 30 minutes each. No-antibody negative controls slides were 
prepared without primary antibody staining. Slides were rinsed in Tris-buffered saline + 
0.1% Tween 20 (TBST). DAB solution applied to each slide for 1 minute before 
neutralisation in sodium hypochlorite and a further tap water rinse. All slides were then 
counterstained in Gills II haematoxylin for 5 seconds and blued in Scott’s Tap Water. 
Following dehydration through graded ethanol (50% to 100%) and Xylene, cover-slips 
were applied using DPX mounting medium and allowed to dry.  
 
 
Table 7.1 Antibodies and dilutions used for IHC staining of clinical TMA slides. 
Antigen retrieval was undertaken in citrate buffer (pH 6) in a pressure cooker in all cases. 
Secondary antibodies were applied according to the MenapathÒ protocol using reagents 
supplied in the IHC kit.  
 
 
7.3.4 Slide scanning and data analysis 
Slides were scanned by Ms Xin Xu at the Newcastle University central biobank facility 
using Leica SCN400Ò slide scanner and images were accessed and viewed remotely using 
a web-based Leica digital image hub (slidepath.ncl.uk). A modified H-score was calculated 
for each core in the TMA at the antibody dilution which best allowed differentiation 




The modified H-score was calculated by multiplying the staining intensity of nuclear 
staining (0-3) by the proportional area of tumour positively stained (0-6), to give a 
minimum score of 0 and a maximum score of 18 (Table 7.2). A single score was 
determined for each core, as tumour staining tended to be of uniform intensity in each 
core. The mean score from duplicate cores was calculated. Where there was core loss or 
artefact impeding interpretation the score from the remaining core was used. Cores 
composed of less-than 20% tumour were excluded.  
 
Pearson’s correlation analysis was performed on H-scores determined experimentally 
using Graphpad Prismâ. TCGA mRNA expression data for ATR, CHK1 and WEE1 was 
analysed by Pearson correlation analysis by Dr Sweta Sharma Saha.  Survival analysis of 
TCGA patient cohorts was by Kaplan-Meier plot undertaken on open source software 
available at http://www.proteinatlas.org and significance testing for correlations 




7.4.1 Optimisation of antibody dilutions 
The optimal dilution for CHK1 staining was previously determined to be 1:500 (Figure 
7.2). The antibody dilutions tested for ATR staining were 1:50, 1:100 and 1:200 with an 
optimal dilution of 1:200 selected for quantification of ATR expression in tumour samples 
by modified H-score (Figure 7.3, D-F). The WEE1 antibody failed to stain satisfactorily at 
any of the dilutions tested (Figure 7.3, G-I) and no quantification of WEE1 expression in 






Figure 7.2 Micrographs of human testes positive control tissue demonstrating CHK1 
staining. 
A: H+E stained section showing cellular areas. B: Anti-CHK1 antibody staining at dilution 
of 1:500 with corresponding nuclear staining. C: No-primary antibody negative control 
with anti-mouse secondary antibody.  
 
 
Figure 7.3 Micrographs of human testes positive control tissue demonstrating ATR 
staining but inadequate WEE1 staining. 
A: H+E stained section showing cellular areas. B: No-primary antibody negative control 
with anti-rabbit secondary antibody. C: No-primary antibody negative control with anti-
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mouse secondary antibody. D-F: Anti-ATR antibody staining at 1:50 (D), 1:100 (E) and 
1:200 (F). G-I: Anti-WEE1 antibody staining at 1:100 (G), 1:200 (H) and 1:500 (I).  
 
 
7.4.2 IHC scoring 
ATR and CHK1 stained cores were scored using the method and antibody dilutions 
detailed in section 7.3.4. Figure 7.4 shows representative TMA cores stained for ATR and 
CHK1 and examples of stain intensity used to calculate the modified H-score. H-Scores for 
both ATR and CHK1 varied between 0 and 18 (Table 7.2). The core that scored most 
strongly for both proteins was later noted to be a serous cancer of the cervix, a rare 
tumour that is not associated with HR-HPV infection. With this core excluded, the highest 
H-score for ATR was 12.5 in a squamous cancer. The highest H-score for CHK1 was 10.5 in 
an adenocarcinoma. Due to the limited number of clinical samples and the fact that 
tumour-deficient exclusions were exclusively in the adenocarcinoma group, it was not 
possible to determine if there was a difference in the expression of ATR or CHK1 amongst 






Figure 7.4 Micrographs of representative TMA cores stained for ATR (top) and CHK1 
(bottom). 
A: Positive control tissue (human testes). B: Tumour demonstrating strong stain intensity 
(score = 3). C: Tumour demonstrating moderate stain intensity (score = 2). D: Tumour 
demonstrating weak stain intensity (score = 1). E: Tumour demonstrating no tumour 
staining, including cytoplasmic staining only (score = 0). Antibody dilutions were 1:200 in 





Table 7.2 Modified H-score results for individual cores from a cervical cancer TMA 
stained for ATR and CHK1. 
Sample numbers correspond to the core locations detailed in Figure 7.1. Mean scores 
were calculated from the individual scores from duplicate cores. Where core loss or 
artefact impeded scoring, a single core score was used. Cores with 20% tumour were 
excluded. Sample S2 was later found to be a serous cancer of the cervix and was excluded 
from further analyses. 
 
 
Given the strong negative correlation between ATR and CHK1 expression noted in 
Western blot analysis of baseline proteins in cervical cancer cell lines (Chapter 3), 
correlation analysis was conducted to determine whether a similar relationship between 
ATR and CHK1 existed in these clinical tumour samples. Whilst no correlation was present 
when the whole panel of clinical tumour samples was included, exploration of a 
difference observed in the squamous carcinoma sub-type revealed a significant inverse 
correlation between ATR and CHK1 expression (Figure 7.5) in keeping with that seen in 
the cervical cancer cell lines, however as the cell line data did not similarly exclude those 
derived from glandular cancers, and each correlation relies on a very small number of 
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data points. These investigations should be undertaken in a much larger set of samples 
before concluding that they are meaningful.  
 
 
Figure 7.5 Correlations between ATR and CHK1 expression in clinical tumour samples 
A: Scatter plot of ATR vs CHK1 expression for all cervical cancer sub-types. B: Scatter plot 
and linear regression of ATR vs CHK1 in cervical squamous cancers only. Data is taken 
from that displayed in Table 7.2.  
 
 
7.4.3 ATR, CHK1 and WEE1 expression in a wider context. 
In order to further explore the observed correlation between ATR and CHK1 protein 
expression from cell line data described in Chapter 3 (Figure 3.5) in clinical tumour 
samples, a correlation analysis of ATR and CHK1 mRNA expression derived from the TCGA 
study of cervical cancer (Cancer Genome Atlas Research et al., 2017) was performed by 
Dr Sweta Sharma Saha. The TCGA data included 291 clinical cervical cancer tissue 
samples, of which 75% were SCC. Pearson’s Correlation analysis of ATR and CHK1 mRNA 
expression in the TGCA dataset showed no correlation between ATR and CHK1 
expression (Figure 7.6). Neither protein showed correlation with WEE1 mRNA expression 







Figure 7.6 Correlation between ATR and CHK1 mRNA expression in TCGA data 
Scatter plot showing ATR and CHK1 mRNA expression in 291 cervical cancers (75% SCC). 
The results shown here are based upon data generated by the TCGA Research Network: 
https://www.cancer.gov/tcga, analysed by Dr Sweta Sharma Saha 
 
7.4.4 Clinical correlation 
Clinical diagnostic and treatment data for the cervical cancer patients who donated 
tumour samples to these investigations are given in Table 7.3. The short time period 
between sample collection and data analysis and a median follow up interval of just 18.7 
months at the time of writing, and the presence of a single a single episode of disease 
progression has occurred in this small patient cohort makes assessment of the prognostic 
significance for the expression of ATR and CHK1 in this patient cohort difficult. All 
patients included were treated with primary surgery and two received adjuvant 
radiotherapy without macroscopic disease. No correlations with response to cisplatin or 






Table 7.3 Clinical, diagnostic, treatment and follow-up data for cervical cancer patients 
who donated tumour samples to these investigations. 
Loop excision = local excision with margin. Surgery = hysterectomy with pelvic 
lymphadenectomy. Radical surgery = radical hysterectomy or radical trachelectomy with 
pelvic lymphadenectomy. Patient S11 was diagnosed with primary cervical cancer on 
operative histology. AWD = alive without disease. REC = recurrence with date of 
progression/recurrence. 
 
The TCGA study of cervical cancer (Cancer Genome Atlas Research et al., 2017) did not 
report survival effects of ATR, CHK1 or WEE1 gene alterations, underlining the novel 
nature of the data reported in this thesis. Using data from the Human Protein Atlas, 
available from http://www.proteinatlas.org  (Uhlen et al., 2017), survival data for the 
patients included in the TCGA dataset was categorised by high (above the median) or low 
(below the median) expression (mRNA) of ATR, CHK1 and WEE1 (Figure 7.7 and Table 
7.4). Overall, high expression of any of ATR or CHK1 was not prognostic in cervical cancer. 
High expression of WEE1, however showed a tendency towards increased survival. In this 
data, 75% of patients had SCC versus 25% with adenocarcinoma or adenosquamous 





Figure 7.7 Kaplan-Meier plots showing survival of kinase high vs low expression from 
the TCGA study of cervical cancer dataset 
Data for 291 cervical cancer patients was analysed from Human Protein Atlas data 
http://www.proteinatlas.org. Cut off for low vs high expression was the median mRNA 







Table 7.4 Survival of cervical cancer patients from the TCGA study of cervical cancer 
dataset by checkpoint kinase expression 
Data for 291 cervical cancer patients was analysed from Human Protein Atlas data 
http://www.proteinatlas.org. Cut off for low vs high expression was the median mRNA 
expression for the checkpoint kinase expressed as Fragments Per Kilobase of transcript 
per Million mapped reads (FKPM) and determined by RNA-seq. Log-rank p-value for 
Kaplan-Meier plot is shown. Median follow up is 23.5 months 
 
7.5 Discussion and conclusions. 
It is not possible to draw significant conclusions regarding the prognostic value of ATR or 
CHK1 expression in cervical cancer given the small number of tumour samples included in 
the investigations of protein expression by IHC. The short follow up period and the 
absence of non-surgical primary treatment used in this patient cohort precludes 
meaningful correlation with survival or comparison with primary non-surgical treatment 
modalities. The fact that a range of expression of both kinases was observed in the 
patient FFPE samples is consistent with the cell line data presented in Chapter 3 and that 
seen in the TCGA study of cervical cancer data set. This provides additional validation of 
the cervical cancer cell lines as representative clinical substitutes for the ongoing 
investigation of ATR-CHK1 pathway inhibition.  
 
Published prevalence data suggests that 80% - 90% of cervical cancer worldwide is SCC 
(Mathew and George, 2009), but that the relative incidence of this sub-type is falling 
under the influence of cervical screening programmes which are better able to detect 
pre-cancerous squamous lesions (Castanon et al., 2016). The proportion of SCC in our 
limited clinical sample set was 60% and that in the TCGA data set is broadly comparable 
at 75% with the large majority of patients (70%) undergoing primary surgical treatment 
rather than platinum chemotherapy or IR based therapy. The TCGA patient cohort is 
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therefore a comparable group of patients to those recruited for this study and the data is 
applicable to the global cervical cancer population. No association between high 
expression of either ATR, CHK1 and survival was seen. High WEE1 expression showed a 
potential association with better survival, justifying ongoing investigation of WEE1 as a 
potential biomarker in the investigation of cervical cancer treatment. 
  
In order to broaden the options for further investigations into the expression of DDR 
proteins in cervical cancer and to provide opportunity to validate any future cell line 
findings in clinical samples, biobanking of tissue from women with cervical cancer is 
ongoing.  Efforts will need to be made to identify patients who have received platinum 
and IR, alone and in combination as their primary treatment modality so that any future 
identified determinants of sensitivity can be correlated with tumour response to provide 





8 Final discussion, conclusions and future directions 
 
The investigations in this thesis, for the first time directly compare the relative potential of 
ATR, CHK1 and WEE1 inhibition in cervical cancer cells using potent and selective inhibitors 
of these cell cycle checkpoint kinases. Furthermore, attempts were made to elucidate the 
determinants of sensitivity that may underpin differences in sensitivity across a cervical 
cancer cell line panel and to understand the mechanisms that may be responsible for 
differences in the sensitisation of cisplatin and IR observed between the inhibitors. The aim 
of these investigations was to inform future studies of the relative potential of these drugs 
in cervical cancer therapy so that attention may be focussed on those that are likely to 
provide the best solution to the urgent need for novel therapies for this disease. The 
exploration of the role of HPV and consequent p53/pRb inactivation as a determinant of 
sensitivity was somewhat confounded by the fact that the 2 HPV negative cells (C33A and 
HT-3) are known to harbour mutations in TP53 and RB1. The functional status of p53/pRB 
was not confirmed in the experiments described in this thesis. Nevertheless, the functional 
consequence for the cell: G1/S dysfunction is of primary importance to the rationale of the 
investigations and this was demonstrated in all cell lines in response to cisplatin induced 
DNA damage.  
 
In order to establish that cytotoxicity or sensitisation results later attributed to the 
inhibitors under investigation were due to enzyme inhibition rather than absence of the 
enzymes, the expressions of the key enzymes in the pathway were established by Western 
blot. ATR, CHK1, WEE1 and CDK1 were all expressed by the cervical cancer cell lines and this 
expression did not appear to be related to HPV status. The level of expression of these 
proteins was quantified by densitometric analysis and was seen to vary across the cell line 
panel (Figure 3.4).  The magnitude of the differences between the cell lines, the semi-
quantitative nature of Western blot densitometry as well as the limited number of cell lines 
in the panel make drawing definite conclusions from these results difficult and these are 
limitations that are applicable to many of the results herein. Some of these variations and 




Whilst CHK1 expression correlated with CDK1 expression, there was a negative relationship 
between levels of both of these kinases and ATR levels. Levels of WEE1 showed no 
relationships with expression of any of the kinases in this common pathway. These results 
along with the fact that none of the kinase expressions correlated with the cell doubling 
time, a marker of cell growth suggest that these cells do not have constitutively up-
regulated ATR-CHK1-WEE1 pathways in response to G1/S checkpoint insufficiency induced 
replication stress. In fact, the inverse relationship between ATR expression and that of 
downstream pathway components may suggest a level of functional redundancy in the 
pathway that could form the basis of future investigations. 
 
High ATR expression correlated with high DNA-PKcs expression in this cell line panel (Figure 
3.5) and this relationship has previously been described. Furthermore, a functional 
relationship between these two enzymes has also been previously observed.  High ATR and 
high DNA-PKcs levels have been reported to confer survival advantages in ovarian cancer 
patients (Abdel-Fatah et al., 2014), and High DNA-PKcs has also been shown to confer 
sensitivity to ATR inhibition by VE-821 (Middleton et al., 2015). A potential relationship was 
observed between single agent VE-821 cytotoxicity and DNA-PKcs expression across the cell 
line panel, though this was the inverse to previous reports and suggested that high DNA-
PKcs levels conferred resistance rather than sensitivity to VE-821 cytotoxicity. The results of 
this should be interpreted with caution given the lack of statistical significance, and the 
panel size (Figure 4.13). 
 
A further relationship between ATM expression and VE-821 single agent cytotoxicity was 
observed: though the correlation was not significant, the relative resistance of ME-180 cells 
(which expressed the most ATM) to VE-821 single agent cytotoxicity and the sensitivity of 
HT-3 cells (which expressed the least ATM) to VE-821 is consistent with previous reports 
that ATM is a determinant of sensitivity to ATR inhibition (Middleton et al., 2015, Kwok et 
al., 2016). Although ME-180 cells were, in fact amongst the most sensitive to all three 
inhibitors, clear relationships were not noted to exist between either PF-477736 or MK-1775 




The range of sensitivities of the cell lines to the single agent effects of VE-821, PF-477736 or 
MK-1775 was not wholly explained by the baseline expression of any of the measured 
checkpoint or DDR proteins and nor were the sensitisation effects of the inhibitors on either 
cisplatin or IR. Interestingly, the single agent cytotoxicity of the inhibitors was also unrelated 
to the observed extent of target inhibition of cisplatin induced ATR, CHK1 and WEE1 activity. 
 
The cells displayed a modest range of sensitivity to cisplatin but the difference between the 
most sensitive and least sensitive was only around 2-fold, making it difficult to draw 
conclusions regarding what determines sensitivity. HeLa cells were the most resistant to 
cisplatin and interestingly, the greatest cisplatin mediated ATR and CHK1 activation was 
seen in this cell line. 
 
The cell cycle profile changes associated with exposure to 3 µM cisplatin were uniform 
across the cell line panel with a significant increase in S-phase populations that appeared 
largely at the expense of G1 cells. Whilst this is consistent with a deficient G1/S checkpoint 
either through p53 or pRB mutation or HR-HPV infection as described in Chapter 1, a strong 
S-phase arrest in response to cisplatin is also consistent with the DNA lesions produced by 
this agent. Inter-strand cross links are difficult to resolve, requiring multiple DNA repair 
proteins and the process of repair could itself cause a slowing of progression through S-
phase (Deans and West, 2011). Moreover, Intra-strand cross links are a key cause of 
replication stress and as such are likely to make the cisplatin treated cell heavily dependent 
on the ATR-CHK1-WEE1 pathway to engage the intra-S checkpoint. S-phase arrest 
associated with CHK1 phosphorylation by ATR has previously been reported as the major 
cell cycle response to cisplatin induced DNA damage (Cruet-Hennequart et al., 2009).  
 
HeLa cells showed the greatest cell cycle disturbance in response to cisplatin, with the 
largest increase in S-phase populations (300% increase). There were no clear correlations 
between the size of S-phase accumulations and sensitivity to cisplatin across all cell lines, 
however HeLa cells were the most resistant to cisplatin. This observations is consistent with 
a report that increased S-phase populations in response to cisplatin may be linked to 
platinum resistance (Kielbik et al., 2018). This could represent a greater ability to engage cell 
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cycle arrest or DNA repair during S-phase, slowing the cell cycle progression in response to 
cisplatin and conferring a survival advantage.  
 
In terms of chemo-sensitisation by the inhibitors, ATR inhibition by VE-821 caused the 
greatest sensitisation to cisplatin. Cisplatin sensitisation of over 5-fold was seen in C33A 
cells (PF50 = 5.9 ± 1.3) and at higher cisplatin concentrations ME-180 cells were sensitised by 
over 12-fold (PF0.3-cis = 12.7 ± 2.9) in keeping with previous reports, which suggested up to 
10-fold sensitisation of cells to cisplatin by ATR inhibitors (Reaper et al., 2011). Despite the 
relatively wide variation in cisplatin sensitisation by VE-821 across the cell line panel (Table 
5.1) with the least sensitised cell lines (HT-3 and SiHa) being sensitised by less than 2-fold, 
no significant correlations with ATR expression or inhibition or baseline cisplatin sensitivity 
were seen. It is worth noting, however that ME-180 cells showed the least VE-821 inhibition 
of cisplatin induced ATR activity, contrary to what may be expected given the sizeable 
cisplatin sensitisation effects associated with VE-821 in this cell line.  
 
The concentrations of the inhibitors used for chemo-and radio-sensitisation experiments: 1 
µM VE-821, 50 nM PF-477736 and 100 nM MK-1775 caused broadly similar levels of target 
enzyme inhibition. Despite this, CHK1 inhibition by PF-477736 caused a much smaller 
magnitude of sensitisation to cisplatin (Table 4.2). ME-180 cells again showed the greatest 
sensitisation by PF-477736 (PF50 = 2.5 and PF0.3-cis = 1.8). In contrast with the results for VE-
821, PF-477736 did not sensitise HeLa cells to cisplatin. As with VE-821, cisplatin 
sensitisation by PF-477736 was not related to intrinsic cisplatin sensitivity of the cell lines, 
despite ME-180 also being amongst the most sensitive to cisplatin alone. No clear 
relationships were noted with the previously determined phenotypic characteristics of the 
cell lines, including HPV or p53 status. MK-1775 showed the least overall sensitisation of the 
cell lines to cisplatin with a maximum but non-significant effect seen, in ME-180 cells (PF50 = 
2.3 ± 0.5 and PF0.3-cis = 1.5 ± 0.5) and no sensitisation seen in SiHa CaSki or HT-3 cells. 
Despite this, MK-1775 sensitisation of cisplatin did appear to correlate strongly with 





The cells showed little change in their cell cycle profiles in response to exposure to all three 
inhibitors alone at the concentrations used in sensitisation experiments in keeping with 
previous reports (Vendetti et al., 2015, Middleton et al., 2018). However, strikingly different 
responses to the inhibitors were seen within the cell line panel on cisplatin-induced S-phase 
arrest that were similar for VE-821 and PF-477736. Both inhibitors induced a substantial 
reduction in S-phase accumulation in HeLa, SiHa and C33A but a substantial further increase 
in ME-180 (and HT-3 for PF-477736). Whilst the reductions of cisplatin induced S-phase 
accumulations may be attributable to attenuation of ATR-CHK1 mediated S-phase arrest 
(Cruet-Hennequart et al., 2009), the response in ME-180 and HT-3 cells is, so far 
unexplained.  
 
That such a difference in the response of the cells to ATR or CHK1 inhibition in the face of 
cisplatin induced DNA damage exists, along with the fact that neither the magnitude of the 
S-phase or other cell cycle population changes correlated with the sensitisation of the cells 
to cisplatin in cytotoxicity assays suggests that any observed cisplatin sensitisation by VE-
821 or PF-477736 is unlikely to be directly attributable to cell cycle checkpoint abrogation. 
Instead it is possible that it is due to inhibition of homologous recombination DNA repair 
(HRR) by inhibition of the ATR-CHK1-WEE1 pathway. HRR is needed to resolve DNA damage-
induced collapsed replication forks and there is emerging evidence of a coupling of ATR-
mediated checkpoint activation and HRR function (Buisson et al., 2017). This should be 
considered in future investigations of ATR and CHK1 inhibitors in particular, and their utility 
as sensitisers to cisplatin or IR in cervical cancer. 100 nM MK-1775 caused a broadly similar 
pattern of cell cycle changes but with much smaller effects in keeping with the smaller 
sensitisation effects observed in chemo-sensitisation assays and the slightly lower overall 
target inhibition observed at this concentration compared to 1 µM VE-821 and 50 nM PF-
477736. 
 
The rank order of sensitivity of the cells was different for IR and cisplatin, implying different 
determinants of sensitivity to each agent, which might be expected given their different 
types of DNA damage (Table 1.2). Resistance to IR correlated with high ATR and low CHK1 
expression. Surprisingly, given the relationship between ATR and DNA-PKcs discussed 
above, no correlation existed between DNA-PK-cs and IR sensitivity. NHEJ function is a 
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known determinant of sensitivity to IR (Mahaney et al., 2009). Although there was no 
correlation between IR sensitivity and expression of the key NHEJ proteins: DNA-PKcs; Ku70; 
or Ku80, HeLa cells (which were the most radio-resistant) expressed amongst the highest 
levels of all three proteins. Unexpectedly, ATM expression also showed no correlation with 
IR sensitivity despite its established role in the detection of IR induced DSBs (Maréchal and 
Zou, 2013) but SiHa with high ATM and DNA-PKcs were also radioresistant. Overall, the 
detection of IR induced DNA damage and the functioning of repair pathways such as NHEJ is 
complex (Thompson, 2012) and functional assays may need to be developed to capture the 
activity of the entire pathway.    
 
Compared to the results for chemo-sensitisation assays, radio-sensitisation by VE-821 was 
of a smaller magnitude and over a smaller range at the LD50, though still greater than that 
seen for PF-477736 and MK-1775.  Maximum sensitisation by 1 µM VE-821 was seen in HeLa 
cells (PF50 = 1.7 ± 0.4) compared to no sensitisation in C33A cells (PF50 = 1.1 ± 0.2). Despite 
this smaller range of sensitisations and the lack of statistical significance, radio-sensitisation 
by VE-821 did correlate with intrinsic IR resistance of the cell lines. Unfortunately, it was not 
possible to complete cell cycle investigations using IR as the DNA damaging agent within the 
scope of these investigations, and therefore we are unable to relate IR cell cycle changes 
and the response of the cell to IR + inhibitors to the results obtained for cisplatin, described 
above.  The cell line panel displayed not only a different rank order of sensitivity to IR and 
cisplatin but also chemo- and radio-sensitisation by the inhibitors, no-doubt reflecting the 
different nature of the DNA lesions caused by IR and cisplatin and their dependence on 
different DNA damage signalling and repair pathways. Future experiments should therefore 
aim at quantifying these differences though, for example DSB-quantification (Rogakou et al., 
1998). 
 
The data presented in these investigations comparing the effects of cell cycle checkpoint 
kinase inhibitors in a panel of cervical cancer specific cell lines is novel. Attempts have been 
made to determine whether the observed differences and similarities can be explained by 
relationships with previously described determinants of sensitivity, or through observation 
of inhibitor specific changes in the cell’s engagement of cell cycle checkpoints in the 
presence of induced DNA damage. Previously identified determinants of sensitivity were not 
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confirmed, partially due to the size of the panel and the relatively narrow spectrum of data. 
Due to time limitations, further mechanistic studies were not undertaken. However, the 
data serve to highlight the difficulty in translating a determinant of sensitivity identified 
using genetic knockdown/ isogenic pairs of cells to the much more complex phenotype of a 
cancer cell. In this respect, use of these cell lines relates to the difficulty in identifying 
predictive biomarkers that will be useful clinically. These results do, however allow 
identification of future directions that have the potential to provide mechanistic evidence 
that might underly the observed findings using previously described assays. 
 
8.1 Final conclusions 
Inhibitors of ATR, CHK1 and WEE1 caused a range of single agent cytotoxicity to cervical 
cancer cells that was independent of HR-HPV, p53 or pRB status. The cervical cancer cell 
lines showed variable expressions of checkpoint and DDR proteins and clinical samples 
showed a range of expression of ATR and CHK1. Because the spectrum of differences in 
cytotoxicity and protein levels was quite narrow, no clear determinants of single agent 
activity to PF-477736 and MK-1775 were identified. Nevertheless, ATM deficiency appeared 
to correlate with VE-821 sensitivity, in keeping with prior reports.  
 
 VE-821 sensitised cervical cancer cells lines to cisplatin and IR, independent of HR-HPV, p53 
or pRB status and to a greater extent than either PF-477736 and MK-1775 at concentrations 
that caused broadly similar levels of target enzyme inhibition, suggesting that this is the 
most promising candidate for future studies. This sensitisation was greatest for cisplatin and 
this is consistent with cisplatin induced DNA lesions causing greater replication stress and 
dependence on ATR signalling to cell cycle checkpoints and DNA repair than lesions typically 
resulting from IR.  
 
Cell cycle analysis suggests that intra-S events predominate in the cell lines’ response to 
cisplatin induced DNA damage.  VE-821 and PF-477736 increased cisplatin induced S-phase 
arrest in some cells but attenuated it in others and this was not related to the extent of 
cisplatin sensitisation by these drugs. It seems likely, therefore that cisplatin sensitisation by 
ATR pathway inhibition is not solely dependent on intra-S or G2/M cell cycle checkpoint 
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abrogation but may be influenced by a balance between the effects of pathway inhibition 
on checkpoint and DNA repair pathways (Figure 8.1). The repair pathways that may 
influence this balance have not been determined in these investigations.  
 
 
Figure 8.1 Schematic representation of proposed balance of DNA damage checkpoint and 
repair reactions influencing cell cycle progression in response to DNA damage. 
ATR-CHK1-WEE1 inhibition is likely to lead to abrogation of S-phase arrest in cells. The 
relative effect of ATR-CHK1-WEE1 inhibition on DNA repair (for example on HRR or NHEJ 




8.2 Future directions 
Whilst the investigations described in this thesis did not identify clear determinants of 
sensitivity to ATR, CHK1 and WEE1 inhibitors, some associations between the cell lines’ 
response to either single agent inhibitors or their sensitisation of cisplatin and IR and 
baseline protein expressions are worthy of expansion in wider studies. These include: 
 
1. The relationship between ATM and DNA-PKcs expression and VE-821 single agent 
cytotoxicity. Despite some conflict with existing literature, the presence of potential 
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relationships between these enzyme expressions and cells’ sensitivity to ATR 
inhibitors may provide a useful biomarker for future clinical use. 
2. MK-1775 sensitisation of cisplatin and expression of WEE1. Though MK-1775 was, 
overall a poor sensitiser of cisplatin a strong correlation with WEE1 expression 
suggests that future studies using this agent should be targeted at cells with WEE1 
overexpression for maximum effect. 
 
Cisplatin induced S-phase arrest was not uniformly attenuated by the inhibitors across the 
cell line panel it is likely therefore that rather than abrogation of cell cycle checkpoints, 
some other function of ATR, CHK1 and to a lesser extent WEE1 are responsible for chemo-
sensitisation. Investigation of the effects of ATR, CHK1 and WEE1 inhibition on DNA repair 
mechanisms implicated in the response to cisplatin and IR induced DNA damage 
(particularly HRR and NHEJ) may provide further insight into the reasons for the differences 
in the cell cycle responses seen and help identify useful determinants of sensitivity for 
future exploitation. Furthermore, investigations aimed at establishing the cell cycle effects 
of IR and IR + inhibitor combinations are needed. This is likely to provide further insight into 
the differences seen between IR and cisplatin with regard to both the cervical cancer cells 
intrinsic sensitivity to these agents and their sensitisation to them by ATR, CHK1 or WEE1 
inhibitors.   
 
There are currently over 70 ongoing early-phase clinical trials of ATR, CHK1 and WEE1 
inhibitors as monotherapy or in combinations with chemotherapy agents or IR 
(www.clinicaltrials.gov). None specifically targets cervical cancer, though patients with 
advanced cervical cancer may be included in cohorts of patients with solid organ tumours. 
Ultimately, an understanding of the mechanisms involved in the sensitivity to these 
inhibitors or their sensitisation of standard of care therapies will enable better 
interpretation of these clinical trial results and targeting of patients who are likely to receive 
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